0001214659-24-02026410-Q Alzamend Neuro, Inc. 20241211202412111630341630341630341

Â Â Â

the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815. Â Loss per Common Share Â The Company utilizes FASB ASC 260,Â Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Â Â 12Â Â Â Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. Â The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share: Schedule of antidilutive securities excluded from computation of earnings per shareÂ Â Â Â Â Â Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Stock options (1)Â Â 116,999Â Â Â 121,054Â Restricted stock unitsÂ Â 84Â Â Â 250Â WarrantsÂ Â 873,450Â Â Â 67,665Â Â Â Â 990,533Â Â Â 188,969Â Â (1)The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14. Â Recent Accounting Standards Â From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Companyâ€™s financial position or results of operations upon adoption. Â Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its condensed financial statements. Â Â 4.PREPAID EXPENSES AND OTHER CURRENT ASSETS Â Prepaid expenses and other current assets were as follows: Schedule of prepaid expenses and other current assetsÂ Â Â Â Â Â Â Â Â Â October 31, 2024Â Â April 30, 2024Â Prepaid clinical trial expensesÂ $490,911Â Â $-Â Prepaid insuranceÂ Â 163,332Â Â Â 60,523Â Other prepaid expensesÂ Â 19,426Â Â Â 18,671Â Total prepaid expenses and other current assetsÂ $673,669Â Â $79,194Â Â On October 22, 2024, the Company entered into a Study Start-up Agreement with Massachusetts General Hospital (â€œMass General Agreementâ€) in preparation for five clinical research trials for its AL001 product candidate. The Mass General Agreement required a prepayment of $514,000. Prepaid clinical trial expenses at October 31, 2024 represented the unamortized portion of clinical trial expense and will be amortized as used. Â On June 14, 2024, the Company purchased directorsâ€™ and officersâ€™ insurance for 12 months in the amount of $227,000. Prepaid insurance at October 31, 2024 represented the unamortized portion of directorsâ€™ and officersâ€™ insurance. Â 5.STOCK-BASED COMPENSATION Â 2016 Stock Incentive Plan Â On April 30, 2016, the Companyâ€™s stockholders approved the Companyâ€™s 2016 Stock Incentive Plan (the â€œPlanâ€). The Plan provides for the issuance of a maximum of 83,333 shares of Common Stock to be offered to the Companyâ€™s directors, officers, employees, and consultants. On March 1, 2019, the Companyâ€™s stockholders approved an additional 50,000 shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant. Â Â 13Â Â Â 2021 Stock Incentive Plan Â In February 2021, the Companyâ€™s board of directors (the â€œBoardâ€) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the â€œ2021 Planâ€). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Â Stock Subject to the 2021 Plan.Â The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 66,667 shares, which number will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2021 Plan. Â Restricted Stock. In May 2021, the Company issued restricted stock awards pursuant to the 2021 Plan to one employee. The restricted stock award vests over 48 months. The award requires continued service to the Company during the vesting period. The vesting provisions of individual awards may vary as approved by the Board. Compensation expense for restricted stock is generally recorded based on its market value on the date of grant and recognized ratably over the associated service and performance period. Â Stock Options. All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Companyâ€™s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life calculated using the simplified method. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments.Â Â A summary of stock option activity for the six months ended October 31, 2024 is presented below:Â Schedule of share-based payment arrangement, option, activityÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Outstanding OptionsÂ Â Â Shares Available for GrantÂ Â Number of SharesÂ Â Weighted Average Exercise PriceÂ Â Weighted Average Remaining Contractual Life (years)Â Â Aggregate Intrinsic ValueÂ Balance at April 30, 2024Â Â 62,000Â Â Â 98,000Â Â $178.12Â Â Â 5.22Â Â $70,500Â Options grantedÂ Â -Â Â Â -Â Â $-Â Â Â -Â Â Â Â Â Options exercisedÂ Â -Â Â Â -Â Â $-Â Â Â -Â Â Â Â Â Options expiredÂ Â 3,333Â Â Â (3,333)Â $150.00Â Â Â -Â Â Â Â Â Balance at October 31, 2024Â Â 65,333Â Â Â 94,667Â Â $179.11Â Â Â 4.90Â Â $15,100Â Options vested and expected to vest at October 31, 2024Â Â Â Â Â Â 88,001Â Â $179.39Â Â Â 4.65Â Â $15,100Â Options exercisable at October 31, 2024Â Â Â Â Â Â 87,043Â Â $178.87Â Â Â 4.63Â Â $15,100Â Â The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. Â Â 14Â Â Â Restricted stock unit activity for the six months ended October 31, 2024 is presented below: Schedule of nonvested restricted stock units activityÂ Â Â Â Â Â Â Â Â Â Â Â Â SharesÂ Â Weighted Average Grant Date Fair ValueÂ Unvested at April 30, 2024Â Â Â Â Â 167Â Â $375.00Â GrantedÂ Â Â -Â Â Â -Â VestedÂ Â Â 83Â Â $375.00Â CancelledÂ Â Â -Â Â Â -Â Unvested at October 31, 2024Â Â Â 84Â Â $375.00Â Â Â Performance Contingent Stock Options Granted to Employee Â On November 26, 2019, the Board granted 28,333 performance and market contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $225.00 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Companyâ€™s initial public offering (â€œIPOâ€) for its common stock, or (ii) stepped target prices for a change in control transaction. The target prices ranged from $1,500 per share to $6,000 per share. In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. Â On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $1,500 per share to $3,000 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of October 31, 2024, management believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards. Â On November 29, 2022, the Compensation Committee of the Board granted 13,333 performance-based stock option to the Chief Executive Officer at an exercise price of $175.50 per share, of which 50% vest upon the completion and announcement of topline data from the Companyâ€™s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Companyâ€™s Phase II clinical trial of ALZN002 within four years from the grant date. During the three months ended July 31, 2023, management believed that it was probable that the performance condition of the completion and announcement of topline data from the Companyâ€™s Phase II clinical trial of AL001 would be achieved and had recognized the related stock-based compensation. As of October 31, 2024, management believed that the achievement of the second performance condition was not probable and, as a result, no compensation cost has been recognized related to Phase I/IIA of ALZN002. Â Performance Contingent Stock Options Granted to TAMM Net Â On March 23, 2021, the Company issued performance-based stock options to certain team members at TAMM Net, Inc. (â€œTAMM Netâ€) to purchase an aggregate of 3,000 shares of Common Stock at a per share exercise price of $225.00 per share, of which 50% would vest upon the completion of Phase I of AL001 by March 31, 2022, and the remaining 50% would vest upon completion of Phase I/IIA of ALZN002 by December 31, 2022. Â On January 19, 2023, the Board modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. The modified performance criteria was not met on or before March 31, 2024 and, as a result, the remaining unvested stock options were cancelled and no compensation cost has been recognized for these awards related to ALZN002. Â Performance Contingent Stock Options Granted to Consultants Â On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of 1,334 shares of Common Stock with an exercise price of $363.00 per share, of which 333 vest upon completion of each of the Phase II clinical trials of AL001 for a BD indication, AL001 for a PTSD indication, AL001 for an MDD indication and ALZN002 for an Alzheimerâ€™s indication. Â Â 15Â Â Â On January 19, 2023, the Board modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate and the indication listed below, and (b) obtained a â€œStudy May Proceedâ€ letter from the U.S. Food and Drug Administration (â€œFDAâ€) for the additional Investigational New Drug (â€œINDâ€) on/or before December 31, 2023, as follows: (i) AL001 â€“ BD; (ii) AL001- MDD; (iii) AL001 â€“ PTSD; and (iv) ALZN002 â€“ Alzheimerâ€™s. Â During the year ended April 30, 2024, the Company filed INDs for BD, MDD and PTSD and received a â€œStudy May Proceedâ€ letter for BD in October 2023, MDD in November 2023 and PTSD in December 2023. As a result, 75% of the performance grant vested and the Company recognized stock-based compensation related to the vesting. As of October 31, 2024, management believed that the achievement of the remaining requisite performance condition was not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002 â€“ Alzheimerâ€™s. Â Stock-Based Compensation Expense Â The Companyâ€™s results of operations included expenses relating to stock-based compensation for three and six months ended October 31, 2024 and 2023, were comprised as follows: Schedule of stock-based compensationÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â For the Three Months Ended October 31,Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Research and developmentÂ $-Â Â $-Â Â $-Â Â $142,603Â Â General and administrativeÂ Â 81,277Â Â Â 175,733Â Â Â 162,554Â Â Â 545,113Â Â TotalÂ $81,277Â Â $175,733Â Â $162,554Â Â $687,716Â Â As of October 31, 2024, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $284,000. The weighted-average period over which such stock-based compensation expense will be recognized was approximately 0.9 years. Â 6.WARRANTS Â During the three months ended October 31, 2024, the Company issued warrants to purchase an aggregate of 440,000 shares of common stock at an exercise price of $12.50 per share. Â (i)On August 19, 2024, the Company issued a warrant to purchase 160,000 shares of Common Stock at an exercise price of $12.50 in connection with the sale of convertible preferred stock to Orchid Finance, LLC (â€œOrchidâ€) for $2,000,000. Based on the terms of the Companyâ€™s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $571,000. Â (ii)On August 21, 2024, the Company issued a warrant to purchase 200,000 shares of Common Stock at an exercise price of $12.50 in connection with the sale of convertible preferred stock to Orchid for $2,500,000. Based on the terms of the Companyâ€™s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $486,000. Â (iii)On September 11, 2024, the Company issued a warrant to purchase 80,000 shares of Common Stock at an exercise price of $12.50 in connection with the sale of convertible preferred stock to Orchid for $1,000,000. Based on the terms of the Companyâ€™s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $69,000. Â Â 16Â Â Â Warrant activity for the six months ended October 31, 2024 is presented below: Schedule of warrant activityÂ Â Â Â Â Â Â Â Â Number OutstandingÂ Â Weighted Average Exercise PriceÂ Outstanding at April 30, 2024Â Â Â 240,449Â Â $67.45Â GrantedÂ Â Â 640,000Â Â $12.50Â Cancelled/ExpiredÂ Â Â (6,999)Â $320.28Â Outstanding at October 31, 2024Â Â Â 873,450Â Â $24.35Â Â The following table summarizes information about Common Stock warrants outstanding and exercisable at October 31, 2024: Schedule of common stock warrants outstandingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OutstandingÂ Â ExercisableÂ Â Â Â Â Â Â Â Â WeightedÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â AverageÂ Â WeightedÂ Â Â Â Â Â Â Â Â Â WeightedÂ Â Â Â Â Â Â Â Â RemainingÂ Â AverageÂ Â Â Â Â Â AverageÂ ExerciseÂ Â NumberÂ Â ContractualÂ Â ExerciseÂ Â NumberÂ Â ExerciseÂ PriceÂ Â OutstandingÂ Â Life (years)Â Â PriceÂ Â ExercisableÂ Â PriceÂ $12.00-$12.50Â Â Â 850,000Â Â Â 4.7Â Â $12.38Â Â Â 850,000Â Â $12.38Â $450.00Â Â Â 23,042Â Â Â 1.8Â Â $450.00Â Â Â 23,042Â Â $450.00Â $937.50Â Â Â 408Â Â Â 1.6Â Â $937.50Â Â Â 408Â Â $937.50Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $12.00 - $937.50Â Â Â 873,450Â Â Â 4.7Â Â $24.35Â Â Â 873,450Â Â $24.35Â Â Â 7.COMMITMENTS AND CONTINGENCIES Â Contractual Obligations Â On July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of South Florida (the â€œAL001 Licensesâ€), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the field of Alzheimerâ€™s, under United States Patent Nos. (i) 9,840,521, entitled â€œOrganic Anion Lithium Ionic Cocrystal Compounds and Compositionsâ€, filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled â€œLithium Co-Crystals for Treatment of Neuropsychiatric Disordersâ€, filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021, the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments to the AL001 Licenses (collectively, the â€œAL001 License Agreementsâ€). The Third Amendments to the AL001 Licenses modified the timing of the payments of the license fees. Â The AL001 License Agreements require that the Company pay combined royalty payments ofÂ 4.5%Â on net sales of products developed from the licensed technology for AL001.Â The Company has already paid an initial license fee of $200,000Â for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor receivedÂ 14,853 shares of Common Stock. Minimum royalties for AL001 License Agreements are $40,000Â on the first anniversary of the first commercial sale, $80,000Â on the second anniversary of the first commercial sale and $100,000Â on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. Â On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the â€œALZN002 Licenseâ€), pursuant to which the Licensor granted the Company a royalty-bearing exclusive worldwide license limited to the field of Alzheimerâ€™s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled â€œAmyloid Beta Peptides and Methods of Use,â€ filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31, 2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, the Company entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, the Company entered into the Seventh Amendment to the ALZN002 License (collectively, the â€œALZN002 License Agreementâ€). The Seventh Amendment to the ALZN002 License modified the timing of the payments of the license fees. Â Â 17Â Â Â The ALZN002 License Agreement requires the Company to pay royalty payments ofÂ 4%Â on net sales of products developed from the licensed technology for ALZN002.Â The Company has already paid an initial license fee of $200,000Â for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor receivedÂ 24,012 shares of

Common Stock. Minimum royalties for ALZN002 are $20,000Â on the first anniversary of the first commercial sale, $40,000Â on the second anniversary of the first commercial sale and $50,000Â on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. Â On November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the â€œNovember AL001 Licenseâ€), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimerâ€™s and (ii) psychiatric diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17, 2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the â€œNovember AL001 License Agreementsâ€). The Second Amendments to the November AL001 License modified the timing of the payments for the license fees. Â The November AL001 License Agreements require the Company to pay royalty payments ofÂ 3%Â on net sales of products developed from the licensed technology for AL001 in those fields.Â The Company paid an initial license fee of $20,000Â for the additional indications. Minimum royalties for November AL001 License Agreements are $40,000Â on the first anniversary of the first commercial sale, $80,000Â on the second anniversary of the first commercial sale and $100,000Â on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements. Â These license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which the Companyâ€™s obligations to pay royalties expire under the applicable license agreement. Under the various license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while the Licensor remains the owner of any equity securities of the Company. Â Additionally, the Company is required to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows: Â Original AL001 Licenses: Â Schedule of contractual obligation, fiscal year maturity Â Â Â Â Payment Â Due Date Â Event $ 50,000 * Completed September 2019 Â Pre-IND meeting Â Â Â Â Â Â $ 65,000 * Completed June 2021 Â IND application filing Â Â Â Â Â Â $ 190,000 * Completed December 2021 Â Upon first dosing of patient in a clinical trial Â Â Â Â Â Â $ 500,000 * Completed March 2022 Â Upon completion of first clinical trial Â Â Â Â Â Â $ 1,250,000 Â March 2025 Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â Â $ 10,000,000 Â 8 years from the effective date of the agreement Â Upon FDA new drug application approval *Milestone met and payment made Â Â 18Â Â Â ALZN002 License: Â Payment Â Due Date $ 50,000 Â * Completed January 2022 Â Â Â Â $ 50,000 Â Upon first dosing of patient in first Phase I clinical trial Â Â Â Â $ 500,000 Â Upon completion of first Phase IIB clinical trial Â Â Â Â $ 1,000,000 Â Upon first patient treated in a Phase III clinical trial Â Â Â Â $ 10,000,000 Â Upon first commercial sale *Milestone met and payment made Â Additional AL001 Licenses: Â Payment Â Due Date Â Event $ 2,000,000 Â March 2026 Â Â Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â Â $ 16,000,000 Â August 1, 2029 Â Â First commercial sale Â 8.EQUITY TRANSACTIONS Â The Company is authorized to issue 10,000,000 shares of Preferred Stock, $0.0001 par value. The Board has designated 3,000 shares as Series A Convertible Preferred Stock and 6,000 shares as Series B Convertible Preferred Stock. The rights, preferences, privileges and restrictions on the remaining authorized 9,991,000 shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.Â Â Series A Convertible Preferred Stock Â On May 8, 2024, the Company and Orchid entered into a securities purchase agreement (the â€œOrchid SPAâ€) for the purchase of up to 2,500 shares of Series A Convertible Preferred Stock and warrants to purchase shares up to 2,000,000 shares of Common Stock in several tranche closings. Â On May 10, 2024, the Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of Common Stock with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid by the surrender and cancellation of a term note issued by the Company to Orchid of $311,356, consisting of $310,000 of principal and $1,356 of accrued and unpaid interest, $100,000 discount and net cash of $588,644. Â On June 25, 2024, the Company sold 150 shares of Series A Convertible Preferred Stock and warrants to purchase 120,000 shares of Common Stock with an exercise price of $12.50, for a total purchase price of $1.5 million. The purchase price was paid in cash. Â On August 19, 2024, the Company sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase 160,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $2.0 million. The purchase price was paid in cash. Â On August 21, 2024, the Company sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase 200,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $2.5 million less $100,000 discount. The purchase price was paid in cash. Â On September 11, 2024, the Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $1.0 million. The purchase price was paid in cash. Â Â 19Â Â Â The Series A Convertible Preferred Stock has a stated value of $1,000 per share and holders of the Series A Convertible Preferred Stock are entitled to cumulative cash dividends at an annual rate of 15%, or $1,500.00 per share (â€œDividend Amountâ€), based on the stated value per share. Notwithstanding the foregoing, for as long as any share(s) of Series A Preferred Stock shall remain outstanding, the Dividend Amount shall be paid either in shares of Series A Preferred Stock or cash, at Orchidâ€™s discretion, in each case equal to the Dividend Amount. Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock cased on the conversion price (â€œSeries A Conversion Priceâ€), which is defined as (a) the state value of the Series A Preferred Stock being converted pus all accrued but unpaid dividends, divided by (b) the greater of (i) $2.50 per share (â€œFloor Priceâ€), and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of the Common Stock during the three trading days immediately prior to the date of the conversion. The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, but not below the Floor Price. The Floor Price shall, however, be adjusted for stock splits, stock dividends, combinations or similar transactions. The holders of the Series A Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series A Convertible Preferred Stock is entitled to cast, shall not be lower than $5.63 (the â€œVoting Floor Priceâ€), which represents the closing sale price of the Common Stock on the trading day immediately prior to the execution date of the Orchid SPA. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event, the holders of Series A Convertible Preferred Stock receive a liquidation preference ahead of holders of Common Stock. Â Series B Convertible Preferred Stock Â On January 31, 2024, the Company and Ault Lending, LLC (â€œAult Lendingâ€) entered into a securities purchase agreement (the â€œAL SPAâ€) for the purchase of up to 6,000 shares of Series B Convertible Preferred Stock and warrants to purchase shares up to 600,000 shares of the Companyâ€™s Common Stock. The AL SPA provides that Ault Lending may purchase up to $6 million of Series B Convertible Preferred Stock in one or more closings. Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the â€œTermination Dateâ€). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination Date. Â On January 31, 2024, the Company sold 1,220 shares of Series B Convertible Preferred Stock and warrants to purchase 122,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $1.22 million. The purchase price was paid by the cancellation of $1.15 million of cash advances made by Ault Lending to the Company between November 9, 2023 and January 31, 2024 and a subscription receivable of $70,000. Â On March 26, 2024, the Company sold 780 shares of Series B Convertible Preferred Stock and warrants to purchase 78,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $780,000. Â On April 29, 2024, the Company sold 100 shares of Series B Convertible Preferred Stock and warrants to purchase 10,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $100,000. Â The Series B Convertible Preferred Stock has a stated value of $1,000 per share (â€œStated Valueâ€) and does not accrue dividends. Each share of Series B Convertible Preferred Stock is convertible into a number of shares of Common Stock determined by dividing the Stated Value by $10.00 (the â€œConversion Priceâ€). The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series B Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Company Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to cast, shall not be lower than $8.73 (the â€œVoting Floor Priceâ€), which represents the closing sale price of the Common Stock on the trading day immediately prior to the Execution Date. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series B Convertible Preferred Stock receive a liquidation preference ahead of holders of Common Stock. Â The warrants have an exercise price of $12.00 (the â€œExercise Priceâ€) and become exercisable on the first business day after the six-month anniversary of issuance (the â€œInitial Exercise Dateâ€) and have a five-year term, expiring on the fifth anniversary of the Initial Exercise Date. The Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. Â Â 20Â Â Â Common Stock Â At-the-Market Offering Â On October 3, 2024, the Company entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the â€œATM Offeringâ€), as sales agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the ATM Offering. On October 3, 2024, the Company filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately $6.5 million in shares of Common Stock in the ATM Offering. Â The offer and sale of the shares will be made pursuant to the Companyâ€™s effective â€œshelfâ€ registration statement on FormÂ S-3 and an accompanying base prospectus contained therein (Registration Statement No.Â 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. Â During the six months ended October 31, 2024, the Company sold an aggregate of 755,888 shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $1.2 million. Â Orchid SPA Â During the three months ended October 31, 2024, Orchid converted 649.5363 shares of Series A Convertible Preferred Stock into 3,613,951 shares of Common Stock. During the six months ended October 31, 2024, Orchid converted 712.0133 shares of Series A Convertible Preferred Stock into 3,787,284 shares of Common Stock. Â 9.RELATED PARTY TRANSACTIONS Â In connection with the Orchid SPA, the Company agreed to pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. During the three and six months ended October 31, 2024, origination fees due to Ault Lending were $275,000 and $400,000, respectively. Â 10.SUBSEQUENT EVENTS Â From November 1, 2024 to December 10, 2024, the Company sold an aggregate of 201,543 shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $280,000. Â Management has evaluated events through the date the financial statement were available to be issued and determined that there have been no other events that occurred that would require adjustment to our disclosures in the condensed financial statements. Â Â 21Â Â Â ITEM 2.MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â You should read the following managementâ€™s discussion and analysis of financial condition and results of operations in conjunction with our unaudited condensed financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes thereto and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or the SEC, on July 30, 2024. Â NOTE ABOUT FORWARD-LOOKING STATEMENTS Â This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). This section should be read in conjunction with our unaudited condensed financial statements and related notes included in Part I, Item 1 of this report. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Â These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including â€œanticipates,â€ â€œbelieves,â€ â€œexpects,â€ â€œcan,â€ â€œcontinue,â€ â€œcould,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œplans,â€ â€œpotential,â€ â€œpredict,â€ â€œshouldâ€ or â€œwillâ€ or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Â In this Quarterly Report, unless the context requires otherwise, references to the â€œCompany,â€ â€œAlzamend,â€ â€œwe,â€ â€œour companyâ€ and â€œusâ€ refer to Alzamend Neuro, Inc., a Delaware corporation. Â Overview Â We were incorporated on February 26, 2016, as Alzamend Neuro, Inc. under the laws of the State of Delaware. We were formed to acquire and commercialize patented intellectual property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimerâ€™s disease (â€œAlzheimerâ€™sâ€). With our two product candidates, we aim to bring treatment or cures not only for Alzheimerâ€™s, but also bipolar disorder (â€œBDâ€), major depressive disorder (â€œMDDâ€) and post-traumatic stress disorder (â€œPTSDâ€). Existing Alzheimerâ€™s treatments only temporarily relieve symptoms but do not, to our knowledge, slow or halt the underlying progression of the disease. We have developed a novel approach to combat Alzheimerâ€™s through immunotherapy. Â Critical Accounting Policies and Estimates Â Research and Development Expenses.Â Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of our company. Â We have acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense, provided that there is no alternative future use of the rights in other research and development projects. Â Stock-Based Compensation.Â We maintain a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards. Â We recognize stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Â Â 22Â Â Â The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include: Â Â·Risk-Free Interest Rate.Â The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. Â Â·Expected Volatility.Â Because we do not have a sufficient trading history for our common stock (â€œCommon Stockâ€), the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. Â Â·Expected Term.Â The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term. Â Â·Expected Dividend Yield.Â We have never paid dividends on our Common Stock and have no plans to pay dividends on our Common Stock. Therefore, we used an expected dividend yield of zero. Â Certain of these assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different. Â Preferred Stock Classification. We analyze the terms of our preferred stock using Accounting Standards Codification (â€œASCâ€) 480, Distinguishing Liabilities from Equity, to determine whether our preferred stock should be classified as a liability or equity, and if classified as equity, permanent or temporary. Common criteria we consider are redemption provisions, conversion options, cumulative of mandatory fixed dividends, discretionary dividends based on earning, voting rights and collateral requirements. Â Â Plan of Operations Â We intend to develop and commercialize therapeutics and vaccines that are better than existing treatments and have the potential to significantly improve the lives of individuals afflicted by Alzheimerâ€™s, BD, MDD and PTSD. To achieve these goals, we are pursuing the following key business strategies:

Â Â·Advance clinical development of AL001 for Alzheimerâ€™s, BD, MDD and PTSD treatment; Â Â·Advance clinical development of ALZN002 for Alzheimerâ€™s treatment; Â Â·Expand our pipeline of pharmaceuticals to include additional indications for AL001 and delivery methods; Â Â·Focus on translational and functional endpoints to efficiently develop product candidates; and Â Â·Optimize the value of AL001 and ALZN002 in major markets. Â Our pipeline consists of two novel therapeutic drug candidates: Â Â·AL001 - A patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the â€œLicensorâ€); and Â Â·ALZN002 - A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimerâ€™s through a royalty-bearing exclusive worldwide license from the Licensor. Â Â 23Â Â Â Our most advanced product candidate (lead product) licensed and in clinical development in humans is AL001, an ionic cocrystal of lithium for the treatment of Alzheimerâ€™s, BD, MDD and PTSD. Based on our preclinical data involving mice models, AL001 treatment prevented cognitive deficits, depression and irritability and is superior in improving associative learning and memory and irritability compared with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimerâ€™s, BD, MDD and PTSD in humans. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially mitigating the regulatory burden for safety data. Â On May 5, 2022, we initiated a multiple-dose, steady-state, double-blind, ascending dose safety, tolerability, pharmacokinetic clinical trial of AL001 in patients with mild to moderate Alzheimerâ€™s and healthy subjects. We completed the Phase IIA clinical trial in March 2023 and announced positive topline data in June 2023, followed by the full data set in October 2024.Â Â We announced that we successfully identified a maximum tolerated dose (â€œMTDâ€) for development of AL001 from a multiple-ascending dose study as assessed by an independent safety review committee. This dose, providing lithium at a lithium carbonate equivalent dose of 240 mg 3-times daily (â€œTIDâ€), is designed to be unlikely to require lithium therapeutic drug monitoring (â€œTDMâ€). Also, this MTD is risk mitigated for the purpose of treating fragile populations, such as Alzheimerâ€™s patients. Â Lithium is a commonly prescribed drug for manic episodes in BD type 1 as well as maintenance therapy of BD in patients with a history of manic episodes. Lithium is also prescribed off-label for MDD, BD and treatment of PTSD, among other disorders. Lithium was the first mood stabilizer approved by the U.S. Food and Drug Administration (â€œFDAâ€) and is still a first-line treatment option (considered the â€œgold standardâ€) but is underutilized perhaps because of the need for TDM. Lithium was the first drug that required TDM by regulatory authorities in product labelling because the effective and safe range of therapeutic drug blood concentrations is narrow and well defined for treatment of BD when using lithium salts. Excursions above this range can be toxic, and below can impair effectiveness.Â Existing lithium drugs suffer from chronic toxicity, poor physicochemical properties, and poor brain bioavailability. Alzamendâ€™s novel AL001 formulation, a lithium-salicylate/L-proline engineered ionic cocrystal, is designed to overcome the toxicities associated with conventional lithium salts, promising a next-generation lithium treatment with an enhanced safety profile and advantageous distribution to brain and brain structures. Â Based on the results from our Phase IIA MAD study, we plan to initiate five clinical trials to determine relative increased lithium levels in the brain compared to a marketed lithium salt for healthy subject and patients diagnosed with mild to moderate Alzheimerâ€™s, BD, MDD and PTSD, based on published mouse studies that predict that lithium can be given at lower doses for equivalent therapeutic benefit when treating with AL001. For example, the goal is to replace the amount of lithium needed for maintenance treatment of BD with a clinically relevant, lower AL001 lithium carbonate equivalent lithium dose. Such lithium dose mitigation could redefine the landscape of neuropsychiatric, neurodegenerative, and neurological treatment practices. In August 2024, we announced that we had partnered with Massachusetts General Hospital to serve as the CRO for these clinical trials. Â On November 19, 2024, we announced final full data set from a nonclinical study comparing brain and plasma lithium exposures between AL001 and lithium carbonate in Alzheimerâ€™s transgenic mice. The study was conducted at the University of South Florida and the bioanalytical procedures for determination of lithium concentration in the brain and plasma samples were conducted under good laboratory practice standards by Sannova Analytical LLC. The study involved administering AL001, a good manufacturing practices-quality active pharmaceutical ingredient (â€œAPIâ€) to 5XFAD mice, a recognized model for Alzheimerâ€™s research, to compare its effects against lithium carbonate, an FDA approved and marketed API. Mice received either high or low doses scaled to humans of both AL001 and lithium carbonate over a 14-day period to observe pharmacokinetic steady-state drug conditions. On the 15th day, the mice were analyzed to assess how the treatments affected lithium concentrations in different brain regions and in their plasma. Â Based on the study, both treatments had no negative impact on the mice's body weight or clinical signs during the treatment period. AL001 showed lower plasma lithium levels than lithium carbonate, reducing the risk of adverse systemic effects, suggesting an expansion for safety of lithiumâ€™s therapeutic index. Further, AL001 showed consistently higher lithium concentrations in brain tissues, particularly at lower doses, compared to lithium carbonate. Finally, the study found that different brain regions absorb and retain lithium differently. This means treatments can potentially be tailored to target specific brain areas, allowing for more precise treatment of various brain-related conditions when applied in human studies. Â These results highlight the potential clinical advantages of AL001 for conditions like Alzheimerâ€™s, BD, MDD and PTSD at low doses. By reducing the systemic burden, AL001 could lessen the risk of side effects such as thyroid and kidney complications often associated with extant lithium therapies. This positions AL001 as a promising candidate for safer long-term treatment options, without the need for TDM. This innovation is specifically designed to address the needs of fragile populations, such as elderly and Alzheimerâ€™s patients, by offering a potentially more efficient and safer alternative to existing treatments. Â Â Â 24Â Â Â The dosing level identified as optimal in this robust nonclinical study will serve as the foundation for advancing the evaluation of AL001 in the comprehensive â€¯Lithium in Brainâ€™ Phase II clinical trials. These trials, conducted in collaboration with Massachusetts General Hospital, will encompass a diverse cohort of both healthy subjects and patients diagnosed with mild to moderate Alzheimerâ€™s disease, BD, MDD and PTSD. Â Â Â On September 28, 2022, we submitted an IND application to the FDA for ALZN002 and received a â€œstudy may proceedâ€ letter on October 31, 2022. The product candidate is an immunotherapy vaccine designed to treat mild to moderate dementia of the Alzheimerâ€™s type. ALZN002 is a proprietary â€œactiveâ€ immunotherapy product, which means it is produced by each patientâ€™s immune system. It consists of autologous DCs that are activated white blood cells taken from each individual patient so that they can be engineered outside of the body to attack Alzheimerâ€™s-related amyloid-beta proteins. These DCs are pulsed with a novel amyloid-beta peptide (E22W) designed to bolster the ability of the patientâ€™s immune system to combat Alzheimerâ€™s, with the goal being to foster tolerance to treatment for safety purposes while stimulating the immune system to reduce the brainâ€™s beta-amyloid protein burden, resulting in reduced Alzheimerâ€™s signs and symptoms. Compared to passive immunization treatment approaches that use foreign blood products (such as monoclonal antibodies), active immunization with ALZN002 is anticipated to offer a more robust and long-lasting effect on the clearance of amyloid. This could provide a safer approach due to its reliance on autologous immune components, using each individual patientâ€™s own white blood cells rather than foreign cells and/or blood products. Â On April 3, 2023, we announced the initiation of a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of the Alzheimerâ€™s type. The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of a placebo in 20-30 subjects with mild to moderate morbidity. The primary goal of this clinical trial is to determine an appropriate dose of ALZN002 for treatment of patients with Alzheimerâ€™s in a larger Phase IIB efficacy and safety clinical trial. On February 13, 2024, we received notice from the company we engaged as our contract research organization (â€œCROâ€), Biorasi, LLC (â€œBiorasiâ€) that Biorasi was terminating our contract with them. We are currently pursuing the engagement of a replacement CRO. Â Â The continuation of our current plan of operations with respect to initiating and conducting the series of human clinical trials for each of our therapeutics requires us to raise additional capital to fund our operations. Â Because our working capital requirements depend upon numerous factors, including the progress of our preclinical and clinical testing, timing and cost of obtaining regulatory approvals, changes in levels of resources that we devote to the development of manufacturing and marketing capabilities, competitive and technological advances, status of competitors, and our ability to establish collaborative arrangements with other organizations, we will require additional financing to fund future operations. Â Â 25Â Â Â Results of Operations Â Results of Operations for the Three Months Ended October 31, 2024 and 2023 Â The following table summarizes the results of our operations for the three months ended October 31, 2024 and 2023: Â Â Â For the Three Months Ended October 31,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ OPERATING EXPENSESÂ Â Â Â Â Â Â Â Â Â Â Research and developmentÂ $311,088Â Â $1,996,783Â Â $(1,685,695)Â Â -84% General and administrativeÂ Â 1,046,980Â Â Â 904,939Â Â Â 142,041Â Â Â 16% Total operating expensesÂ Â 1,358,068Â Â Â 2,901,722Â Â Â (1,543,654)Â Â -53% Loss from operationsÂ Â (1,358,068)Â Â (2,901,722)Â Â 1,543,654Â Â Â 53% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER EXPENSE, NETÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest expenseÂ Â (3,495)Â Â (4,311)Â Â 816Â Â Â -19% Total other expense, netÂ Â (3,495)Â Â (4,311)Â Â 816Â Â Â -19% Â NET LOSSÂ Â (1,361,563)Â Â (2,906,033)Â Â 1,544,468Â Â Â 53% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Dividends on preferred sharesÂ Â (53,651)Â Â -Â Â Â Â Â (53,651)Â Â *Â NET LOSS AVAILABLE TO COMMON SHARESÂ $(1,415,214)Â $(2,906,033)Â $1,490,819Â Â Â 51% Â Basic and diluted net loss per common shareÂ $(0.40)Â $(4.43)Â $4.03Â Â Â *Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted weighted average commonÂ shares outstandingÂ Â 3,531,702Â Â Â 656,378Â Â Â Â Â Â *Â Â *Not meaningful Â Revenue Â We currently have only two product candidates, AL001 and ALZN002. These products are in the clinical stage of development and will require extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment before either or both of them, and any respective successors, will provide us with any revenue. We did not generate any revenues during the three months ended October 31, 2024 and 2023, and we do not anticipate that we will generate revenue for the foreseeable future. Â Â 26Â Â Â Research and Development Expenses Â Research and development expenses for the three months ended October 31, 2024 and 2023 were $311,000 and $2.1 million, respectively. As reflected in the table below, research and development expenses primarily consisted of professional fees and clinical trial fees:Â Â Â Â For the Three Months Ended October 31,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Professional feesÂ $181,233Â Â $1,045,212Â Â $(863,979)Â Â -83% Clinical trial feesÂ Â 124,123Â Â Â 794,676Â Â Â (670,553)Â Â -84% Stock-based compensation expenseÂ Â -Â Â Â Â Â 142,603Â Â Â (142,603)Â Â *Â Other research and development expensesÂ Â 5,732Â Â Â 14,292Â Â Â (8,560)Â Â -60% Total research and development expensesÂ $311,088Â Â $1,996,783Â Â $(1,685,695)Â Â -84% Â *Not meaningful Â Professional Fees Â During the three months ended October 31, 2024 and 2023, we incurred professional fees of $181,000 and $1.0 million, respectively, which were primarily comprised of professional fees attributed to various types of scientific services, including FDA consulting services. The decrease relates to lower professional fees incurred related to minimal clinical trial activities. Â Clinical Trial Fees Â During the three months ended October 31, 2024 and 2023, we incurred clinical trial fees of $124,000 and $795,000, respectively. Clinical trial fees for the three months ended October 31, 2024 were for our initial set-up for our Phase IIA brain imaging study with Massachusetts General. Clinical trial fees for the three months ended October 31, 2023 were for our Phase IIA clinical trial for AL001 and our Phase I/IIA clinical trial for ALZN002. Â Stock-Based Compensation Expense Â During the three months ended October 31, 2024 and 2023, we incurred research and development stock-based compensation expense of nil and $143,000, respectively, related to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation expense for the three months ended October 31, 2024 was a result of fewer stock options vesting during the period compared to the prior year period. Â Other Research and Development Expenses Â During the three months ended October 31, 2024 and 2023, we incurred other fees of $6,000 and $14,000, respectively, which were primarily comprised of scientific materials required for our clinical trials. Â General and Administrative Expenses Â General and administrative expenses for the three months ended October 31, 2024 and 2023 were $1.0 million and $0.9 million, respectively. As reflected in the table below, general and administrative expenses primarily consisted of the following expense categories: salaries and benefits; professional fees; insurance; stock-based compensation expense; marketing fees; as well as board of director fees. For the three months ended October 31, 2024 and 2023, the remaining general and administrative expenses of $83,000 and $93,000, respectively, primarily consisted of payments for filing fees, transfer agent fees, travel and entertainment and other office expenses, none of which was significant individually.Â Â Â 27Â Â Â Â Â For the Three Months Ended October 31,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Salary and benefitsÂ $325,764Â Â $225,934Â Â $99,830Â Â Â 44% Professional feesÂ Â 148,669Â Â Â 283,585Â Â Â (134,916)Â Â -48% InsuranceÂ Â 60,239Â Â Â 88,988Â Â Â (28,749)Â Â -32% Stock-based compensation expenseÂ Â 81,277Â Â Â 175,733Â Â Â (94,456)Â Â -54% Marketing feesÂ Â 304,000Â Â Â -Â Â Â Â Â 304,000Â Â Â *Â Board of director feesÂ Â 43,750Â Â Â 37,500Â Â Â 6,250Â Â Â 17% Other general and administrative expensesÂ Â 83,281Â Â Â 93,199Â Â Â (9,918)Â Â -11% Total general and administrative expensesÂ $1,046,980Â Â $904,939Â Â $142,041Â Â Â 16% Â *Not meaningful Â Salaries and Benefits Â During the three months ended October 31, 2024 and 2023, we incurred $326,000 and $226,000, respectively, in employee-related expenses. The increase in salaries and benefits was due to a bonus paid to our chief executive officer. As of October 31, 2024, we had four full-time and three part-time employees. Â Professional FeesÂ Â During the three months ended October 31, 2024 and 2023, we incurred professional fees of $149,000 and $284,000, respectively. During the three months ended October 31, 2024, we incurred $96,000 in audit fees, $35,000 in legal fees, $14,000 in tax preparation fees, and $2,000 in consulting fees. During the three months ended October 31, 2023, we incurred $92,000 in audit fees, $89,000 in investor relations fees, 67,000 in legal fees, $13,000 in tax preparation fees, $12,000 in related party consulting, and $11,000 in Sarbanes-Oxley compliance fees. The decrease in professional fees was due mainly to lower investor relations and legal fees. Â Insurance Expense Â During the three months ended October 31, 2024 and 2023, we incurred insurance expense of $60,000 and $89,000, respectively, which was primarily directorsâ€™ and officersâ€™ insurance. Â Stock-Based Compensation Expense Â During the three months ended October 31, 2024 and 2023, we incurred general and administrative stock-based compensation expense of $81,000 and $176,000, respectively, related to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation expense for the three months ended October 31, 2024, was a result of fewer stock options vesting during the period compared to the prior year period. Â Marketing FeesÂ Â During the three months ended October 31, 2024 and 2023, we incurred marketing fees of $304,000 and nil, respectively. The increase was due to a marketing program launched to promote our company and our stock during the three months ended October 31, 2024. Â Â 28Â Â Â Results of Operations for the Six Months Ended October 31, 2024 and 2023 Â The following table summarizes the results of our operations for the six months ended October 31, 2024 and 2023: Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ OPERATING EXPENSESÂ Â Â Â Â Â Â Â Â Â Â Research and developmentÂ $517,659Â Â $4,362,920Â Â $(3,845,261)Â Â -88% General and administrativeÂ Â 1,802,814Â Â Â 2,064,732Â Â Â (261,918)Â Â -13% Total operating expensesÂ Â 2,320,473Â Â Â 6,427,652Â Â Â (4,107,179)Â Â -64% Loss from operationsÂ Â (2,320,473)Â Â (6,427,652)Â Â 4,107,179Â Â Â 64% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER EXPENSE, NETÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest expenseÂ Â (15,501)Â Â (6,147)Â Â (9,354)Â Â -152% Total other expense, netÂ Â (15,501)Â Â (6,147)Â Â (9,354)Â Â -152% NET LOSSÂ Â (2,335,974)Â Â (6,433,799)Â Â 4,097,825Â Â Â 64% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Dividends on preferred sharesÂ Â (53,651)Â Â -Â Â Â Â Â (53,651)Â Â *Â NET LOSS AVAILABLE TO COMMON SHARESÂ $(2,389,625)Â $(6,433,799)Â $4,044,174Â Â Â 63% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per common shareÂ $(1.11)Â $(9.80)Â $8.69Â Â Â *Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted weighted average commonÂ shares outstandingÂ Â 2,154,761Â Â Â 656,323Â Â Â Â Â Â *Â Â *Not meaningful Â Revenue Â We currently have only two product candidates, AL001 and ALZN002. These products are in the clinical stage of development and will require extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment before either or both of them, and any respective successors, will provide us with any revenue. We did not generate any revenues during the six months ended October 31, 2024 and 2023, and we do not anticipate that we will generate revenue for the foreseeable future. Â Research and Development Expenses Â Research and development expenses for the six months ended October 31, 2024 and 2023 were $518,000 and $4.4 million, respectively. As reflected in the table below, research and development expenses primarily consisted of professional fees and clinical trial fees:Â Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Professional feesÂ $365,398Â Â $2,114,802Â Â $(1,749,404)Â Â -83% Clinical trialsÂ Â 124,123Â Â Â 2,039,794Â Â Â (1,915,671)Â Â -94% Stock-based compensation expenseÂ Â -Â Â Â Â Â 142,603Â Â Â (142,603)Â Â *Â Other research and development expensesÂ Â 28,138Â Â Â 65,721Â Â Â (37,583)Â Â -57% Total research and development expensesÂ $517,659Â Â $4,362,920Â Â $(3,845,261)Â Â -88% Â *Not meaningful Â Â 29Â Â Â Professional Fees Â During the six months ended October 31, 2024 and 2023, we incurred professional fees of $365,000 and $2.1 million, respectively, which were primarily comprised of professional fees attributed to various types of scientific services, including FDA consulting services. The decrease relates to lower professional fees incurred related to minimal clinical trial activities. Â Clinical Trial Fees Â During the six months ended October 31, 2024 and 2023, we incurred clinical trial fees of $124,000 and $2.0 million, respectively. Clinical trial fees for the six months ended October 31, 2024 were for our initial set-up for our Phase IIA brain imaging study with Massachusetts General. Clinical trial fees for the six months ended October 31, 2023 were for our Phase

IIA clinical trial for AL001 and our Phase I/IIA clinical trial for ALZN002. Â Stock-Based Compensation Expense Â During the six months ended October 31, 2024 and 2023, we incurred research and development stock-based compensation expense of nil and $143,000, respectively, related to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation expense for the six months ended October 31, 2024 was a result of fewer stock options vesting during the period compared to the prior year period. Â Other Research and Development Expenses Â During the six months ended October 31, 2024 and 2023, we incurred other fees of $28,000 and $66,000, respectively, which were primarily comprised of scientific materials required for our clinical trials. Â General and Administrative Expenses Â General and administrative expenses for the six months ended October 31, 2024 and 2023 were $1.8 million and $2.1 million, respectively. As reflected in the table below, general and administrative expenses primarily consisted of the following expense categories: salaries and benefits; professional fees; insurance; stock-based compensation expense; marketing fees; as well as board of director fees. For the six months ended October 31, 2024 and 2023, the remaining general and administrative expenses of $145,000 and $177,000, respectively, primarily consisted of payments for filing fees, transfer agent fees, travel and entertainment and other office expenses, none of which was significant individually. Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Salaries and benefitsÂ $553,559Â Â $379,258Â Â $174,301Â Â Â 46% Professional feesÂ Â 371,096Â Â Â 434,764Â Â Â (63,668)Â Â -15% InsuranceÂ Â 138,634Â Â Â 206,684Â Â Â (68,050)Â Â -33% Stock-based compensation expenseÂ Â 162,554Â Â Â 545,113Â Â Â (382,559)Â Â -70% Marketing feesÂ Â 344,000Â Â Â 247,334Â Â Â 96,666Â Â Â 39% Board of director feesÂ Â 87,500Â Â Â 75,000Â Â Â 12,500Â Â Â 17% Other general and administrative expensesÂ Â 145,471Â Â Â 176,579Â Â Â (31,108)Â Â -18% Total general and administrative expensesÂ $1,802,814Â Â $2,064,732Â Â $(261,918)Â Â -13% Â Salaries and Benefits Â During the six months ended October 31, 2024 and 2023, we incurred $554,000 and $379,000, respectively, in employee-related expenses. The increase in salaries and benefits was due to a bonus paid to our chief executive officer. As of October 31, 2024, we had four full-time and three part-time employees. Â Â 30Â Â Â Professional FeesÂ Â During the six months ended October 31, 2024 and 2023, we incurred professional fees of $371,000 and $435,000, respectively. During the six months ended October 31, 2024, we incurred $151,000 in audit fees, $109,000 in legal fees, $86,000 in investor relations fees, $22,000 in tax preparation fees, and $2,000 in consulting fees. During the six months ended October 31, 2023, we incurred $170,000 in audit fees, $118,000 in investor relations fees, $69,000 in legal fees, $29,000 in tax preparation fees, $24,000 in related party consulting, and $17,000 in Sarbanes-Oxley compliance fees. The decrease in professional fees was due mainly to lower audit, investor relations, related party consulting and Sarbanes-Oxley compliance fees partially offset by higher legal fees. Â Insurance Expense Â During the six months ended October 31, 2024 and 2023, we incurred insurance expense of $139,000 and $207,000, respectively, which was primarily directorsâ€™ and officersâ€™ insurance. Â Stock-Based Compensation Expense Â During the six months ended October 31, 2024 and 2023, we incurred general and administrative stock-based compensation expense of $163,000 and $545,000, respectively, related to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation expense for the six months ended October 31, 2024, was a result of fewer stock options vesting during the period compared to the prior year period. Â Marketing FeesÂ Â During the six months ended October 31, 2024 and 2023, we incurred marketing fees of $344,000 and $207,000, respectively. The increase was due to a marketing program launched to promote our company and our stock during the six months ended October 31, 2024. Â Liquidity and Capital Resources Â The accompanying condensed financial statements have been prepared assuming that we will continue as a going concern. We have incurred recurring net losses and operations have not provided sufficient cash flows. We believe that we will continue to incur operating and net losses each quarter until at least the time we are able to generate revenues from operations. We believe our current cash on hand is insufficient to fund our planned operations through one year after the date the condensed financial statements are issued. These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our condensed financial statements are issued. Â Our inabilityÂ to continueÂ as a going concernÂ couldÂ have a negativeÂ impactÂ on our company, includingÂ our abilityÂ to obtain neededÂ financing. We intend to finance our future development activities and our working capital needs largely through the sale of equity securities with some additional funding from other sources, including debt financing, until such time as funds provided by operations are sufficient to fund working capital requirements. Our condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern. As of October 31, 2024, we had cash of $4.1 million, working capital of $3.5 million, an accumulated deficit of $56.4 million and stockholdersâ€™ equity of $3.8 million. For the three and six months ended October 31, 2024, we had net losses of $1.4 million and $2.4 million, respectively. For the six months ended October 31, 2024, cash used in operating activities was $4.5 million. Historically, we have financed our operations principally through issuances of equity and debt instruments. Â We will need to obtain substantial additional funding in the future for our clinical development activities and continuing operations. If we are unable to raise capital when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. Our future capital requirements will depend on many factors, including: Â Â·successful enrollment in and completion of clinical trials; Â Â·our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if our product candidates are approved, commercial manufacturing; Â Â 31Â Â Â Â·our ability to maintain our current research and development programs and establish new research and development programs; Â Â·addition and retention of key research and development personnel; Â Â·our efforts to enhance operational, financial, and information management systems, and hire additional personnel, including personnel to support development of our product candidates; Â Â·negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations; Â Â·the timing and amount of milestone and other payments we may receive under our collaboration arrangements; Â Â·our eventual commercialization plans for our product candidates; Â Â·the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property claims; and Â Â·the costs and timing of regulatory approvals. Â A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. Â Series B Preferred Financing Â On January 31, 2024, we entered into a securities purchase agreement (â€œAL SPAâ€) with Ault Lending, LLC (â€œAult Lendingâ€) whereby Ault Lending may purchase of up to 6,000 shares of series B convertible preferred stock (â€œSeries B Convertible Preferred Stockâ€) and warrants to purchase shares up to 600,000 shares of our common stock. The AL SPA provides that Ault Lending may purchase up to $6 million of Series B Convertible Preferred Stock in one or more closings. Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 30, 2025 (the â€œTermination Dateâ€). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination Date. Â During the year ended April 30, 2024, we sold an aggregate of 2,100 shares of Series B Convertible Preferred Stock and warrants to purchase 210,000 shares of common stock with an exercise price of $12.00, for a total purchase price of $2.1 million.Â The purchase price was paid by the cancellation of $1.15 million of cash advances made by Ault Lending to us between November 9, 2023 and January 31, 2024 and the remaining $950,000 in cash. Â TheÂ Series B Convertible Preferred StockÂ has a stated value of $1,000 per share (â€œSeries B Stated Valueâ€) and does not accrue dividends.Â Each share of Series B Convertible Preferred Stock is convertible into a number of shares of common stockÂ determined by dividing the Series B Stated Value by $10.00Â (the â€œSeries BÂ Conversion Priceâ€). TheÂ Series BÂ Conversion Price is subject to adjustment in the event of an issuance of common stock at a price per share lower than theÂ Series BÂ Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series B Convertible Preferred Stock are entitled to vote with the common stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to cast, shall not be lower than $8.73 (the â€œVoting Floor Priceâ€), which represents the closing sale price of the common stock on the trading day immediately prior to the date of execution of the AL SPA. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Â The warrants have an exercise price of $12.00 (the â€œSeries BÂ Exercise Priceâ€) and become exercisable on the first business day after the six-month anniversary of issuance (the â€œSeries BÂ Initial Exercise Dateâ€) and have a five-year term, expiring on the fifth anniversary of theÂ Series BÂ Initial Exercise Date. TheÂ Series BÂ Exercise Price is subject to adjustment in the event of an issuance of common stock at a price per share lower than theÂ Series BÂ Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. Â Â 32Â Â Â Series A Preferred Financing Â On May 8, 2024, we and Orchid Finance, LLC (â€œOrchidâ€), entered into a securities purchase agreement (the â€œOrchid SPAâ€) for the purchase of up to 2,500 shares of Series A Convertible Preferred Stock (â€œSeries A Convertible Preferred Stockâ€) and warrants to purchase shares up to 2,500,000 shares of common stock in several tranche closings. Â On May 10, 2024, we sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid by the surrender and cancellation of a term note issued by us to Orchid of $311,356, consisting of $310,000 of principal and $1,356 of accrued and unpaid interest, $100,000 discount and net cash of $588,644. On June 25, 2024, we sold 150 shares of Series A Convertible Preferred Stock and warrants to purchase 120,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $1.5 million. The purchase price was paid in cash. On August 19, 2024, we sold 200 shares of Series A Convertible Preferred Stock and warrant to purchase 160,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $2.0 million. The purchase price was paid in cash. On August 21, 2024, we sold 250 shares of Series A Convertible Preferred Stock and warrant to purchase 200,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $2.5 million less $100,000 discount. The purchase price was paid in cash. On September 11, 2024, we sold 100 shares of Series A Convertible Preferred Stock and warrant to purchase 80,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid in cash. Â Pursuant to the Orchid SPA, Orchid has agreed to purchase the remaining 1,700 Preferred Shares based on our achievement of the milestones set forth below (the â€œMilestonesâ€): Â Â â€¢ 200 Preferred Shares, for $2,000,000, within 60 days of the effectiveness of the resale registration statement (the â€œRegistration Statementâ€) and the execution of a partnership agreement with a nationally renowned research facility for a clinical trial (the â€œFourth Trancheâ€); and Â Â â€¢ 100 Preferred Shares, for $1,000,000, on each monthly anniversary of the effectiveness of the resale registration statement, which was declared effective on July 9, 2024, until all remaining 1,500 Preferred Shares have been sold (each, a â€œFinal Trancheâ€). Â Notwithstanding the foregoing Milestones, Orchid has the ability to invest any amount in its sole discretion in advance of the dates that the foregoing Milestones shall have been met. In the event that the average closing price of the common stock during the three trading days preceding the date of a tranche closing shall not be equal to or greater than $2.50 a share (the â€œFloor Priceâ€), then the applicable closing shall be delayed until such time as the price meets the required threshold. We agreed to pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. We also agreed to pay Orchid a fee of $100,000 upon the first closing, which occurred on May 10, 2024, $100,000 upon the third closing, which occurred on August 21, 2024, and the fourth, eighth and thirteenth closings constituting parts of the Final Tranche. Â The Registration Statement registering for resale the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and exercise of the warrants was declared effective on July 9, 2024. In addition, we agreed to use our best efforts to hold a special meeting of our stockholders within 90 days of the execution date of the Orchid SPA for purposes of seeking stockholder approval of the issuance of all the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and the exercise of the warrants in excess of the â€œNasdaq Limit,â€ which is 19.99% of our shares of common stock issued and outstanding on the execution date of the Orchid SPA. We held a special meeting of stockholders on July 8, 2024, at which time, the stockholders approved the issuance of all the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and the exercise of the warrants in excess of the â€œNasdaq Limit.â€ Â Â 33Â Â Â The Series A Convertible Preferred Stock has a stated value of $10,000 per share (â€œSeries A Stated Valueâ€) and accrues dividends at the rate of 15% per annum, payable quarterly in arrears in cash or paid-in-kind shares, in Orchidâ€™s sole discretion. Each share of Series A Convertible Preferred Stock is convertible into a number of shares of common stock determined by dividing the Series A Stated Value byÂ (y) the greater of (i) the Floor Price and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of our common stock during the three trading days immediately prior to the date of conversion into conversion shares (the â€œSeries A Conversion Priceâ€). The Series A Conversion Price is subject to adjustment in the event of an issuance of common stock at a price per share lower than the Series A Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series A Convertible Preferred Stock are entitled to vote with the common stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to cast, shall not be lower than $5.63 (the â€œSeries A Voting Floor Priceâ€), which represents the closing sale price of the common stock on the trading day immediately prior to the date of execution of the Orchid SPA. The Series A Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Â The warrants have an exercise price of $12.50 (the â€œSeries A Exercise Priceâ€) and are exercisable upon issuance and have a five-year term, expiring on the fifth anniversary of issuance. The Series A Exercise Price is subject to adjustment in the event of an issuance of common stock at a price per share lower than the Series A Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The warrants are exercisable on a cashless basis in the event that there is not then an effective resale registration statement for the common stock issuable upon exercise of the warrants. Â At-the-Market Offering Â On October 3, 2024, we entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the â€œATM Offeringâ€), as sales agent to sell shares of our common stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the ATM Offering. On October 3, 2024, we filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately $6.5 million in shares of common stock in the ATM Offering. Â The offer and sale of the shares will be made pursuant to our effective â€œshelfâ€ registration statement on FormÂ S-3 and an accompanying base prospectus contained therein (Registration Statement No.Â 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. Â During the six months ended October 31, 2024, we sold an aggregate of 755,888 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $1.2 million. From November 1, 2024 to December 10, 2024, we sold an aggregate of 201,543 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $280,000. Â Cash Flows Â The following table summarizes our cash flows for the six months ended October 31, 2024 and 2023: Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Net cash provided by (used in):Â Â Â Â Â Operating activitiesÂ $(4,455,843)Â $(4,811,624) Investing activitiesÂ Â (90,000)Â Â (147,243) Financing activitiesÂ Â 8,262,868Â Â Â 18,087Â Net increase (decrease) in cash and cash equivalentsÂ $3,717,025Â Â $(4,940,780) Â Operating Activities Â During the six months ended October 31, 2024, net cash used in operating activities was $4.5 million. This consisted primarily of a net loss of $2.4 million and a decrease in our net operating assets and liabilities of $2.3 million, partially offset by non-cash charges of $197,000. The non-cash charges primarily consisted of stock-based compensation expense. The decrease in our net operating assets and liabilities was due to a decrease in accounts payable and accrued liabilities and an increase in prepaid expenses and other current assets. Â Investing Activities Â During the six months ended October 31, 2024, net cash used in investing activities was $90,000 from the purchase of equipment. We purchased equipment, which measures lithium levels in the brain, to be used in the AL001 clinical trial. Â Â 34Â Â Â Financing Activities Â During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million. This consisted of $7.1 million from the sale of Series A Convertible Preferred Stock and $1.2 million from the sale of common stock from our ATM Offering. Â Contractual Obligations Â On July 2, 2018, we entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of South Florida (the â€œAL001 Licensesâ€), pursuant to which the Licensor granted us a royalty bearing exclusive worldwide licenses limited to the field of Alzheimerâ€™s, under United States Patent Nos. (i) 9,840,521, entitled â€œOrganic Anion Lithium Ionic Cocrystal Compounds and Compositions,â€ filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled â€œLithium Co-Crystals for Treatment of Neuropsychiatric Disorders,â€ filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, we entered into the First Amendments to the AL001 Licenses, on March 30, 2021, we entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, we entered into the Third Amendments to the AL001 Licenses (collectively, the â€œAL001 License Agreementsâ€). The Third Amendments to the AL001 Licenses modified the timing of the payments of the license fees. Â The AL001 License Agreements require that we pay combined royalty payments of 4.5% on net

sales of products developed from the licensed technology for AL001. We have already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 14,853 shares of our common stock. Minimum royalties for AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. Â On May 1, 2016, we entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the â€œALZN002 Licenseâ€), pursuant to which the Licensor granted us a royalty bearing exclusive worldwide license limited to the field of Alzheimerâ€™s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled â€œAmyloid Beta Peptides and Methods of Use,â€ filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, we entered into the First Amendment to the ALZN002 License, on May 7, 2018, we entered into the Second Amendment to the ALZN002 License, on January 31, 2019, we entered into the Third Amendment to the ALZN002 License, on January 24, 2020, we entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, we entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, we entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, we entered into the Seventh Amendment to the ALZN002 License (collectively, the â€œALZN002 License Agreementâ€). The Seventh Amendment to the ALZN002 License modified the timing of the payments of the license fees. Â The ALZN002 License Agreement requires us to pay royalty payments of 4% on net sales of products developed from the licensed technology for ALZN002. We have already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 24,012 shares of our common stock. Minimum royalties for ALZN002 are $20,000 on the first anniversary of the first commercial sale, $40,000 on the second anniversary of the first commercial sale and $50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. Â On November 19, 2019, we entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the â€œNovember AL001 Licenseâ€), pursuant to which the Licensor granted us a royalty bearing exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimerâ€™s and (ii) psychiatric diseases and disorders. On March 30, 2021, we entered into the First Amendments to the November AL001 License and on April 17, 2023, we entered into the Second Amendments to the November AL001 License (collectively, the â€œNovember AL001 License Agreementsâ€). The Second Amendments to the November AL001 License modified the timing of the payments of the license fees. Â The November AL001 License Agreements require us to pay royalty payments of 3% on net sales of products developed from the licensed technology for AL001 in those fields. We paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements. Â These license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which the licenseeâ€™s obligations to pay royalties expire under the applicable license agreement. Under our various license agreements, if we fail to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by us while the Licensor remains the owner of any equity securities of our company. Â Â 35Â Â Â Additionally, we are required to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows:Â Â Original AL001 Licenses: Â Payment Â Due Date Â Event $ 50,000 * Â Completed September 2019 Â Pre-IND meeting Â Â Â Â Â Â $ 65,000 * Â Completed June 2021 Â IND application filing Â Â Â Â Â Â $ 190,000 * Â Completed December 2021 Â Upon first dosing of patient in a clinical trial Â Â Â Â Â Â $ 500,000 * Â Completed March 2022 Â Upon completion of first clinical trial Â Â Â Â Â Â $ 1,250,000 Â March 2025 Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â Â $ 10,000,000 Â 8 years from the effective date of the agreement Â Upon FDA new drug application approval *Milestone met and payment made Â ALZN002 License: Â Payment Â Due Date $ 50,000 * Â Upon IND application - completed January 2022 Â Â Â Â Â $ 50,000 Â Upon first dosing of patient in first Phase I clinical trial Â Â Â Â Â $ 500,000 Â Upon completion of first Phase IIB clinical trial Â Â Â Â Â $ 1,000,000 Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â $ 10,000,000 Â Upon first commercial sale *Milestone met and payment made Â Additional AL001 Licenses: Â Payment Â Due Date Â Event $ 2,000,000 Â Â March 2026 Â Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â Â $ 16,000,000 Â Â August 1, 2029 Â Â First commercial sale Â Recent Accounting Standards Â None. Â ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â Because we are a smaller reporting company, this section is not applicable. Â Â 36Â Â Â ITEM 4.CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â We have established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Â Our principal executive officer and principal financial officer, with the assistance of other members of the Companyâ€™s management, have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon our evaluation, each of our principal executive officer and principal financial officer has concluded that the Companyâ€™s internal control over financial reporting was not effective as of the end of the period covered by this Quarterly Report on Form 10-Q because the Company has not yet completed its remediation of the material weakness previously identified and disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended April 30, 2024, the end of its most recent fiscal year. Â Specifically, management has identified the following material weaknesses: Â 1.we do not have sufficient resources in our accounting function, which restricts our ability to perform sufficient reviews and approval of manual journal entries posted to the general ledger and to consistently execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for non-routine transactions; and Â 2.our primary user access controls (i.e., provisioning, de-provisioning, privileged access and user access reviews) to ensure appropriate authorization and segregation of duties that would adequately restrict user and privileged access to the financially relevant systems and data to appropriate personnel were not designed and/or implemented effectively. We did not design and/or implement sufficient controls for program change management to certain financially relevant systems affecting our processes. Â A material weakness is a control deficiency or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Â Planned Remediation Â We are implementing measures designed to improve our internal control over financial reporting to remediate material weaknesses, including the following: Â Â·Continue to formalize our internal control documentation and strengthening supervisory reviews by our management; and Â Â·Developing plans to add additional accounting personnel and segregating duties amongst accounting personnel. Â Management continues to work to improve its controls related to our material weaknesses, specifically relating to user access and change management surrounding our information technology systems and applications. Management will continue to implement measures to remediate material weaknesses, such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) enhancing design and documentation related to both user access and change management processes and control activities; and (ii) developing and communicating additional policies and procedures to govern the area of information technology change management. In order to achieve the timely implementation of the above, management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis: Â Â·Engaging a third-party specialist to assist management with improving the Companyâ€™s overall control environment, focusing on change management and access controls; and Â Â·Implementing new applications and systems that are aligned with managementâ€™s focus on creating strong internal controls. Â We are currently working to improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material weaknesses will not be considered to be remediated until the applicable remediated controls are operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. Â Â 37Â Â Â Despite the existence of these material weaknesses, we believe that the condensed financial statements included in the period covered by this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with U.S. generally accepted accounting principles.Â Â Changes in Internal Control Â Except as detailed above, during the quarter ended October 31, 2024, there was no change in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â Â 38Â Â Â PART II â€” OTHER INFORMATION Â ITEM 1.LEGAL PROCEEDINGS Â From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Â ITEM 1A.RISK FACTORS Â The risks described in Part I, ItemÂ 1A, â€œRisk Factors,â€ in our 2024 Annual Report on Form 10-K, could materially and adversely affect our business, financial condition and results of operations, and the trading price of our Common Stock could decline. These risk factors do not identify all risks that we face; our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. The Risk Factors section of ourÂ 2024Â Annual Report on Form 10-K remains current in all material respects. Â ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â On August 19, 2024, we sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase 160,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $2.0 million. The purchase price was paid in cash. Â On August 21, 2024, we sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase 200,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $2.5 million less $100,000 discount. The purchase price was paid in cash. Â On September 11, 2024, we sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid in cash. Â ITEM 3.DEFAULTS UPON SENIOR SECURITIES Â None. Â ITEM 4.MINE SAFETY DISCLOSURES Â Not applicable. Â ITEM 5.OTHER INFORMATION Â NoneÂ of the Companyâ€™s directors and officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended October 31, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended). Â Â 39Â Â Â ITEM 6.EXHIBITS Â Exhibit No. Â ExhibitÂ Description 3.1 Â Certificate of Incorporation (incorporated by reference to ExhibitÂ 2.1 of Form DOS filed with the SEC on AugustÂ 19, 2016). 3.2 Â Certificate of Amendment to the Certificate of Incorporation, filed with the Delaware Secretary of State on June 10, 2016 (incorporated by reference to Exhibit 3.2 of the Quarterly Report on Form 10-Q filed with the SEC on December 15, 2023). 3.3 Â Certificate of Amendment to the Certificate of Incorporation, filed with the Delaware Secretary of State on December 22, 2020 (incorporated by reference to Exhibit 3.3 of the Quarterly Report on Form 10-Q filed with the SEC on December 15, 2023). 3.4 Â Certificate of Amendment to the Certificate of Incorporation, filed with the Delaware Secretary of State on October 27, 2023 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on October 30, 2023). 3.5 Â Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed with the Delaware Secretary of State on March 1, 2024 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on March 7, 2024). 3.6 Â Certificate of Amendment to the Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed with the Delaware Secretary of State on March 21, 2024 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on March 22, 2024). 3.7 Â Certificate of Designations of Preferences and Rights of Series A Preferred Stock, as filed with the Delaware Secretary of State on May 9, 2024 (incorporated by reference to Exhibit 3.1 of the amended Current Report on Form 8-K/A filed with the SEC on May 10, 2024). 3.8 Â Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the registration statement on Form S-1 filed with the SEC on May 10, 2021). 10.1 Â At-The-Market Issuance Sales Agreement, dated October 3, 2024, with Ascendiant Capital Markets, LLC (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on October 3, 2024). 31.1* Â Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). 31.2* Â Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). 32.1** Â Certification of Chief Executive and Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code. 101.INS* Â XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document. 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â *Filed herewith. Â ** This certification will not be deemed â€œfiledâ€ for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. Â Â 40Â Â Â SIGNATURES Â Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Â ALZAMEND NEURO, INC. Â Â Â Â Date: DecemberÂ 11, 2024 By: Â /s/ Stephan Jackman Stephan Jackman Chief Executive Officer (principal executive officer) Â Â Date: DecemberÂ 11, 2024 By: Â /s/ David J. Katzoff David J. Katzoff Chief Financial Officer (principal financial and accounting officer) Â Â 41 Â Â Â Â EX-31.1 2 ex31_1.htm EXHIBIT 31.1 Â EXHIBIT 31.1 CERTIFICATION Â I, Stephan Jackman, certify that: Â 1.Â Â I have reviewed this quarterly report on Form 10-Q of Alzamend Neuro, Inc.; Â 2.Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.Â Â The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.Â Â The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Dated:Â Â December 11, 2024 Â /s/ Stephan Jackman Â Name: Stephan Jackman Â Title: Chief Executive Officer Â (Principal Executive Officer) Â Â Â Â Â Â Â EX-31.2 3 ex31_2.htm EXHIBIT 31.2 Â EXHIBIT 31.2 CERTIFICATION Â I, David J. Katzoff, certify that: Â 1.Â Â I have reviewed this quarterly report on Form 10-Q of Alzamend Neuro, Inc.; Â 2.Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Â Â Based on my knowledge, the

financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.Â Â The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.Â Â The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Dated:Â Â December 11, 2024 Â /s/ David J. Katzoff Â Name: David J. Katzoff Â Title: Chief Financial Officer Â (Principal Financial and Accounting Officer) Â Â Â Â Â Â Â Â EX-32.1 4 ex32_1.htm EXHIBIT 32.1 Â EXHIBIT 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the quarterly report of Alzamend Neuro, Inc. (theÂ â€œCompanyâ€) on Form 10-Q for the period ended OctoberÂ 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersignedÂ certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Â Date: December 11, 2024 Â Â Â Â By: /s/ Stephan Jackman Â Name: Stephan Jackman Â Title: Chief Executive Officer Â (Principal Executive Officer) Â Date: December 11, 2024 Â Â Â Â By: /s/ David J. Katzoff Â Name: David J. Katzoff Â Title: Chief Financial Officer Â (Principal Financial and Accounting Officer) Â Â Â Â Â Â EX-101.SCH 5 alzm-20241031.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Stockholders' (Deficit) Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995612 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 995613 - Disclosure - LIQUIDITY AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 995614 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 995616 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 995618 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995619 - Disclosure - EQUITY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 995620 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 995621 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 995622 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 995623 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995624 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 995626 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995627 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995628 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995629 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995630 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 995631 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995632 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 995633 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995634 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 995636 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 995637 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995638 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 995639 - Disclosure - WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 995640 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995641 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 995642 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995643 - Disclosure - EQUITY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995644 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 alzm-20241031_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 alzm-20241031_def.xml XBRL DEFINITION FILE EX-101.LAB 8 alzm-20241031_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Note Recievable For Common Stock Related Party [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Equity Option [Member] Restricted Stock Units (RSUs) [Member] Warrant [Member] Product and Service [Axis] A L001 License [Member] Title and Position [Axis] Directors and Officers Liability Insurance [Member] Plan Name [Axis] Stock Incentive Plan2016 [Member] Statistical Measurement [Axis] Maximum [Member] Award Type [Axis] Perfromance Contingent Stock Options [Member] Related and Nonrelated Parties [Axis] Key Employees and Director [Member] Statement of Income Location, Balance [Axis] Unamortized Stock Based Compensation [Member] Stock Based Compensation [Member] Research and Development Expense [Member] General and Administrative Expense [Member] Warrant 2024 [Member] Exercise Price Range [Axis] $12.00 [Member] Minimum [Member] $450.00 [Member] $937.50 [Member] $12.00 - $937.50 [Member] Guaranteed Insurance Contract, Type of Guarantee [Axis] First Anniversary [Member] Second Anniversary [Member] Third Anniversary [Member] ALZN002 License [Member] Additional A L001 License [Member] License Events [Axis] Pre Ind Meeting [Member] Ind Application Filing [Member] Upon First Dosing of Patient in Clinical Trial [Member] Upon Completion of First Clinical Trial [Member] Upon First Patient Treated In A Phase III Clinical [Member] Upon Fda Approval [Member] Upon IND Application Filing [Member] Upon First Dosing Of Patient In First Phase I Clinical Trial [Member] Upon Completion Of First Phase II Clinical Trial [Member] Upon First Patient Treated In Phase III Clinical Trial [Member] Upon FDA BLA Approval [Member] First Commercial Sale [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreements [Member] Legal Entity [Axis] Ault Lending [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Prepaid expenses and other current assets TOTAL CURRENT ASSETS Property, plant and equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERSâ€™ EQUITY (DEFICIT) CURRENT LIABILITIES Accounts payable and accrued liabilities Note payable TOTAL LIABILITIES, ALL CURRENT COMMITMENTS AND CONTINGENCIES STOCKHOLDERSâ€™ EQUITY (DEFICIT) Preferred Stock, Value Common stock, $0.0001 par value: 300,000,000 shares authorized; 5,231,254 and 687,999Â issued and outstanding as of October 31, 2024 and April 30, 2024, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERSâ€™ EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Preferred stock, par value (in dollars per share) Preferred stock shares designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Research and development General and administrative Total operating expenses Loss from operations OTHER EXPENSE, NET Interest expense Total other expense, net NET LOSS Dividends on preferred shares NET LOSS AVAILABLE TO COMMON SHARES Basic net loss per common share Diluted net loss per common share Basic weighted average common shares outstanding Diluted weighted average common shares outstanding Beginning balance, value Beginning balance, shares Issuance of common stock for cash, net of issuance costs Issuance of common stock for cash, net of issuance costs, shares Issuance of common stock for restricted stock awards Issuance of common stock for restricted stock awards, shares Subscription receivable payment received Issuance of preferred stock for cash, net of issuance costs Issuance of preferred stock for cash, net of issuance costs, shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock, shares Conversion of note payable and interest to preferred stock Stock-based compensation to employees and consultants Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Interest expense - debt discount Stock-based compensation to employees and consultants Changes in operating assets and liabilities: Prepaid expenses and other current assets Prepaid expenses - related party Accounts payable and accrued liabilities Net cash used in operating activities Cash flows from investing activities: Purchase of equipment Net cash used in investing activities Cash flows from financing activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Supplemental disclosures of cash flow information: Non-cash financing activities: Conversion of Series A convertible preferred stock Fair value of warrants issued in connection with Series A convertible preferred stock Conversion of note payable and accrued interest into Series B convertible preferred stock Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements [Abstract] LIQUIDITY AND GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Guarantees and Product Warranties [Abstract] WARRANTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] EQUITY TRANSACTIONS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Accounting Estimates Cash and Cash Equivalents Fair Value of Financial Instruments Property and Equipment, Net Research and Development Expenses Stock-Based Compensation Warrants Loss per Common Share Recent Accounting Standards Schedule of antidilutive securities excluded from computation of earnings per share Schedule of prepaid expenses and other current assets Schedule of share-based payment arrangement, option, activity Schedule of nonvested restricted stock units activity Schedule of stock-based compensation Schedule of warrant activity Schedule of common stock warrants outstanding Schedule of contractual obligation, fiscal year maturity Cash Working capital deficiency Accumulated deficit Stockholders' deficit Net loss Cash used in operating activities Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share, amount Cash equivalents Property and equipment estimated useful life Prepaid clinical trial expenses Prepaid insurance Other prepaid expenses Total prepaid expenses and other current assets Prepaid clinical trial fees Insurance purchased Shares available for grant begining (in shares) Number of shares begining (in shares) Weighted average exercise price begining (in dollars per share) Weighted average remaining contractual life begining (years) Aggregate intrinsic value begining Shares available for grant, Options granted Number of shares, Options granted Weighted average exercise price, Options granted Shares available for grant, Options exercised Number of shares, Options exercised Weighted average exercise price, Options exercised Shares available for grant, Options expired Number of shares, Options expired Weighted average exercise price, Options expired Shares available for grant end (in shares) Number of shares end (in shares) Weighted average exercise price end (in dollars per share) Weighted average remaining contractual life end (years) Aggregate intrinsic value end Number of shares, Options vested and expected to vest at end Weighted

average exercise price, Options vested and expected to vest at end Weighted average remaining contractual life, Options vested and expected to vest at end Aggregate intrinsic value, Options vested and expected to vest at end Number of shares, Options exercisable at end Weighted average exercise price, Options exercisable at end Weighted average remaining contractual life, Options exercisable at end Aggregate intrinsic value, Options exercisable at end Unvested shares, Beginning balance Unvested Weighted Average Grant Date Fair Value, Beginning balance Unvested shares, Granted Unvested Weighted Average Grant Date Fair Value, Granted Unvested shares, Vested Unvested Weighted Average Grant Date Fair Value, Vested Unvested shares, Cancelled Unvested Weighted Average Grant Date Fair Value, Cancelled Unvested shares, Ending balance Unvested Weighted Average Grant Date Fair Value, Ending balance Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based compensation arrangement by share-based payment award, number of shares authorized Share-based compensation arrangement by share-based payment award, number of additional shares authorized Share-based compensation arrangement by share-based payment award, expiration period Options granted Terms of award Unamortized stock-based compensation expense related to unvested employee and non-employee awards Weighted-average period Class of warrant or right, outstanding, beginning Weighted average exercise price, beginning Class of warrant or right, outstanding, granted Weighted average exercise price, granted Class of warrant or right, outstanding, cancelled/expired Weighted average exercise price, cancelled/expired Class of warrant or right, outstanding, ending Weighted average exercise price, ending Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercse price (in dollars per share) Class of Warrant or Right, Outstanding Weighted average remaining contractual life (years) Warrant outstanding, weighted average exercise price (in dollars per share) Number of warrant exercisable Warrant exercisable, weighted average exercise price (in dollars per share) Aggregate number of stock repurchase Exercise price (in dollars per share) Value of common stock sold Fair value of warrant Product Liability Contingency [Table] Product Liability Contingency [Line Items] Payment Due date Percentage of royalty payments on net sales of product Description of licenses agreements Initial license fees Payments for royalties Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock, shares authorized Number of shares purchase Exercise price Shares purchase price Principal issued Principal amount Accrued interest Discount Net cash Termination loans description Number of common stock sold Cancellations of cash advances Subscription receivable Converted shares Number of shares issued Origination fees The element represents a l001 license member. The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term. The element represents stock incentive plan2016 member. The element represents perfromance contingent stock options member. The element represents key employees and director member. The element represents unamortized stock based compensation member. The element represents exercise price1 member. The element represents exercise price3 member. The element represents exercise price4 member. The element represents aggregate number of stock repurchase. The element represents license events axis. The element represents pre ind meeting member. The element represents ind application filing member. The element represents upon first dosing of patient in clinical trial member. The element represents upon completion of first clinical trial member. The element represents upon fda approval member. The element represents additional a l001 license member. The element represents percentage of royalty payments on net sales of product.. The element represents description of licenses agreements. Amount of initial license fees. The element represents number of shares purchase. The element represents securities purchase agreements member. The element represents shares purchase price. Assets, Current Assets Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Operating and Nonoperating Nonoperating Income (Expense) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest DividendsOnPreferredShares Net Income (Loss) Available to Common Stockholders, Basic Equity, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expense and Other Assets IncreaseDecreaseInPrepaidExpensesRelatedParty Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Machinery and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Commitments and Contingencies Disclosure [Text Block] Cash [Default Label] Retained Earnings, Appropriated Net Income (Loss) Available to Common Stockholders, Diluted Prepaid Expense and Other Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value EX-101.PRE 9 alzm-20241031_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 6 Months Ended Oct. 31, 2024 Dec. 10, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Oct. 31, 2024 Â Document Fiscal Period Focus Q2 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --04-30 Â Entity File Number 001-40483 Â Entity Registrant Name ALZAMEND NEURO, INC. Â Entity Central Index Key 0001677077 Â Entity Tax Identification Number 81-1822909 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 3480 Peachtree Road NE Â Entity Address, Address Line Two Second Floor Suite 103 Â Entity Address, City or Town Atlanta Â Entity Address, State or Province GA Â Entity Address, Postal Zip Code 30326 Â City Area Code 844 Â Local Phone Number 722-6303 Â Title of 12(b) Security Common Stock, $0.0001 par value per share Â Trading Symbol ALZN Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Elected Not To Use the Extended Transition Period false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 5,432,797 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Unaudited) - USD ($) Oct. 31, 2024 Apr. 30, 2024 CURRENT ASSETS Â Â Cash $ 4,093,073 $ 376,048 Prepaid expenses and other current assets 673,669 79,194 TOTAL CURRENT ASSETS 4,766,742 455,242 Property, plant and equipment, net 240,976 176,346 TOTAL ASSETS 5,007,718 631,588 CURRENT LIABILITIES Â Â Accounts payable and accrued liabilities 1,254,750 2,925,059 Note payable 300,714 TOTAL LIABILITIES, ALL CURRENT 1,254,750 3,225,773 STOCKHOLDERSâ€™ EQUITY (DEFICIT) Â Â Common stock, $0.0001 par value: 300,000,000 shares authorized; 5,231,254 and 687,999Â issued and outstanding as of October 31, 2024 and April 30, 2024, respectively 523 69 Additional paid-in capital 60,162,478 51,426,154 Accumulated deficit (56,410,033) (54,020,408) TOTAL STOCKHOLDERSâ€™ EQUITY (DEFICIT) 3,752,968 (2,594,185) TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY 5,007,718 631,588 Series A Preferred Stock [Member] Â Â STOCKHOLDERSâ€™ EQUITY (DEFICIT) Â Â Preferred Stock, Value Series B Preferred Stock [Member] Â Â STOCKHOLDERSâ€™ EQUITY (DEFICIT) Â Â Preferred Stock, Value X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:

http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares Oct. 31, 2024 Apr. 30, 2024 Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares issued 5,231,254 687,999 Common stock, shares outstanding 5,231,254 687,999 Series A Preferred Stock [Member] Â Â Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock shares designated 3,000 3,000 Preferred stock, shares issued 87.9867 0 Preferred stock, shares outstanding 87.9867 0 Series B Preferred Stock [Member] Â Â Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock shares designated 6,000 6,000 Preferred stock, shares issued 2,100 2,100 Preferred stock, shares outstanding 2,100 2,100 X - ReferencesNo definition available. + Details Name: alzm_PreferredStockSharesDesignated Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards

Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Operations (Unaudited) - USD ($) 3 Months Ended 6 Months Ended Oct. 31, 2024 Oct. 31, 2023 Oct. 31, 2024 Oct. 31, 2023 OPERATING EXPENSES Â Â Â Â Research and development $ 311,088 $ 1,996,783 $ 517,659 $ 4,362,920 General and administrative 1,046,980 904,939 1,802,814 2,064,732 Total operating expenses 1,358,068 2,901,722 2,320,473 6,427,652 Loss from operations (1,358,068) (2,901,722) (2,320,473) (6,427,652) OTHER EXPENSE, NET Â Â Â Â Interest expense (3,495) (4,311) (15,501) (6,147) Total other expense, net (3,495) (4,311) (15,501) (6,147) NET LOSS (1,361,563) (2,906,033) (2,335,974) (6,433,799) Dividends on preferred shares (53,651) (53,651) NET LOSS AVAILABLE TO COMMON SHARES $ (1,415,214) $ (2,906,033) $ (2,389,625) $ (6,433,799) Basic net loss per common share $ (0.40) $ (4.43) $ (1.11) $ (9.80) Diluted net loss per common share $ (0.40) $ (4.43) $ (1.11) $ (9.80) Basic weighted average common shares outstanding 3,531,702 656,378 2,154,761 656,323 Diluted weighted average common shares outstanding 3,531,702 656,378 2,154,761 656,323 X - ReferencesNo definition available. + Details Name: alzm_DividendsOnPreferredShares Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the

business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Note Recievable For Common Stock Related Party [Member] Retained Earnings [Member] Total Beginning balance, value at Apr. 30, 2023 Â $ 65 $ 62,001,395 $ (14,883,295) $ (44,072,662) $ 3,045,503 Beginning balance, shares at Apr. 30, 2023 Â 646,268 Â Â Â Â Â Issuance of common stock for cash, net of issuance costs Â 18,087 18,087 Issuance of common stock for cash, net of issuance costs, shares Â Â 615 Â Â Â Â Â Issuance of common stock for restricted stock awards Â Issuance of common stock for restricted stock awards, shares Â Â 83 Â Â Â Â Â Subscription receivable payment received Â (7,002) 7,002 Stock-based compensation to employees and consultants Â 687,716 687,716 Net loss Â (6,433,799) (6,433,799) Ending balance, value at Oct. 31, 2023 Â $ 65 62,700,196 (14,876,293) (50,506,461) (2,682,493) Ending balance, shares at Oct. 31, 2023 Â 646,966 Â Â Â Â Â Beginning balance, value at Jul. 31, 2023 Â $ 65 62,370,775 (14,883,295) (47,600,428) (112,883) Beginning balance, shares at Jul. 31, 2023 Â 646,268 Â Â Â Â Â Issuance of common stock for cash, net of issuance costs Â 18,087 18,087 Issuance of common stock for cash, net of issuance costs, shares Â Â 615 Â Â Â Â Â Issuance of common stock for restricted stock awards Â Issuance of common stock for restricted stock awards, shares Â Â 83 Â Â Â Â Â Subscription receivable payment received Â (7,002) 7,002 Stock-based compensation to employees and consultants Â 318,336 318,336 Net loss Â (2,906,033) (2,906,033) Ending balance, value at Oct. 31, 2023 Â $ 65 62,700,196 (14,876,293) (50,506,461) (2,682,493) Ending balance, shares at Oct. 31, 2023 Â 646,966 Â Â Â Â Â Beginning balance, value at Apr. 30, 2024 $ 69 51,426,154 Â (54,020,408) (2,594,185) Beginning balance, shares at Apr. 30, 2024 2,100 687,999 Â Â Â Â Â Issuance of common stock for cash, net of issuance costs $ 76 1,174,148 Â 1,174,224 Issuance of common stock for cash, net of issuance costs, shares Â Â 755,888 Â Â Â Â Â Issuance of common stock for restricted stock awards Â Issuance of common stock for restricted stock awards, shares Â Â 83 Â Â Â Â Â Issuance of preferred stock for cash, net of issuance costs 7,088,644 Â 7,088,644 Issuance of preferred stock for cash, net of issuance costs, shares 800 Â Â Â Â Â Â Â Conversion of preferred stock to common stock $ 378 (378) Â Conversion of preferred stock to common stock, shares (712) Â 3,787,284 Â Â Â Â Â Conversion of note payable and interest to preferred stock 311,356 Â 311,356 Stock-based compensation to employees and consultants 162,554 Â 162,554 Net loss Â (2,389,625) (2,389,625) Ending balance, value at Oct. 31, 2024 $ 523 60,162,478 (56,410,033) 3,752,968 Ending balance, shares at Oct. 31, 2024 88 2,100 5,231,254 Â Â Â Â Â Beginning balance, value at Jul. 31, 2024 $ 86 53,782,414 (54,994,819) (1,212,319) Beginning balance, shares at Jul. 31, 2024 188 2,100 861,332 Â Â Â Â Â Issuance of common stock for cash, net of issuance costs $ 76 1,174,148 Â 1,174,224 Issuance of common stock for cash, net of issuance costs, shares Â Â 755,888 Â Â Â Â Â Issuance of common stock for restricted stock awards Â Issuance of common stock for restricted stock awards, shares Â Â 83 Â Â Â Â Â Issuance of preferred stock for cash, net of issuance costs 5,125,000 Â 5,125,000 Issuance of preferred stock for cash, net of issuance costs, shares 550 Â Â Â Â Â Â Â Conversion of preferred stock to common stock $ 361 (361) Â Conversion of preferred stock to common stock, shares (650) Â 3,613,951 Â Â Â Â Â Stock-based compensation to employees and consultants 81,277 Â 81,277 Net loss (1,415,214) (1,415,214) Ending balance, value at Oct. 31, 2024 $ 523 $ 60,162,478 $ (56,410,033) $ 3,752,968 Ending balance, shares at Oct. 31, 2024 88 2,100 5,231,254 Â Â Â Â Â X - ReferencesNo definition available. + Details Name: alzm_ConversionOfNotePayableAndInterestToPreferredStock Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_ConversionOfPreferredStockToCommonStock Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_ConversionOfPreferredStockToCommonStockShares Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_IssuanceOfCommonStockForCashNetOfIssuanceCosts Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_IssuanceOfCommonStockForCashNetOfIssuanceCostsShares Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_IssuanceOfPreferredStockForCashNetOfIssuanceCosts Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_StockbasedCompensationToEmployeesAndConsultants Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type:

credit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_SubscriptionReceivablePaymentReceived Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31:

http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Cash Flows (Unaudited) - USD ($) 6 Months Ended Oct. 31, 2024 Oct. 31, 2023 Cash flows from operating activities: Â Â Net loss $ (2,389,625) $ (6,433,799) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation expense 25,370 25,370 Interest expense - debt discount 9,286 Stock-based compensation to employees and consultants 162,554 687,716 Changes in operating assets and liabilities: Â Â Prepaid expenses and other current assets (594,475) (134,213) Prepaid expenses - related party 247,334 Accounts payable and accrued liabilities (1,668,953) 795,968 Net cash used in operating activities (4,455,843) (4,811,624) Cash flows from investing activities: Â Â Purchase of equipment (90,000) (147,243) Net cash used in investing activities (90,000) (147,243) Cash flows from financing activities: Â Â Net proceeds from the issuance of common stock 1,174,224 18,087 Net proceeds from the issuance of preferred stock 7,088,644 Net cash provided by financing activities 8,262,868 18,087 Net increase (decrease) in cash 3,717,025 (4,940,780) Cash at beginning of period 376,048 5,140,859 Cash at end of period 4,093,073 200,079 Non-cash financing activities: Â Â Conversion of Series A convertible preferred stock 7,120,133 Fair value of warrants issued in connection with Series A convertible preferred stock 1,635,489 Conversion of note payable and accrued interest into Series B convertible preferred stock $ 311,356 X - ReferencesNo definition available. + Details Name: alzm_ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_ConversionOfSeriesConvertiblePreferredStock Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_IncreaseDecreaseInPrepaidExpensesRelatedParty Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_NoncashFinancingActivitiesAbstract Namespace Prefix: alzm_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -

Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for acquisition of machinery and equipment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireMachineryAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 6 Months Ended Oct. 31, 2024 Oct. 31, 2023 Oct. 31, 2024 Oct. 31, 2023 Pay vs Performance Disclosure [Table] Â Â Â Â Â Net Income (Loss) $ (1,415,214) $ (2,906,033) $ (2,389,625) $ (6,433,799) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 6 Months Ended Oct. 31, 2024 Insider Trading Arrangements [Line Items] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 DESCRIPTION OF BUSINESS 6 Months Ended Oct. 31, 2024 Accounting Policies [Abstract] Â DESCRIPTION OF BUSINESS Â 1.DESCRIPTION OF BUSINESS Â Organization Â Alzamend Neuro, Inc. (the â€œCompanyâ€ or â€œAlzamendâ€), is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimerâ€™s disease (â€œAlzheimerâ€™sâ€), bipolar disorder (â€œBDâ€), major depressive disorder (â€œMDDâ€) and post-traumatic stress disorder (â€œPTSDâ€). With two current product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Companyâ€™s current pipeline consists of two novel therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the â€œLicensorâ€); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimerâ€™s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor. Â The Company is devoting substantially all its efforts towards research and development of its two product candidates and raising capital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (â€œCommon Stockâ€) and its preferred stock, par value $0.0001 per share. The Company expects to continue to incur net losses in the foreseeable future. Â Reverse Stock Split Â On October 27, 2023, pursuant to the authorization provided by the Companyâ€™s stockholders at a special meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Companyâ€™s issued and outstanding Common Stock by a ratio of one-for-fifteen (the â€œFirst

Reverse Splitâ€). The First Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the First Reverse Split, each fifteen shares of Common Stock issued and outstanding prior to the First Reverse Split were converted into one share of Common Stock. The First Reverse Split became effective in the State of Delaware on October 31, 2023. All share amounts in these financial statements have been updated for all periods presented to reflect the First Reverse Split. Â On July 10, 2024, pursuant to the authorization provided by the Companyâ€™s stockholders at its annual meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Companyâ€™s issued and outstanding Common Stock by a ratio of one-for-ten (the â€œSecond Reverse Splitâ€). The Second Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Second Reverse Split, each ten shares of Common Stock issued and outstanding prior to the Second Reverse Split were converted into one share of Common Stock. The Second Reverse Split became effective in the State of Delaware on July 16, 2024. All share amounts in these financial statements have been updated for all periods presented to reflect the Second Reverse Split. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 LIQUIDITY AND GOING CONCERN 6 Months Ended Oct. 31, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â LIQUIDITY AND GOING CONCERN Â 2.LIQUIDITY AND GOING CONCERN Â The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of October 31, 2024, the Company had cash of $4.1 million, working capital of $3.5 million, an accumulated deficit of $56.4 million and stockholdersâ€™ equity of $3.8 million. For the three and six months ended October 31, 2024, the Company had net losses of $1.4 million and $2.4 million, respectively. For the six months ended October 31, 2024, cash used in operating activities was $4.5 million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments. Â Management believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued. These factors create substantial doubt about the Companyâ€™s ability to continue as a going concern for at least one year after the date that these condensed financial statements are issued. Â The Companyâ€™s inabilityÂ to continueÂ as a going concernÂ couldÂ have a negativeÂ impactÂ on the Company, includingÂ its abilityÂ to obtain neededÂ financing. The Companyâ€™s condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should it be unable to continue as a going concern. Â The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. These factors create substantial doubt about our ability to continue as a going concern. However, based on the Companyâ€™s current business plan, management believes that the Companyâ€™s cash and cash equivalents at October 31, 2024, together with the anticipated receipt of funds from its â€œat-the-marketâ€ offering and from the sale of its Series A and Series B Convertible Preferred Stock pursuant to the securities purchase agreements related thereto, will be sufficient to meet the Companyâ€™s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Oct. 31, 2024 Accounting Policies [Abstract] Â SIGNIFICANT ACCOUNTING POLICIES Â 3.SIGNIFICANT ACCOUNTING POLICIES Â Basis of Presentation Â The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and the rules of the Securities and Exchange Commission (â€œSECâ€) applicable to interim reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Companyâ€™s Report on Form 10-K for the year ended April 30, 2024, filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Companyâ€™s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K. Â Accounting Estimates Â The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Companyâ€™s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates. Â Cash and Cash Equivalents Â The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024 and AprilÂ 30, 2024, the Company had no cash equivalents. Â Fair Value of Financial Instruments Â Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Â Level 1: Quoted prices in active markets for identical assets or liabilities. Â Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Â Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. Â The fair values of warrants are determined using the Black-Scholes valuation model, a â€œLevel 3â€ fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrantsâ€™ contractual life. Â Property and Equipment, Net Â Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of 5 five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred. Â Research and Development Expenses Â Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company. Â The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses, provided that there is no alternative future use of the rights in other research and development projects. Â Stock-Based Compensation Â The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Companyâ€™s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Â The Company recognizes stock-based compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Companyâ€™s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock. Â The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Companyâ€™s stock-based compensation could be materially different. Â Warrants Â The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480,Â Distinguishing Liabilities from Equity and FASB ASC 815,Â Derivatives and Hedging (â€œASC 815â€),Â depending on the specific terms of the warrant agreement. Â Based on the terms of the Companyâ€™s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815. Â Loss per Common Share Â The Company utilizes FASB ASC 260,Â Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Â Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. Â The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share: Schedule of antidilutive securities excluded from computation of earnings per shareÂ Â Â Â Â Â Â Â Â Â Â Â Â For the Six Months Ended October 31,Â Â Â Â 2024Â Â Â 2023Â Stock options (1)Â Â Â 116,999Â Â Â Â 121,054Â Â Restricted stock unitsÂ Â Â 84Â Â Â Â 250Â Â WarrantsÂ Â Â 873,450Â Â Â Â 67,665Â Â Â Â Â 990,533Â Â Â Â 188,969Â Â Â (1)The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14. Â Recent Accounting Standards Â From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Companyâ€™s financial position or results of operations upon adoption. Â Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its condensed financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 PREPAID EXPENSES AND OTHER CURRENT ASSETS 6 Months Ended Oct. 31, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â PREPAID EXPENSES AND OTHER CURRENT ASSETS Â Â 4.PREPAID EXPENSES AND OTHER CURRENT ASSETS Â Prepaid expenses and other current assets were as follows: Schedule of prepaid expenses and other current assetsÂ Â Â Â Â Â Â Â Â Â Â Â Â October 31, 2024Â Â Â April 30, 2024Â Prepaid clinical trial expensesÂ $490,911Â Â $-Â Prepaid insuranceÂ Â 163,332Â Â Â 60,523Â Other prepaid expensesÂ Â 19,426Â Â Â Â 18,671Â Total prepaid expenses and other current assetsÂ $673,669Â Â $79,194Â Â Â On October 22, 2024, the Company entered into a Study Start-up Agreement with Massachusetts General Hospital (â€œMass General Agreementâ€) in preparation for five clinical research trials for its AL001 product candidate. The Mass General Agreement required a prepayment of $514,000. Prepaid clinical trial expenses at October 31, 2024 represented the unamortized portion of clinical trial expense and will be amortized as used. Â On June 14, 2024, the Company purchased directorsâ€™ and officersâ€™ insurance for 12 months in the amount of $227,000. Prepaid insurance at October 31, 2024 represented the unamortized portion of directorsâ€™ and officersâ€™ insurance. X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION 6 Months Ended Oct. 31, 2024 Share-Based Payment Arrangement [Abstract] Â STOCK-BASED COMPENSATION Â 5.STOCK-BASED COMPENSATION Â 2016 Stock Incentive Plan Â On April 30, 2016, the Companyâ€™s stockholders approved the Companyâ€™s 2016 Stock Incentive Plan (the â€œPlanâ€). The Plan provides for the issuance of a maximum of 83,333 shares of Common Stock to be offered to the Companyâ€™s directors, officers, employees, and consultants. On March 1, 2019, the Companyâ€™s stockholders approved an additional 50,000 shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant. Â 2021 Stock Incentive Plan Â In February 2021, the Companyâ€™s board of directors (the â€œBoardâ€) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the â€œ2021 Planâ€). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Â Stock Subject to the 2021 Plan.Â The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 66,667 shares, which number will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2021 Plan. Â Restricted Stock. In May 2021, the Company issued restricted stock awards pursuant to the 2021 Plan to one employee. The restricted stock award vests over 48 months. The award requires continued service to the Company during the vesting period. The vesting provisions of individual awards may vary as approved by the Board. Compensation expense for

restricted stock is generally recorded based on its market value on the date of grant and recognized ratably over the associated service and performance period. Â Stock Options. All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Companyâ€™s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life calculated using the simplified method. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments.Â Â A summary of stock option activity for the six months ended October 31, 2024 is presented below:Â Schedule of share-based payment arrangement, option, activityÂ Â Â Â

market exclusivity granted by a governmental regulatory body, or the date on which the Companyâ€™s obligations to pay royalties expire under the applicable license agreement. Under the various license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while the Licensor remains the owner of any equity securities of the Company. Â Additionally, the Company is required to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows: Â Original AL001 Licenses: Â Schedule of contractual obligation, fiscal year maturity Â Â Â Â Payment Â Due Date Â Event $ 50,000 * Completed September 2019 Â Pre-IND meeting Â Â Â Â Â Â $ 65,000 * Completed June 2021 Â IND application filing Â Â Â Â Â Â $ 190,000 * Completed December 2021 Â Upon first dosing of patient in a clinical trial Â Â Â Â Â Â $ 500,000 * Completed March 2022 Â Upon completion of first clinical trial Â Â Â Â Â Â $ 1,250,000 Â March 2025 Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â Â $ 10,000,000 Â 8 years from the effective date of the agreement Â Upon FDA new drug application approval *Milestone met and payment made Â ALZN002 License: Â Payment Â Due Date $ 50,000 Â * Completed January 2022 Â Â Â Â $ 50,000 Â Upon first dosing of patient in first Phase I clinical trial Â Â Â Â $ 500,000 Â Upon completion of first Phase IIB clinical trial Â Â Â Â $ 1,000,000 Â Upon first patient treated in a Phase III clinical trial Â Â Â Â $ 10,000,000 Â Upon first commercial sale *Milestone met and payment made Â Additional AL001 Licenses: Â Payment Â Due Date Â Event $ 2,000,000 Â March 2026 Â Â Upon first patient treated in a Phase III clinical trial Â Â Â Â Â Â $ 16,000,000 Â August 1, 2029 Â Â First commercial sale X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 EQUITY TRANSACTIONS 6 Months Ended Oct. 31, 2024 Equity [Abstract] Â EQUITY TRANSACTIONS Â 8.EQUITY TRANSACTIONS Â The Company is authorized to issue 10,000,000 shares of Preferred Stock, $0.0001 par value. The Board has designated 3,000 shares as Series A Convertible Preferred Stock and 6,000 shares as Series B Convertible Preferred Stock. The rights, preferences, privileges and restrictions on the remaining authorized 9,991,000 shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.Â Â Series A Convertible Preferred Stock Â On May 8, 2024, the Company and Orchid entered into a securities purchase agreement (the â€œOrchid SPAâ€) for the purchase of up to 2,500 shares of Series A Convertible Preferred Stock and warrants to purchase shares up to 2,000,000 shares of Common Stock in several tranche closings. Â On May 10, 2024, the Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of Common Stock with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid by the surrender and cancellation of a term note issued by the Company to Orchid of $311,356, consisting of $310,000 of principal and $1,356 of accrued and unpaid interest, $100,000 discount and net cash of $588,644. Â On June 25, 2024, the Company sold 150 shares of Series A Convertible Preferred Stock and warrants to purchase 120,000 shares of Common Stock with an exercise price of $12.50, for a total purchase price of $1.5 million. The purchase price was paid in cash. Â On August 19, 2024, the Company sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase 160,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $2.0 million. The purchase price was paid in cash. Â On August 21, 2024, the Company sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase 200,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $2.5 million less $100,000 discount. The purchase price was paid in cash. Â On September 11, 2024, the Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $1.0 million. The purchase price was paid in cash. Â The Series A Convertible Preferred Stock has a stated value of $1,000 per share and holders of the Series A Convertible Preferred Stock are entitled to cumulative cash dividends at an annual rate of 15%, or $1,500.00 per share (â€œDividend Amountâ€), based on the stated value per share. Notwithstanding the foregoing, for as long as any share(s) of Series A Preferred Stock shall remain outstanding, the Dividend Amount shall be paid either in shares of Series A Preferred Stock or cash, at Orchidâ€™s discretion, in each case equal to the Dividend Amount. Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock cased on the conversion price (â€œSeries A Conversion Priceâ€), which is defined as (a) the state value of the Series A Preferred Stock being converted pus all accrued but unpaid dividends, divided by (b) the greater of (i) $2.50 per share (â€œFloor Priceâ€), and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of the Common Stock during the three trading days immediately prior to the date of the conversion. The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, but not below the Floor Price. The Floor Price shall, however, be adjusted for stock splits, stock dividends, combinations or similar transactions. The holders of the Series A Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series A Convertible Preferred Stock is entitled to cast, shall not be lower than $5.63 (the â€œVoting Floor Priceâ€), which represents the closing sale price of the Common Stock on the trading day immediately prior to the execution date of the Orchid SPA. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event, the holders of Series A Convertible Preferred Stock receive a liquidation preference ahead of holders of Common Stock. Â Series B Convertible Preferred Stock Â On January 31, 2024, the Company and Ault Lending, LLC (â€œAult Lendingâ€) entered into a securities purchase agreement (the â€œAL SPAâ€) for the purchase of up to 6,000 shares of Series B Convertible Preferred Stock and warrants to purchase shares up to 600,000 shares of the Companyâ€™s Common Stock. The AL SPA provides that Ault Lending may purchase up to $6 million of Series B Convertible Preferred Stock in one or more closings. Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the â€œTermination Dateâ€). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination Date. Â On January 31, 2024, the Company sold 1,220 shares of Series B Convertible Preferred Stock and warrants to purchase 122,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $1.22 million. The purchase price was paid by the cancellation of $1.15 million of cash advances made by Ault Lending to the Company between November 9, 2023 and January 31, 2024 and a subscription receivable of $70,000. Â On March 26, 2024, the Company sold 780 shares of Series B Convertible Preferred Stock and warrants to purchase 78,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $780,000. Â On April 29, 2024, the Company sold 100 shares of Series B Convertible Preferred Stock and warrants to purchase 10,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $100,000. Â The Series B Convertible Preferred Stock has a stated value of $1,000 per share (â€œStated Valueâ€) and does not accrue dividends. Each share of Series B Convertible Preferred Stock is convertible into a number of shares of Common Stock determined by dividing the Stated Value by $10.00 (the â€œConversion Priceâ€). The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series B Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Company Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to cast, shall not be lower than $8.73 (the â€œVoting Floor Priceâ€), which represents the closing sale price of the Common Stock on the trading day immediately prior to the Execution Date. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series B Convertible Preferred Stock receive a liquidation preference ahead of holders of Common Stock. Â The warrants have an exercise price of $12.00 (the â€œExercise Priceâ€) and become exercisable on the first business day after the six-month anniversary of issuance (the â€œInitial Exercise Dateâ€) and have a five-year term, expiring on the fifth anniversary of the Initial Exercise Date. The Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. Â Common Stock Â At-the-Market Offering Â On October 3, 2024, the Company entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the â€œATM Offeringâ€), as sales agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the ATM Offering. On October 3, 2024, the Company filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately $6.5 million in shares of Common Stock in the ATM Offering. Â The offer and sale of the shares will be made pursuant to the Companyâ€™s effective â€œshelfâ€ registration statement on FormÂ S-3 and an accompanying base prospectus contained therein (Registration Statement No.Â 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. Â During the six months ended October 31, 2024, the Company sold an aggregate of 755,888 shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $1.2 million. Â Orchid SPA Â During the three months ended October 31, 2024, Orchid converted 649.5363 shares of Series A Convertible Preferred Stock into 3,613,951 shares of Common Stock. During the six months ended October 31, 2024, Orchid converted 712.0133 shares of Series A Convertible Preferred Stock into 3,787,284 shares of Common Stock. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 RELATED PARTY TRANSACTIONS 6 Months Ended Oct. 31, 2024 Related Party Transactions [Abstract] Â RELATED PARTY TRANSACTIONS Â 9.RELATED PARTY TRANSACTIONS Â In connection with the Orchid SPA, the Company agreed to pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. During the three and six months ended October 31, 2024, origination fees due to Ault Lending were $275,000 and $400,000, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS 6 Months Ended Oct. 31, 2024 Subsequent Events [Abstract] Â SUBSEQUENT EVENTS Â 10.SUBSEQUENT EVENTS Â From November 1, 2024 to December 10, 2024, the Company sold an aggregate of 201,543 shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $280,000. Â Management has evaluated events through the date the financial statement were available to be issued and determined that there have been no other events that occurred that would require adjustment to our disclosures in the condensed financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 SIGNIFICANT ACCOUNTING POLICIES (Policies) 6 Months Ended Oct. 31, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of Presentation Â The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and the rules of the Securities and Exchange Commission (â€œSECâ€) applicable to interim reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Companyâ€™s Report on Form 10-K for the year ended April 30, 2024, filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Companyâ€™s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K. Â Accounting Estimates Accounting Estimates Â The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Companyâ€™s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates. Â Cash and Cash Equivalents Cash and Cash Equivalents Â The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024 and AprilÂ 30, 2024, the Company had no cash equivalents. Â Fair Value of Financial Instruments Fair Value of Financial Instruments Â Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Â Level 1: Quoted prices in active markets for identical assets or liabilities. Â Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Â Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. Â The fair values of warrants are determined using the Black-Scholes valuation model, a â€œLevel 3â€ fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrantsâ€™ contractual life. Â Property and Equipment, Net Property and Equipment, Net Â Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of 5 five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred. Â Research and Development Expenses Research and Development Expenses Â Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company. Â The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses, provided that there is no alternative future use of the rights in other research and development projects. Â Stock-Based Compensation Stock-Based Compensation Â The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Companyâ€™s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Â The Company recognizes stock-based compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Companyâ€™s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock. Â The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Companyâ€™s stock-based compensation could be materially different. Â Warrants Warrants Â The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480,Â Distinguishing Liabilities from Equity and FASB ASC 815,Â Derivatives and Hedging (â€œASC 815â€),Â depending on the specific terms of the warrant agreement. Â Based on the terms of the Companyâ€™s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815. Â Loss per Common Share Loss per Common Share Â The Company utilizes FASB ASC 260,Â Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Â Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. Â The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share: Schedule of antidilutive securities excluded from computation of earnings per shareÂ Â Â Â Â Â Â Â Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Stock options (1)Â Â 116,999Â Â Â 121,054Â Restricted stock unitsÂ Â 84Â Â Â 250Â WarrantsÂ Â 873,450Â Â Â 67,665Â Â Â Â 990,533Â Â Â 188,969Â Â (1)The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14. Â Recent Accounting Standards Recent Accounting Standards Â From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Companyâ€™s financial position or results of operations upon adoption. Â Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its condensed financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ExtendedProductWarrantyPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 SIGNIFICANT ACCOUNTING POLICIES (Tables) 6 Months Ended Oct. 31, 2024 Accounting Policies [Abstract] Â Schedule of antidilutive securities excluded from computation of earnings per share Schedule of antidilutive securities excluded from computation of earnings per shareÂ Â Â Â Â Â Â Â Â Â For the Six Months Ended October 31,Â Â Â 2024Â Â 2023Â Stock options (1)Â Â 116,999Â Â Â 121,054Â Restricted stock unitsÂ Â 84Â Â Â 250Â WarrantsÂ Â 873,450Â Â Â 67,665Â Â Â Â 990,533Â Â Â 188,969Â Â (1)The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) 6 Months Ended Oct. 31, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Schedule of prepaid expenses and other current assets Schedule of prepaid expenses and other current assetsÂ Â Â Â Â Â Â Â Â Â October 31, 2024Â Â April 30, 2024Â Prepaid clinical trial expensesÂ $490,911Â Â $-Â Prepaid insuranceÂ Â 163,332Â Â Â 60,523Â Other prepaid expensesÂ Â 19,426Â Â Â 18,671Â Total prepaid expenses and other current assetsÂ $673,669Â Â $79,194Â X - ReferencesNo definition available. + Details Name: alzm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock Namespace Prefix: alzm_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Tables) 6 Months Ended Oct. 31, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of share-based payment arrangement, option, activity Schedule of share-based payment arrangement, option, activityÂ Â Â Â Â Â Â Â Â Â

http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit) not available for dividend distribution. Includes, but is not limited to, retained earnings appropriated for specific business purpose. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-4 + Details Name: us-gaap_RetainedEarningsAppropriated Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock. + ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityBeforeTreasuryStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 SIGNIFICANT ACCOUNTING POLICIES (Details) - shares 6 Months Ended Oct. 31, 2024 Oct. 31, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of earnings per share, amount 990,533 188,969 Equity Option [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of earnings per share, amount [1] 116,999 121,054 Restricted Stock Units (RSUs) [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of earnings per share, amount 84 250 Warrant [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of earnings per share, amount 873,450 67,665 [1] The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14. X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) Oct. 31, 2024 Apr. 30, 2024 Accounting Policies [Abstract] Â Â Cash equivalents $ 0 $ 0 Property and equipment estimated useful life 5 years Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) Oct. 31, 2024 Apr. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Â Prepaid clinical trial expenses $ 490,911 Prepaid insurance 163,332 60,523 Other prepaid expenses 19,426 18,671 Total prepaid expenses and other current assets $ 673,669 $ 79,194 X - ReferencesNo definition available. + Details Name: alzm_PrepaidClinicalTrialExpenses Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. + ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) - USD ($) Oct. 22, 2024 Jun. 14, 2024 Directors and Officers Liability Insurance [Member] Â Â Insurance purchased Â $ 227,000 A L001 License [Member] Â Â Prepaid clinical trial fees $ 514,000 Â X - ReferencesNo definition available. + Details Name: alzm_InsurancePurchased Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: alzm_PrepaidClinicalTrialFees Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_TitleOfIndividualAxis=us-gaap_DirectorsAndOfficersLiabilityInsuranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=alzm_AL001LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Details) 6 Months Ended Oct. 31, 2024 USD ($) $ / shares shares Share-Based Payment Arrangement [Abstract] Â Shares available for grant begining (in shares) 62,000 Number of shares begining (in shares) 98,000 Weighted average exercise price begining (in dollars per share) | $ / shares $ 178.12 Weighted average remaining contractual life begining (years) 5 years 2 months 19 days Aggregate intrinsic value begining | $ $ 70,500 Shares available for grant, Options granted Number of shares, Options granted Weighted average exercise price, Options granted | $ / shares Shares available for grant, Options exercised Number of shares, Options exercised Weighted average exercise price, Options exercised | $ / shares Shares available for grant, Options expired 3,333 Number of shares, Options expired (3,333) Weighted average exercise price, Options expired | $ / shares $ 150.00 Shares available for grant end (in shares) 65,333 Number of shares end (in shares) 94,667 Weighted average exercise price end (in dollars per share) | $ / shares $ 179.11 Weighted average remaining contractual life end (years) 4 years 10 months 24 days Aggregate intrinsic value end | $ $ 15,100 Number of shares, Options vested and expected to vest at end 88,001 Weighted average exercise price, Options vested and expected to vest at end | $ / shares $ 179.39 Weighted average remaining contractual life, Options vested and expected to vest at end 4 years 7 months 24 days Aggregate intrinsic value, Options vested and expected to vest at end | $ $ 15,100 Number of shares, Options exercisable at end 87,043 Weighted average exercise price, Options exercisable at end | $ / shares $ 178.87 Weighted average remaining contractual life, Options exercisable at end 4 years 7 months 17 days Aggregate intrinsic value, Options exercisable at end | $ $ 15,100 X - DefinitionThe element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term. + ReferencesNo definition available. + Details Name: alzm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm Namespace Prefix: alzm_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_SharesAvailableForGrantOptionsExercised Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_SharesAvailableForGrantOptionsExpired Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_SharesAvailableForGrantOptionsGranted Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-option equity instruments exercised by participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Details 1) 6 Months Ended Oct. 31, 2024 $ / shares shares Share-Based Payment Arrangement [Abstract] Â Unvested shares, Beginning balance | shares 167 Unvested Weighted Average Grant Date Fair Value, Beginning balance | $ / shares $ 375.00 Unvested shares, Granted | shares Unvested Weighted Average Grant Date Fair Value, Granted | $ / shares Unvested shares, Vested | shares 83 Unvested Weighted Average Grant Date Fair Value, Vested | $ / shares $ 375.00 Unvested shares, Cancelled | shares Unvested Weighted Average Grant Date Fair Value, Cancelled | $ / shares Unvested shares, Ending balance | shares 84 Unvested Weighted Average Grant Date Fair Value, Ending balance | $ / shares $ 375.00 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Details 2) - USD ($) 3 Months Ended 6 Months Ended Oct. 31, 2024 Oct. 31, 2023 Oct. 31, 2024 Oct. 31, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Total $ 81,277 $ 175,733 $ 162,554 $ 687,716 Research and Development Expense [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Total 142,603 General and Administrative Expense [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Total $ 81,277 $ 175,733 $ 162,554 $ 545,113 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Details Narrative) - USD ($) 6 Months Ended Nov. 26, 2019 Mar. 01, 2019 Apr. 30, 2016 Oct. 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Options granted Â Â Â Unamortized Stock Based Compensation [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Unamortized stock-based compensation expense related to unvested employee and non-employee awards Â Â Â $ 284,000 Stock Based Compensation [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Weighted-average period Â Â Â 10 months 24 days Perfromance Contingent Stock Options [Member] | Key Employees and Director [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Options granted 28,333 Â Â Â Terms of award In the event any of the stock price milestones are not achieved within three years Â Â Â Stock Incentive Plan2016 [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation arrangement by share-based payment award, number of shares authorized Â Â 83,333 Â Share-based compensation arrangement by share-based payment award, number of additional shares authorized Â 50,000 Â Â Stock Incentive Plan2016 [Member] | Maximum [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation arrangement by share-based payment award, expiration period Â Â 10 years Â X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable

information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms of award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=alzm_UnamortizedStockBasedCompensationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=alzm_StockBasedCompensationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=alzm_PerformanceContingentStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alzm_KeyEmployeesAndDirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=alzm_StockIncentivePlan2016Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 WARRANTS (Details) 6 Months Ended Oct. 31, 2024 $ / shares shares Guarantees and Product Warranties [Abstract] Â Class of warrant or right, outstanding, beginning | shares 240,449 Weighted average exercise price, beginning | $ / shares $ 67.45 Class of warrant or right, outstanding, granted | shares 640,000 Weighted average exercise price, granted | $ / shares $ 12.50 Class of warrant or right, outstanding, cancelled/expired | shares (6,999) Weighted average exercise price, cancelled/expired | $ / shares $ 320.28 Class of warrant or right, outstanding, ending | shares 873,450 Weighted average exercise price, ending | $ / shares $ 24.35 X - ReferencesNo definition available. + Details Name: alzm_ClassOfWarrantOrRightOutstandingCancelledexpired Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_ClassOfWarrantOrRightOutstandingGranted Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_WeightedAverageExercisePriceCancelledexpired Namespace Prefix: alzm_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_WeightedAverageExercisesPriceGranted Namespace Prefix: alzm_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GuaranteesAndProductWarrantiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 WARRANTS (Details 1) - $ / shares Oct. 31, 2024 Apr. 30, 2024 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) $ 24.35 $ 67.45 Class of Warrant or Right, Outstanding 873,450 240,449 $12.00 [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Class of Warrant or Right, Outstanding 850,000 Â Weighted average remaining contractual life (years) 4 years 8 months 12 days Â Warrant outstanding, weighted average exercise price (in dollars per share) $ 12.38 Â Number of warrant exercisable 850,000 Â Warrant exercisable, weighted average exercise price (in dollars per share) $ 12.38 Â $12.00 [Member] | Minimum [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) 12.00 Â $12.00 [Member] | Maximum [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) 12.50 Â $450.00 [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) $ 450.00 Â Class of Warrant or Right, Outstanding 23,042 Â Weighted average remaining contractual life (years) 1 year 9 months 18 days Â Warrant outstanding, weighted average exercise price (in dollars per share) $ 450.00 Â Number of warrant exercisable 23,042 Â Warrant exercisable, weighted average exercise price (in dollars per share) $ 450.00 Â $937.50 [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) $ 937.50 Â Class of Warrant or Right, Outstanding 408 Â Weighted average remaining contractual life (years) 1 year 7 months 6 days Â Warrant outstanding, weighted average exercise price (in dollars per share) $ 937.50 Â Number of warrant exercisable 408 Â Warrant exercisable, weighted average exercise price (in dollars per share) $ 937.50 Â $12.00 - $937.50 [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Class of Warrant or Right, Outstanding 873,450 Â Weighted average remaining contractual life (years) 4 years 8 months 12 days Â Warrant outstanding, weighted average exercise price (in dollars per share) $ 24.35 Â Number of warrant exercisable 873,450 Â Warrant exercisable, weighted average exercise price (in dollars per share) $ 24.35 Â $12.00 - $937.50 [Member] | Minimum [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) 12.00 Â $12.00 - $937.50 [Member] | Maximum [Member] Â Â Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Â Â Exercse price (in dollars per share) $ 937.50 Â X - ReferencesNo definition available. + Details Name: alzm_NumberOfWarrantExercisable Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: alzm_WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare Namespace Prefix: alzm_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: alzm_WarrantOutstandingWeightedAverageExercisePrice Namespace Prefix: alzm_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alzm_ExercisePrice1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alzm_ExercisePrice3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alzm_ExercisePrice4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alzm_ExercisePrice5Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 WARRANTS (Details Narrative) - USD ($) 1 Months Ended 6 Months Ended Sep. 11, 2024 Dec. 10, 2024 Aug. 21, 2024 Aug. 19, 2024 Oct. 31, 2024 Apr. 30, 2024 Exercise price (in dollars per share) Â Â Â Â $ 24.35 $ 67.45 Value of common stock sold Â $ 280,000 Â Â $ 1,200,000 Â Warrant 2024 [Member] Â Â Â Â Â Â Aggregate number of stock repurchase 80,000 Â 200,000 160,000 440,000 Â Exercise price (in dollars per share) $ 12.50 Â $ 12.50 $ 12.50 $ 12.50 Â Value of common stock sold $ 1,000,000 Â $ 2,500,000 $ 2,000,000 Â Â Fair value of warrant $ 69,000 Â $ 486,000 $ 571,000 Â Â X - DefinitionThe element represents aggregate number of stock repurchase. + ReferencesNo definition available. + Details Name: alzm_AggregateNumberOfStockRepurchase Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-

types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=alzm_Warrant2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Details) 6 Months Ended Oct. 31, 2024 USD ($) Pre Ind Meeting [Member] | A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 50,000 Due date Completed September 2019 [1] Ind Application Filing [Member] | A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 65,000 Due date Completed June 2021 [1] Upon First Dosing of Patient in Clinical Trial [Member] | A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 190,000 Due date Completed December 2021 [1] Upon Completion of First Clinical Trial [Member] | A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 500,000 Due date Completed March 2022 [1] Upon First Patient Treated In A Phase III Clinical [Member] | A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 1,250,000 Due date March 2025 Upon First Patient Treated In A Phase III Clinical [Member] | Additional A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 2,000,000 Due date March 2026 Upon Fda Approval [Member] | A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 10,000,000 Due date 8 years from the effective date of the agreement Upon IND Application Filing [Member] | ALZN002 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 50,000 Due date Completed January 2022 [2] Upon First Dosing Of Patient In First Phase I Clinical Trial [Member] | ALZN002 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 50,000 Due date Upon first dosing of patient in first Phase I clinical trial Upon Completion Of First Phase II Clinical Trial [Member] | ALZN002 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 500,000 Due date Upon completion of first Phase IIB clinical trial Upon First Patient Treated In Phase III Clinical Trial [Member] | ALZN002 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 1,000,000 Due date Upon first patient treated in a Phase III clinical trial Upon FDA BLA Approval [Member] | ALZN002 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 10,000,000 Due date Upon first commercial sale First Commercial Sale [Member] | Additional A L001 License [Member] Â Product Liability Contingency [Line Items] Â Payment $ 16,000,000 Due date August 1, 2029 [1] Milestone met and payment made [2] Milestone met and payment made X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the nature and terms of commitment. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_ProductLiabilityContingencyLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: alzm_LicenseEventsAxis=alzm_PreIndMeetingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=alzm_AL001LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_IndApplicationFilingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponFirstDosingOfPatientInClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponCompletionOfFirstClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponFirstPatientTreatedInAPhaseIIIClinicalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=alzm_AdditionalAL001LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponFdaApprovalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponINDApplicationFilingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=alzm_ALZN002LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponCompletionOfFirstPhaseIIClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_UponFDABLAApprovalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: alzm_LicenseEventsAxis=alzm_FirstCommercialSaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) 1 Months Ended Jul. 02, 2018 May 02, 2016 Nov. 19, 2019 A L001 License [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Percentage of royalty payments on net sales of product 4.50% Â Â Description of licenses agreements The Company has already paid an initial license fee of $200,000Â for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor receivedÂ 14,853 shares of Common Stock. Minimum royalties for AL001 License Agreements are $40,000Â on the first anniversary of the first commercial sale, $80,000Â on the second anniversary of the first commercial sale and $100,000Â on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. Â Â Initial license fees $ 200,000 Â Â A L001 License [Member] | First Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties 40,000 Â Â A L001 License [Member] | Second Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties 80,000 Â Â A L001 License [Member] | Third Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties $ 100,000 Â Â ALZN002 License [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Percentage of royalty payments on net sales of product Â 4.00% Â Description of licenses agreements Â The Company has already paid an initial license fee of $200,000Â for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor receivedÂ 24,012 shares of Common Stock. Minimum royalties for ALZN002 are $20,000Â on the first anniversary of the first commercial sale, $40,000Â on the second anniversary of the first commercial sale and $50,000Â on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. Â Initial license fees Â $ 200,000 Â ALZN002 License [Member] | First Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties Â 20,000 Â ALZN002 License [Member] | Second Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties Â 40,000 Â ALZN002 License [Member] | Third Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties Â $ 50,000 Â Additional A L001 License [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Percentage of royalty payments on net sales of product Â Â 3.00% Initial license fees Â Â $ 20,000 Additional A L001 License [Member] | First Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties Â Â 40,000 Additional A L001 License [Member] | Second Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties Â Â 80,000 Additional A L001 License [Member] | Third Anniversary [Member] Â Â Â Product Liability Contingency [Line Items] Â Â Â Payments for royalties Â Â $ 100,000 X - DefinitionThe element represents description of licenses agreements. + ReferencesNo definition available. + Details Name: alzm_DescriptionOfLicensesAgreements Namespace Prefix: alzm_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of initial license fees. + ReferencesNo definition available. + Details Name: alzm_InitialLicenseFees Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe element represents percentage of royalty payments on net sales of product.. + ReferencesNo definition available. + Details Name: alzm_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct. Namespace Prefix: alzm_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of cash paid for royalties during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_ProductLiabilityContingencyLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=alzm_AL001LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis=alzm_FirstAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis=alzm_SecondAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis=alzm_ThirdAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=alzm_ALZN002LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=alzm_AdditionalAL001LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 EQUITY TRANSACTIONS (Details Narrative) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Sep. 11, 2024 May 10, 2024 May 08, 2024 Dec. 10, 2024 Aug. 21, 2024 Aug. 19, 2024 Jun. 25, 2024 Apr. 29, 2024 Mar. 26, 2024 Jan. 31, 2024 Oct. 31, 2024 Oct. 31, 2024 Apr. 30, 2024 Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock, shares authorized Â Â Â Â Â Â Â Â Â Â Â Â Â 10,000,000 10,000,000 Â Preferred stock, par value (in dollars per share) Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0.0001 $ 0.0001 $ 0.0001 Exercise price Â Â Â Â Â Â Â Â Â Â Â Â Â $ 24.35 $ 24.35 67.45 Value of common stock sold Â Â Â $ 280,000 Â Â Â Â Â Â Â Â $ 1,200,000 Â Number of common stock sold Â Â Â 201,543 Â Â Â Â Â Â Â 755,888 Â Converted shares Â Â Â Â Â Â Â Â Â Â 649.5363 712.0133 Â Number of shares issued Â Â Â Â Â Â Â Â Â Â 3,613,951 3,787,284 Â Warrant 2024 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares purchase 80,000 Â Â Â 200,000 160,000 Â Â Â Â Â Â Â Â Exercise price $ 12.50 Â Â Â Â $ 12.50 $ 12.50 Â Â Â $ 12.50 $ 12.50 Â Value of common stock sold $ 1,000,000 Â Â Â $ 2,500,000 $ 2,000,000 Â Â Â Â Â Â Â Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of common stock sold Â Â Â Â Â Â Â 10,000 78,000 122,000 Â Â Â Securities Purchase Agreements [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Principal issued Â $ 311,356 Â Â Â Â Â Â Â Â Â Â Â Â Principal amount Â 310,000 Â Â Â Â Â Â Â Â Â Â Â Â Accrued interest Â 1,356 Â Â Â Â Â Â Â Â Â Â Â Â Discount Â 100,000 Â Â Â Â Â Â Â Â Â Â Â Net cash Â $ 588,644 Â Â Â Â Â Â Â Â Â Â Securities Purchase Agreements [Member] | Series B Convertible Preferred Stock [Member] | Ault Lending [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares purchase Â Â Â Â Â Â Â Â Â Â 600,000 Â Â Â Termination loans description Â Â Â Â Â Â Â Â Â Â Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the â€œTermination Dateâ€). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination Date. Â Â Â Series A Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock, shares authorized Â Â Â Â Â Â Â Â Â Â 9,991,000 9,991,000 Â Preferred stock, par value (in dollars per share) Â Â Â Â Â Â Â Â Â Â $ 0.0001 $ 0.0001 $ 0.0001 Preferred stock shares designated Â Â Â Â Â Â Â Â Â Â 3,000 3,000 3,000 Series A Preferred Stock [Member] | Securities Purchase Agreements [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares purchase Â Â 2,500 Â Â Â Â Â Â Â Â Â Â Â Â Â Series B Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock, par value (in dollars per share) Â Â Â Â Â Â Â Â Â Â $ 0.0001 $ 0.0001 $ 0.0001 Preferred stock shares designated Â Â Â Â Â Â Â Â Â Â 6,000 6,000 6,000 Exercise price Â Â Â Â Â Â Â $ 12.00 $ 12.00 $ 12.00 Â Â Â Shares purchase price Â Â Â Â Â Â Â Â $ 100,000 $ 780,000 $ 1,220,000 Â Â Â Number of common stock sold Â Â Â Â Â Â Â 100 780 1,220 Â Â Â Cancellations of cash advances Â Â Â Â Â Â Â Â Â $ 1,150,000 Â Â Â Subscription receivable Â Â Â Â Â Â Â Â Â $ 70,000 Â Â Â Common Stock [Member] | Securities Purchase Agreements [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares purchase Â 80,000 Â Â Â Â 120,000 Â Â Â Â Â Â Exercise price Â $ 12.50 Â Â Â Â $ 12.50 Â Â Â Â Â Â Shares purchase price Â $ 1,000,000.0 Â Â Â Â $ 1,500,000 Â Â Â Â Â Â X - ReferencesNo definition available. + Details Name: alzm_CancellationsOfCashAdvances Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_NetCash Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe element represents number of shares purchase. + ReferencesNo definition available. + Details Name: alzm_NumberOfSharesPurchase Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: alzm_PreferredStockSharesDesignated Namespace Prefix: alzm_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe element represents shares purchase price. + ReferencesNo definition available. + Details Name: alzm_SharesPurchasePrice Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of principal of debt issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentIssuedPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDiscount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.4-07) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-2 + Details Name: us-gaap_PreferredStockDiscountOnShares Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNote received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2 + Details Name: us-gaap_StockholdersEquityNoteSubscriptionsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGeneral description of liabilities to third parties under a termination loan agreement, whether or not guaranteed by the government, including a cross reference to the related termination claim or claims recorded or disclosed at the latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 912 -SubTopic 405 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478788/912-405-45-4 + Details Name: us-gaap_TerminationLoansDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=alzm_Warrant2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=alzm_SecuritiesPurchaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=alzm_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=alzm_AultLendingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Oct. 31, 2024 Oct. 31, 2024 Related Party Transactions [Abstract] Â Â Origination fees $ 275,000 $ 400,000 X - ReferencesNo definition available. + Details Name: alzm_OriginationFees Namespace Prefix: alzm_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS (Details Narrative) - USD ($) 1 Months Ended 6 Months Ended Dec. 10, 2024 Oct. 31, 2024 Subsequent Events [Abstract] Â Â Number of common stock sold 201,543 755,888 Value of common stock sold $ 280,000 $ 1,200,000 X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

MB%2WXL'*,T%)5#HEL84A]*R$L+35ZY;?W8A>EQO[AE#U.IO[!ZW8P\T!&5=]F-4'=6A1*QA*8YXRD0='+:ZJ/C ;:U0VGQ MD]%9OG(-
="CWG#_JFV%TVH*:$8UI*#4$41]/=$#C6",I'K\6H*WJF=IQ]?H5 M_5L9O KFGN1TP._6"2GIZU."T1T0HI8WO+9=[H(R-5X(8_S\C^8+6QA"X1% M+GFR<%8,$I;./\GS(A$K#LC9XH
7#GA7!WOA4&;.FC,KPSHGDO2Z@L^ T-8* M35^4N2F]530LUO2WP);"]6N0K6;T'L#DD]- -RV#\; M7@['PPLCRP-;B#:IX@\;5Z(*@27LPPVDK_BDKX2-XZJ1G=S9H%Q M:,%:"+8J2K2EQZ"5:8QVV
PKQ=8& 7YQ._KRJ8.1?P(N?K\;CO\$!^<7WX:#X=BL'/8Z: >%MIZ$ MY;1%;QO\$!^<7WX:#X=BL'%CZVP6=X!"%$JA@%>")Q08^5BH%M./\#^90(/?L*.>6" M_4.C$^""VL9)):N7*'>=U `80!"-
^+,_U[BLG92%SJ2Y8^J#F). 3H 06OU?3 M\U5CE69*-K&XTDUMI?SC):".7XQKH1=;[)X4Q 8C+QM6W8!U"S'NA'2F,J M/4]BH'7!(4M!2#(F26SD:5 $'G8\3>G@<'210[VD+MMCRZ% &I6 JI%%DD1
M$R6-]0L#"YEQJ*+ZA#]T/0=!:-^ M[;LX\&KYKAL>8C=P4,?=$L%2'Z!=!,)*3P3]J_.&B(QQ["HB#(9-,@(M=01J M'-N]$15J;((^4 IX0I72CG80]H:V ?BXE"FZ6*!NKWP8_]70POHCN2ZSL
6@]V*6:P6YB"F$X4,CWPU*<3\]'!^(WE6GK;=&PO M=V]R:W-H965T&ULM9?1;ILP%(9?Q6+3U$I=P"0A29=$:C-- MVT6UJ%&WBVD7+IP$JV SVTFZ/?UL(0:"DG7Y2)@..?X^PV'7QYON7B0(8!"
MCW'$Y,0*E4HN;5OZ(<1$=G@"3-]9CA.R@@6HNV0N],@N MJ@0T!B8I9TC OO*A5S&D2R^>[ZI]2\5K,/9$PX]%W&JAP8@TM%,"2K"-UR[>7 M(1?4-_5\'LGT'VVS6,^SD+^6BL=YLB:
(*]2G:>F,\X" 5 @0-=3 M7=3NL},^=57'=3%%\AUW%Y-^JPY_2H1.MVI2[>U^&(%W&(%W+1>[YEZ<_W> M@!!Z!?1B^P\7*"$;4BT!G1&&0IX%!$A40(B4WQ>ISB;8I!.83IG,W4ZCN(@
ML;TI*VL-JRCH%@ZJCO1F/(YU1_P#?ORX,/?IQ _$] MB))UR(TEC2%>RH3X,+&TXTD0&["F[]Y@S_E0]Q5ZI6(5]<-"_?# _?Y.&QS5U M:UA%P:A0,#I%P>Z="T#2%2.JODE&MM>&M'YP6')9#A
MH#,:>H,GP'E@F?@YW))KXQ?AMO1T7O4(9GPT\]YG<;/1YBU]?5)+-]<\M:=? MJUIU!?8^C9N-^E7:&A]IUNUQ5I5[N\;-?OVBUL:'1NP=]G9;5)5X;]6XV:M? MT-
R'/NSB0]R6J"KNWJQoLUM_M+D/G;B.NZ24J8]9+.PJSG;LA8D691!$L=9K3 M&>A\D>V0LH'B2;K)N.=*;UG2TU#O*D&8 'U_R;G:#&PO=V]R:W-H965T&ULK5CO<^(V$/U7-+33N9O)8"
[9"8)&4BN_>I@ 9ZS+6H)2/_[M2K8Q8"\N[9$/"39OW_H]K5<;]78L^\%7E KTD<0I[W=60JQO-8W/5S0)>)>M M:2J_6; L"82\S)8:7VU)(C2SJ"7WWO)!CVV$7&4TI<,\4V2 M!-G?
=S1FNWX'=_8WIM%R)=0-;=!;!TLZH^)M_9+)*ZUB":.$ICQB* TY'+/XC"L6JWW$[**2+8!.+*=O=TU*0I?CF+.;Y M;[0KL);30?,-%RPI@^43)%%:_T^2B.. B0/'&"4 48]P#P30,H ;HG7I.I*NK&7?
F>T$D[FHHL(OD&& M;IC \XPN#R>0G)_+[O_O["=FD*H.2,Y'SO&]^-/AZ\'S-^3 ^>(_S PJM%,(% MAPESJ)YVR]?!G/8[LFEQFFUI9_#;+]C6?X?LO2;9^)ID_I7(3A;"K!;";&,? M3"5CD,U7*$A#V?
&VLI6OuL5)+4?!9.=,:D?8#@C&NNOVM.VQT4T8]CS;<\4YC=A)K$-S] KW(EPJQ)NM0K_1E/9J2F:0S0N;KA8K.FO8DS=-MTB %KMROM=JOV5R:D M;CTHL5[?KJ[$&9Z.'<.H20=PQ-
"EIIKT)LXV#5D> M9Z0[E72G5?HCXQPM,I;LYOV7.O23:^)IE_);*3A?"JA?!::_ A%52RBOU[!RV#URP" M8GI6K?@ E"E[Q=5+? M4$$D(9;GU/<5"&FA#B>=T:T<1!MM(H>1]M(COBA'.M3)%^>!
[S59#! M&TS)=_(L%&M7/>A-2_\RB)P[KLH7^%A*<>'H9CW#KR586#AM^'M*#X_#NT4X<9 M%;\.(RMN'UN'4?Q1OYO_!_=L"YR T!!;@ PR T =JD;AT$6 MMT^R167L\O,9:4JPE3/=DI[X(1O11G
AYWPYZH+F-$=-8A'LZ$;=\'V FE?W: M<>L& 3,NMDS';E@$$QKDC"V'(1>W3[G[(OE)8YJ3Z!ECFD#8F";NC#$P8<,8 M[>@D*J'9,C\"Y%+E)A7%841UMSIF'.:'[7[=_AVA('[8W4LF9]\'>B+,\VG
M(%M&*4M>1#YL5QX3%A6#K_!SLG0G!DOSCB@8AS11 ?K]@3.PO5(+J ML';P#U!+ P04 " #.@XM93*N6H-P+ #6=P & 'AL+W=OOUA/*[F3WR55N^+-
<_%7QZ*I5D^NKW>_NYS>7M=;.IEEO//I55M5JNT_/Z)+XN7FQ$9_?C%E^SQJ6Y^ M,;Z]7J>/_([77]>?2W%K?* LLA7/JZS(K9(_W(P^D@^)2YL)VQ'_ROA+=?2S MU=R5^Z+XUMSX97$SLIL5\26?
UPTB%?\]\RE?+AN26,?O>^CH$+.9>/SS#WJT MO?/BSMRG%9\6RW]GB_KI9A2,K 5_2#?+^DOQDO#]'7(;WKQ85MM_K9?=6-\? M6?--51>K_62Q@E66[_Y/_]@_$$<3F'=B MU/H)=.
MQ*UB_NVI6"YX6?W5>C/C#]D\]J]:X>^;K/YNO?F:IYM%5O/%6^O*^GHWL|[\ M^>WUN!8K:KCC^3[ZIUUT>B+Z'2\S7ED?+;&,9U[6V?V26Y^%>GE9;I^NN?E?S7XZ47X3T/Q,S-
^6JQ6XNEW%A.:,1\7XH$4S^-T:7U.L\55EEO3 M=)W5XK8!&IFAOQ4UM[[P><:?T^9>BR>Z):WW"U^* _5Z(D*783T.@V!SH"Z]% MAA2@,"WS+'^L3*S/IG(>ZT/&TL]'P0-3V(FFXY[
3G$W _,\F8Q(JTMTWS. MWUG/Z7+#K;2V/J[+]Y9CO[.H31V=8HWHYJ7D0[5.Y_QF)%XK*EX^\]'M7_Y$ M//MO.GT.@%DZ(>XXWI;3O!P]WWKN]?CY6&2:(>(%C#B3SL!('7A%6! XM#LR
MUHQDS/:IYU%Y9**.=&SFNK9S&"=MI'/82*?O1E9J7BH+MI)([OO3@Z :7=R MQW&/MXEYU LZNXE<>X2$Q4A8 H))XF('<3&CN'ZIJDVCJ>;E;KY+C=4V-8HK
M0FN>5D_OK%Q3XY#Q(B0L1L(2$$S26W#06V#4V]WFOIJ7 MV;K>>6)SGNW>MZ[3[XTGL?\57^BT923WU=8 F#:O@3AAH,CSRK?MSONO2!VE M#HI!2TI>SY$D,CE(9&*62)-
JKAJC7+4F&V*V]:1M% M\YNX&E\6E58'YJE]A3*$IE4"""A2B0!$*%.]!4C;SF./XDTG'4+IDI"R)(\>; M&"41Y@N]-?B/>?W>NB6#?4M5W;8Q[I[J=F*/4"RB8G+$+2FKW$[/9V][-U",JO*-3L'4+3
M;RC5F803S^MN*G+Y$9060VD)BB9+K+6A26\?^I U_KY9GA$9U(<>0M.+S+D@ M:VC<:NKXMN]WBPJ:D:>J"KJAS/=LF]&@FS5T5$*#X%32:+U?8C9_C96%\UL*
M]7N'T/1;JG>VN("=/D1E!9#:0F*)JNL=8O)S[&+M9]#^L1#:'K-@4 A4=UF M79D!%2]&@9*S"Y?%T[J^Y!6V[\!:@SED;Q$A:;,]S5QN@(:,H+082DM0-%E] MK?]+\ :P5G%0YW<(39^V0*
0!8I0H!@%2@ @67RM&4S,;C"Z^F .UUN$2-J, MJ-ZM4H" 1HR@M!A*2U T67BMQ4S.>,RO*$.8T;U%AC*64:"0J!ZMKA2A&::I M1:!6E0! 8X_1N.43YT"A02%4OUR&!XW2=1U3 & 5*SJ<
MUD[K05.S!VTJ2YBG]I8#RF5&@4(4*$*!8JHSIR>V9SN=%^+DDI&R)(YZEOO9 MV)>7)\:O*$N8 MR;TW%.484VWOLEJ6@"X_@M)B*"U!T62)M28V[6UB:S_GP+0B [G.4Q1HM@=)
M"6/2U99J<;N%48^XK)LPH+:T)NZ5RVQJ,[M;M- -I>Z$D<]D5-:/YF: >2+ M/P^AWW&0XSFEJN-)B6W+C\-,\H+_$FWU!\.698A74![B*&T!$63U=,:ROA3 M&,I:+8'Z6ZOO+*I%K,A/A,7$=TDP?
4&$;=Q^3$^BEE)S)+:_?2 M5]B] XL-YI"]+V.@7;]4;?OU73<(NJ52:-0(2HNAM 1%DP786KX4;_EJ10?J M (T8 M06DQE):@:/+'FUL/V3%[R,?"6Q\)AA\56:..UB/YH4 S%"AT5"O6MX/ 8]WW M?
4,B&C[MC+*2+UB_K*'62W;,7O(K-&3*88YJ=0;=]WA3\]+ZR8T\F8+832(B@M MAM(2%$T68.M<.V;G>G>ZRO8T(XT$ZT)Z2=5*#60Y3U&@F:,Y7),/7SFC0F,?* MJ&C(F@S"=W#! "2Y7)TIH?
9&.\E%V.&TG0'^X1V4Q32\9UI8HHMJVG NN+ MGN"!/<(#>X;'SS#!G=8$=\PFN"RGO#GW:)U^WW9M-+7W++*]Y@R)*!!.Z@6[?/+E[736NJ.V5(W]7&8I_:1 \HB1X%"%"@: M
C+H1;7'KZ@33,16=VITEXR4)=$ZZ8[92;^HCT-;GS.#^P@&U26]!QU?!KNT M:Q8YJI7NV>+IQ=1+852+LR;DE>LQ8JL=.YJACN_2R=&'HN2-;AUKQ^Q87];@
MH=]I3<]OT+UN5<=HBJR:46*"".UFYM!\9WI?CT(=9"@M0=%D6;1>LF/VDB_] MK*A>&*"VF'M!\9WI?CT(=9"@M0=%D6;1>LF/VDB_] MK*A>&*"VF'M*--N#CE- T"VK.JJE[(IW1901Y?H =>Z$)N25RR83%I#*M0*Z MH802\2PY<90
:^U;9K9O+_X4J7:SF6H)$B4-: 9ITH!F5. 1Q^F\&0[-]Z=O M%H#28B@M0=%D9;2F++OD MS9CJ62J]%M"($9060VD)BB8+K_5YV>6'<0!Z+?PVR>VD,, M*- ,!0I1H @%BEW-PN
MUL@U@T[4R%'KBC4A3J7(-4.--7*WM;I=Q-G,^1U676.E.*89HRF.:4;I:^3F M.]/W.@)*BZ&T!$7;R6)\]/VCS3?>_IJ6CUE>64O^(/#V>U\\].7N2V1W-^IB MO?U*TONBKHO5]L9;3@]?Y7O[/U!+ P04 "
#. M@XM95+RJ+"?&\;%)27HUFT_K9@YQ-Q487O&(/$JE-65+Y?,* ML;L=X=`^P1?^M-+FP60V7=,G]LCTU_6#A+M)YR7G):L4%Q62;'D[NL,W.AUU[S0# M#Z_WWC_4Y(',@BHV%\6_/-
>KVU$R0CE;TDVAOXC=7ZPE%!I_F2A4_1_M6EMO MA+*-TJ)L!P."DE?-)_W1!N)@ /BQ#R#M 'Z(#@SP&\'^#71!EE-ZSW5=#:5
M8H>DL09OYJ*.33T:V/#*I/%12_B6PS@]FXLJAZ2P'#UJJADD2"LDEFA.U0I] M@"0K].9K13/353E6O.U(TM;(W;P.[6+.,;M:89NQW!.E5,;MEH]MLO M./+^L'&^DK.C" 1=! *7]]EGJ#J%4,I&LAD9U2--
:=G.QL1/THB$T\GVD(#% M, IVT[3SO (7-B!"YWIN5*6<+33*NH)7Y?GXV_(5>,0DM74JH06U@K%W&4Z&1'G*9!$))]62ILA@\" M?7LB\8$FP"_#/X9Z68 \R-&:2OULA>UT>=']B:6GA83N.0JJ!L+-
USQXV,EM!G3<*FWW?\+71(U;6X3 3J0=_IQFSV.$@)LE&Y&M#+M .S6 8/I9LN8%?JPYJNA6^RQ@$:$.)*;2 8]0P$K5&"RE!&?EC#8=$3. X(.144-L/$
M2^(SB>P5!7;VZ0LH0.26##IJ[F"1#@NRER11,&#Q"M'@DG^DUPO$K1>ZM09D MMQQVQVCQ;)VU-GYD* ,2$H&X34[X60P=62*]6B!NM6#0\RJ3S!2V-SEKKMZ: MFF%(63$/>[P?X]@;[
8MAN,@#;PX,.'(+T<(&XY4%<)JM&"/?&J,G$V\XE) M+G(KY&%?J^/("P91'MJ'%./"2\,S^E?0"@+@%P!XP,V+2*778QQ@,0]WXM-]; M#
D4ZO@W_RRJ<3VA+RZ]Y*IM_EK>CNGW;9ZXV_Q<0*^4]4DG.N1 M$@4:^L[LWN"QYD9[7E"XR+"WQYAXV!^'D\17G!<["U8L$XA8)'RB7:$N+35V, M=U1*LS6M*W0C&H!RU1[8[KA>O3X60[&
(S\,DO0T%D[KXA%KSJ(^U3B..F5 MT,RZT>#[PPNX$/MXW+\X'O'@F,S'V]/3S3) @ Q < !@ !X;"]W;W)K-F0]0G*@M5?#G1@@;0OC<"+V&8%-WZ]QMX1*B2#P4?(N$06LUL[#5
MMVQ=KX*9=S)70N\6FJ?B&7E &XEF(.R;8RF@I) IY7(M)VBVWF'3MZ^[I* M!S,4-VV$Q[5P\(0P1M>X&\0'E]=FO\8=P*#O11[&A\"D"X@O^E'0!
M.P1..X!1B/%YO]\"Z[S=O;94@EC9>2!1RM=,U4^U];8CY])VVD?^L3^8^!W^ M1(^H>J+\DZ_GVS41JX))1&&I0WEPGEY[IKBGIFU(;BE6V*"ZYTB[7+7(]9$:@ M]Y>&PO M=V]R:W-
H965T&ULG95=;],P%(;_BF4DKMCRT2]4DDCM %&) M0=4-N$!JF!?Z_MRK".4XB=S:5B:1 M:#2C'+82]::JB'Q> Q-MC -\6-C1HM1VP4NBFA1P! I;O95FY@TN&:V *RHX MDI#'>!4LUPL;
[P*^4VC5T1C93/9"/-C))HNQ;X& 0;JM S&O1[@!QJR1P?C= M>^+A2"L\'A_B_01)/C[MPFJFW!.U M7>PTQ"AME!95+8$%>7=FSSU=3@2&)_3@K 7A(Z[.\A!OB>:))$4+9(VVKC9
M@4O5J0T29)07:"4EX068LFL5>=]<:8..\M'=; M=V[A&;\=3AJ^#75UV@2O$&A'TY'_"9#NA/G M-[D@7?3SLXE&&PV5^G4J]\YZ>MK:WIZEJDD*,3;70X%\)R\?A7, 7&.&^:$*1@!FPU@LU&?+X)?
70 W;OH2 MW'R FU]4M7N0YBZ1,VSCGB^Q+0:VQ<6%&^<;]SW+YQUUB0IDX7JA0JEHN.X: MQK ZM-M5UV7^AG>]^I;(@G*%&.1&ZE\OS.>47?_K)EK4KN?LA38=S U+\\L M:0/,?BZ$/DSL <-
/*/D#4$L#!!0 (,Z#BUDO0PS=V]R:W-H965T&ULU&JO*$?W.7S'0+2Y20)9DV3<) MX@?@1X*ZN(D-*^D%6O3#BAR*6Y.[O+M+*\JO[YGEPW(BNW!,%"A@6'S,SIR9 M.6>6Y(':NCM?, ?
Z6I7&GXR*$.IWTZE/"ZZ4G]B:#>[DUE4JX-2MIKYVK+*X MJ"JG\]GL];12VHQ.C^.U&W=Z;)M0:L,WCGQ35%+?>-P-AV\9+IBX[4UY#@_&9WMOSL_%/MH\!?-:[]U3+)TMH[M.;G*3D8S
<0EIT$*/S<\P67I3@"C-\[GZ,AI"SE\GQAR]]T M%HJ3T=L199RKI@RW=OTG[O+Y1?REMO3Q/ZU;VP-$3!L?;-4MQGFE23?NKOG9U
MV%KP=O;$@GFW8!YQMX$BRDL5U.FQLVMR8@UO\L36UC@C8K MNK&E3C5[^MO9T@<'9OQ]5*MO\/=_D0M[WRM4CX900Z>W3V/3G_^:?_U[.@9 MM(<#VL/GO+^D+\\
[VI_0$[[HVJV4T=]4E,=9^4U!;!E]XL;9,5V9=$*O0L') MSS^]G<]G1Q>VJI79Q+/](*.NAO]RN[.\>D/2E*@42GJMSS >JFI;9UH:"C ME)L@UREM'5)NP7/."" ROL>8J*5'QN*0:F>S)@T>1BX!& J8/ '1
ME<,!>, M$>$D]/Z(;T^9]@R-TJL';(\M'D N=6U+Y62)=1F[84KCP%2TN'0B5=1;ST! XXWL2(O<-,5_C#%3>&K4L&47W MN.+I]T:G=^5&#H'8:]R;T&<4>*O-L:(#(EVS< L>,)&]1,LCY-
@HZ8U3=6PM M9:Y9;2%_1Z\T:D,U3DQ HT$W6*4V=1MPHZ3 :6%L:5<;5+I$E24O+-CV";(L MM6FIBL E"J:;;BR%BJBD]%Y!UIL28<);G;%K(]F=_3J;88B$PMEFU1;9V8TJ
MPV9OR2I&XJJIV<3N8@Q)*4?EZKB4-B,@"Y6 MI&J"DEYP'02DE\TQZ&\P3+&O2;HJ'NW)1I5M%S"Y5VDJA0H%*.&9[R)+0)9@ M'<<$U5*77781@0:$@0:ZJIK8HRA=C\9Q)0ZD+W#X@\[&M-
6!OWZ:S>9##Q+U MD@X\-,"#_=27[1%99>!@=-@XW'V#F8XJ:566FP3_2(.LG&.*1,EYK5SF)?&V M8U+U;NST8T7LA2< BC!:.Z5C.U)5:]#W,9("".1L;:,,4&M9<6XFK2>W(9[)6 MPHF_'Y?
FX+A)12,BL%I<@$N^7P!(&L+6$&Y/Z(R7H5L&4"W"@>RQ:E!]FU2" M9E70#UJ>WD$Z&'[WJ@2G _$\\MU M'IC-HPGP03O,XJ'6$OAA1Q!B[## 11)%?JF80D1IF@I=242V7?F!T6.OY3BC
MM]')O.2<,=&S+E],)?C03@11-KMR[,#WSAA!5'U MZ>Y&\40=A=P"QS[EG-;LXOZ#:W$?,;!%A=LPWT>9)$_5<,FIC)*6!9*P-C'D M(G2$N>12K:-+0SWINR?1 U0"(Z6-
J"IYHO3=>IE5K0YE0HJON"LGA4*(I92C MJ;,X$L (DL&$\FJ+812?'\.CR,Y+_O6[D _$27^N<$$V)^US\;_;1G*Z%'& M-/]"A[V?Y/])A^$[#2X8=_J>$^$NBZ=5B%C)_UB%NP'.2628A/],@CM3?YD&
MI83)3C\O$F'+]] G=AG^QZOYMNO8/C.6@5OS3@\5GPM:_C MP]7A8\99^P[_8-Y^"?FHW$ICTR\YQ]+9Y,TO(W+MUX7V)-@ZOM$O;0BVBH<% M*RA3#'_MS;T)Q)@^,1S^D]02P,$% @
SH.+6<6UA1!$! (@H !D M !X;"]W;W)K&ULE59M;]LV$/[N7W%0AWX*+%MQ MTB"U#21.VQE87I:T&X9A'RCI)'&E2(VD[&2_?G>4HKAHXF8?;/'MGGONX1W) M^=;8KZY"]'!?*^T64>5]BQ#OT
M7YH;2[UX0,EEC=I)H\%BL8C.IJ?G,UX?%OPF<>MVVL'1I,9Y9I0+_[#MUTXBR%KG3=T;$X-:ZNXK[GL=7F.0] 9)-TY"IOP MA!?+N35;L+R:T+@10@W61$YJW10[,VE6DIU?_K+^]6 @A/B
%9&.Z-D+KK\T#G<6'2H M?3=@"O%M="9% KN:! I&;V#\]2YRVETU_/*=01F#U/@$OLU#4BPT74L"^[MP6CY]LWT>/)^3WBS(;S9/O3_NYG[P9(Q[,&9X52266F;H1^D+J$S-"F:X?Y
MJ!A4#RCQ@E,Z9O0 M;T:#ET+3,<1L1RDJB1MT((EYUEI+@SV,ID@H4XBQ-I.[J*0F>1I;Z!H>89, M&B6TY@@;M"&9.#YKVI(!$!Y06!"%)],,E1(00V.0$ 8)1SL2DFCDU[68CUE^
MAU!0%AI+%.D\)@S74F8*4HRDSTV;>A I'<2[@KQ]##'22A9?XQ ML7KP T+-5)NS.6 .3N0F]71OC31B_L18E\]S^T%HN0D9T2DB5I3"(O^;3O!N MYQBCD2!W#(BCD2!W#(BCD2!W#(BCD2!W#
:<4YD2SDG*I^\X466J=$$>G< IE-=U*8-T+K@H*RC#0&?=O?^TO'L]70I;2MI]A069 M3L;OCB*PW8NDZWC3A%= :CR]*4*SHD<<<6EY \X4Q_K'##H9GX?(_4$L#!!0 M (,Z#BUD#)^DSQ T .TD 9
>&PO=V]R:W-H965TJAOE/M;O&GPZZ*3D MNE25U:82C5J^W#N;/3L_HO6\X#>MUG;PMR!+%L9\I@_7^VP92&MNC#%[SIWJY=[IWLB5TO9%NZ] M6?^L@CW')"\SA>7_B[5?>SC?
$UEKG2G#9FA0ZLK *^^#'P8;3J7ZXOKRYL6!PR&T]" + L^]P/D# D _$&U.YE167 M5:[R\?X#*-=I.(\:GL\?%&[)BY&9B(<):*^71^](B\P\[B0Y9W^("\LRPS;>5T M=2O>F4)G6EGQK[.%=0TRY-
^[#/;RCG;+HZIY9FN9J9=[* NKFCNU]^K[[V8G MT^>/:'O4:7OTF/2_$1_'!1Y.Q#=DBG-IM15F*=Z1/9637#\?5@HUE)FREM6& MO)
<91+BR*D^6NI)5IF4A+!8KU*SC_0Y;+OP&L9)W2BR4J@2\5,M&Y4)7++#) ML5DA[]V*/X?@U(V&S+I >&Y5I1I9%!OZ7M.[R7I'RM-GV[H6)O@R+-2-3J3 MXH?OOSN=SZ?//TYN)N*GL[-
W_'GV_$J*QMM*-;RHI=5U\@@N2B4< 8Z.1Q>)K#/-X#WETD=JD+LDKB &%+ M&*,:X1=Z7[*7)N1EJWK7BIVNM2O3%CF*0B'R1?8*FM/-"Q(V%4(MNB0KBJ3:Y39#Z+"'JH O2(D<:<47*'1GE
M02V$6=W7Z&*D3W#WLBT*[W,\H/(R%$4\=BW$^Z,FXD(U%-$89S,V;G?9NI5T MZ*247[8%*DI4(Y=>WG*N.^^B7-NL,!:GV:\3Y]'$BR:4QCJ8F>$A-+&9# :A
M0GQ=_'>)V..+*;7#YLDCB(5&7C#H>.(#BSEIDYB/D&:],*0&H@)3&E..;-LM MHKZ['1 R[#QV.Q2D/E$S73;N-+K .\%&[\ MH]44H+Z4NC17W;$$!-*"E-4^9SD!Y'*)A N9&
((A2]*941;K5<"00LL%H*V# MSCXQ@@%D)9W\T!Y_2DZ)%7+_&^47 #S95HRV4Z%@IT6V-N3=W@!N*:$N/NS(M*:MO*[U$@I.J@RX4*0*[15=WID">#18GG]K\EEU+>O5NC= #!I=]WB?BF#/*
M0ST.;RK6LFGHM#M9M.$1B>@^DCW@EZKQO1*;47KR7EG*']?"*1$D,BK7)-<(M6A,SU=A!D $%TJY8//]QB<3 .>S.@3/(\U8CY2TCY@J,%H5?:*PF#>Y4Q$_?
MJW^T7YRTZA_KGQ(6P4E3>S0!0[VBQVK*CSMPWZ*GG"PUI&NJA>%QC&403E M,PN8$EE?0HIOM94MM6[I\,B!'^HMAP8Y)X(;4H2SFYXBG,ZA\4"Q-TI2<7#&_*+N5"%F MS\0_6T.)#
LS3IW$#RMP: -9!X<^ MS[#M'Q&1AG?U:RK:MMZX!"ZH;Y[S2E8E:L;54)Q[$ MXK8!]H0NO:2,N8NI_*"2 6:0D\GPJ0<&RE1& UTN5$[4C+L9\PQ+\@SJP$5N ME@6R$&")^4(L6.;!2/ ;
C./G[V"7+)Q%].;7)%WN?FU-L+P>2$!A#?9RA#O M[E&N-+DJ 'TB%$_P>BB@H2/*OG12X1'5>((0@2X?+*<^-50[%[M5QH@W7!1#99P D%&S/*.RJ<=3$;34"Z@E@V*I6Y,WF:A2?
F8)YFLM9.%_M*A M.I>4SW:J:<="V8[(\PJ]5&,E>ZREGDJS*G6 819W@>LF'&T_(P&4\AP43DJH M8,9R=0E:AX\;K4#YY)V$L5QKE:<2'QKV^F8X(@7X[T"_A "8OE6T%Y'.I-M M$\R6Q)-#)5
_JCFNR5M4R>@[%;_CU&(>D!-KR, ?4[!H1_:C8[=E6_!WN0*+ MHLR&MR?B]>"3T);#V+I19M+H3Y.J6,HB$ M(<$[M&@>TC,@'6TT!-DK62RW[@1&(1(PIM\R8L>8D#>UB$_ACR^-U^#*D-N+%
M$!7.Y/,16XS_U-SU%W07M8[U2&TCUSD3L\"/--H\J+9'>M*CK?$-%*_E)DQ" MW9' UHQB-*AOP+#7(14#]Y$=808#:"!S#!Q"DP9ZS54S EVT8R0F ;(_\4' M_T%71E*;)CC^3A.0<1G^1!2J\\B-DT
#IVDV3WETT[')'SP*!WP" M L$EC)G[YPP5%P/>.H!99X =\MQDR'.CJ]XX7TR(,R'[2H$O9K>); ^*NG6'L\ MP5C,6X):+H(0+P?6CP?8\Y;PD>P^.HY"N-36*
":'F)7\E\B"DS]3VH9P+R.S]#;$9.\N=ZC4!)XT2[M^,23F0F7(BN-\"L ;)/WQ3C]$TV-=@OW;4")ZB_;>U8U,YSSBP/IM0'4Z&7@E+?/+/ S8';LRK:-I&FW4W_+& M&X688BVU[H%XNOWBX3K<8W0.
(*%QQAY-I'\&:<(5+FUNPA5;/&0B?H]D;ICZ M(>ELCZ5)3_IL'.0H#([N%+NA-QT0_^'TD'X]37QU(T\CL,! *XY.,_'LX9<.[/*K^E:D[%^1 DB+W&FD^V/1>O1^0M&&PP MPWWMC,&EZ,@77SDA]
(5^U9J[9Y6K>W\AL5T^W04:2E'1*,?(2+=Y*]D$P]B0 MBEF!0$"Z^%8>3F\KNEDFYYW.CC%/&FL)0[QA.2, MP5(GD]H8WS$WC]4C;$ M_/UFO^M&4X08#?
BJSM\)HWCI9H)"VJUZ4,RH#9T;FNH%)S>SW71JGI9WM5U$5V5>.A\7 M!D]3%&9-)]AP-1)>=U1M29=&A S?5&[@*?$7/,7TZP%SDC]KSK,$H*SRME"^ MW3K=^=WVL];855MRU3
Q6&AR%8KA1M^/WL0.+]42OJ'&_PY]IG/IVFQX>' M8G9ZFCX]>9J0Y&VWYDVFZ;3Z72+'<:JMC D7":J;4/\53N%AHQ)&;$220&A M,< J?_E$GOK;=#(]2<-U(=SF.<#?
WN4L"HF4_E<*/+%_JF;;I;CBX:Q!^R M+M8)"XALE"B-KYXH6*./,&];,@@/[HKX6C3>,7CI7>_?IE-Q#AO0J+IM(-G/ MXD,,KWL>]8YY7UA1*>K'06DO@ M$^XMX
6ZY/'OD.@MFE?"=]:,+AHWR@T.B4\[3@!C.=2R:\CAB-BLMOM3_VZB M-I9=GWC^MN,](>/G<%W$F_Z]S%4!S'48+&@ =V(-K9]\$ZB-Y#'-Z/*\F%
M*HB_>ZH4SNKH5K]GK7'&PZ:B.)+'7\!,=OVLX6#P$Q3,X+?\0QM^,U$Y_VN4 M[FGW6YXS_Q.6?KG_(= ;V8 L6%&H);9.)T^.]_P &S\X4_,/6A;&.5/RGRN% MX:BA!?A^:8R+'^B [A=.K_X#4$L#!!0
(,Z#BUF@'2IJ0, 0(9 M>PO=V]R:W-H965TR"]0]3P6.E2&EN9UM65XZ@XPX*IOJBP!)U4R(IFLJ=HRJ)+&F,BMSQ M73=R"L9+:SJUI9R,A*USGF)2PFJ+@HFGVXP%_NQY5G'K17
9=HL.)-1Q7:X M1OVY6DJ:.1U*P@LL%1; 'QSWZL48C)*M$% ,Y&,RMESC M$.88:X/ Z/<-9YCG!HC<^'K M#I*8_AR?$3_T&@G+5NF<";R/WFBL[%U:&^ M*:MSO1+
[6SSHN3!XLW8PL""NE1;%P9@*'C9_MGC(0XO#"[=5PS\ M@X'?^-T2-5[.F6:3D11.D8TH9E!([6Q)N=X:2YEK27M!'F!XEB=C2\C%/8%I)GD/@MM/>T:&89/&8Y: EIV-_!;"H6L//8&[[O3
MO*3[9F6,X$6!'00^1*Y]X0>]-C/^XYXWM$,_ N_2C@9>;R,HK7Y> S%'@\". MHB&-!D/;&X;P4,)1F>^W4FP@6\H+E4X_,T>0R+[4 !FM=)T_T95*_KRN8 M[B1B82CV7&=P1T0LSFIB([K?
L$1)#MX*U3P ^.7=FTO?=Z_-L6ZW@V@VO>M? MB:K5)%E38*E#]%(JL<^A-6G-9)RU,397*X$3X?1WU_7(5B1UK"&F./"$:>$# MA@2=)B6LKS4W EE+^M2L4FJ\A0LOM%W7-3'Z5)=T1>&I
%4U>4+U.X&$<"B6 M4ADEWN"ZO8@TY3$^KSW?N/'\Z%HBQP)-JBL$/61W_<'AO_4JYQ S>.8"Y:[I M/PIB8]P6Z6ZU:W'3MK(_'V_[XQV3.W(*&ULM5IM;]LX$OZN7T%XLXL$ M+4Q+?DU?
CA)V\W>-0GJM ODHJ3_OJ;&8JRG-C9=+>'HHE> MR.&\///,D,J;M=)?S5((R^[SK#!O6TMK5Z\'9,L1 M=,Q*"Y[2I#SKQ-WNL)-S6;1.W]"S&WWZ1I4VDX6XT<[UPYG(U/IM*VKY M!Y_D8FGQ0>?
TS8HOQ%38SZL;#7>=6DHJ!KP18JU M:5PSM&2FU%>\N4S?MKJHD,A$8E$"AU]WXEQD&0H"-?ZH9+;)7%B\]I+?T^V
M@RTS;L2YRGZ7J5V^;8U;+1$7!B@O49FAGVSMQO9[+9:4QJ]\ MF@P:Y+)PO_E]Y8?&A'%WSX2XFA"3WFXATO*"6W[Z1JLUTS@:I.$%F4JS03E9 M8%"F5L-;"?/LZ?3V^OP?
QV>3Z;L+=G[]\>;=U71R>WE]]:9C03Z.Z225I#,G M*=XC:<@^JL(N#7M7I"+=GM\!K6K58J_:6?RLP:0%MEDO"EG+ 1=_WLR,U8#3/ZSRW@GN[];-J;.*[/B MB7C;@MPP0M^)UNDO/T?#
[NMG-._7FO>?D_Y=07I>TJ#-]@D#-T=#-K4J^?QG$T>FT"@W.7*DN% M-HRO5EK=@:MWC-RY%*.E#G$XCHN[K_$!74:OC]KL=ED-0;DR%88!)9%T:4S) M00Q3<\8#2
Z9ESG>C'MAK]=C@V[8[799U$4D1;M<O"S8>S'3)1 3C=IM4XQQ MG:+D5&J@%05V-A4^P]=>8\93M;(B#1DOG!=V^LL]PQ MG4"F8\!3:@;J>:H"/#(B@0+7FV'=>Q5,H9JF9488-
41$SHY5141\0T1AM73(M_-K!=6G!X1"F8N%U#HC.#+LJ3Q4*+!;<"\ /V0R5-@C.> M4:YPNY73H/8PIC0Y&=.O Q:-QNTH9V-',=J!L.NMV@6MV4)8XAG\'^+-^
M(^Z%3J39\VX%B9,REY>'[M<1KC7HMF'1XZ9Z3_PZ'-#XDWXX'(Y(P9-V%+%^ M^X34'8110\$["#FLA B"507%'H"!CW<*'Z/9426U=P)2AX.G4BOC.*;-3BFC ML-OO55$!R:6N599GB"W+
M[Q]/AR1MB[9CDU3.YT(+],V+403C*8+J&/ 4?,N=35-.7>P3+H).3#%)7S MG.6C:'O*1(!XZ,B<,D4-/,*S.8*GX)*U5.K.4+?D=KBVP<4N$Q#HP>Z!I#MO, MT^"20XRR[/C&D0!S
%=E4_43[N88I,H/RY)@>0]".TFI\V:52)NLNY.:.AG MV0*\F4A=P M0F +J.C5?!"/*4D=G@?@Z5>K52QD6IZ:V O.5XH/2P6\E-SJE< M\OBVX0Y?
\M<2DG*&O)"6B5,C'OS<9A>E\/75R$4!/DT0Y5J:KX9(HP0IVL)N MT$IA FZ,PLI?A;0R"\L82H""^U78XZ0&8N5Z9J_\"91#F%'PJEV'G$4/&4<[M**[R&;VM3-/BCU(:B'"P%7-
5N*@8%TR,KYHYWBU26IUCVL/.+H376\T&W$ % M6<(03V*W/ -2?4)@+8@>_*]D/4I%;DRV3"@ZAV:?8H/RCFX8,[>W8NDI[M M>@X1@N4YIN$C-L>D/(B & 8-
R(:HQ'HIDR7TS3^[>EFNJBJ!CLB$VTX76%P+ MA?&N/;Y6N.%@4$$G[3*=S;_-^ \Z$@N60*# 3Y9 /0*=0T$3/Z)-7A'\I,P MU[

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~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`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~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|UWF\]D'YG/ +:,R$N"*ABBL|?>;_=T&?U//% M7B; WB;@TFX4O D.7!:9|"V[#9XG(_!^Y/3.JY_EMG#<|KU<3)=YY N7T&* M?T*J"]^ SZA@!(

YANB>DV8HZ"((U3HK9+6"#.CZW,G7';5< CUGM M$79+PFXCX5RRX#EB)$1>A4H^V#: ^B54_^B! *E0RZHN;57X]26NMF-6.K'$J):V4?)OKX-^]515 MMZNY4{YBQ%=951<@8"F5>24K1\N'PRBKE^9O_S5<0OY"E,!"%HJ5^N\JQ+* M\T]>=R1+LF*X8%*5UJP9[<V#FYXV%DFZKX;,1[R3$4L@1M!9!;'5+R< M0L37(\,V7CMNV2I4>8\)?(BB' EY_"Q!C6K-W'#[M^17]0CN/SLRI!)]'|A"A2.C;Y %+&D6J5N^ @:E0YI@P".I?\FZG&L9),BD MXG%IC QBEA3_]+D48LO [NPP<$H#YZU!=X=!IS3HO#5P=QBXI8&KE2E)T= M>)-$L06+LCR"R0R'3##% -U]#](,/29+P6/B\SC-%-71SI?DG(J$)2M);D^0 M6:XL>?B.P&2](;_-*E0OB!.9T@!&!KX!)(@G,,9__&.9[UE]-$NT) MK":86PGFMJ'7!9,;P: F6%7#%X%2U$P'8J'A,8\2U235@6!KB:0O_N>QH.! MU>W@=C]MJ_!^FMWO#[Q!-:WF7[?RK]OJW_G/C*D7/)+[A"E)OMS.[O$$:DND5MR/QL6> MP&H2#"H)!\BD0;[%&Q/8#7!;&MSA;%^]7%2,MB.] [[[)B4:YCA=JSDA["W[MF=WJW \]!$U2-_>%5G?8V3CL?(H$*&GL2[0]H=5%V]Q [=;[VO^2 M IWW*=#KN%L17BKQ?I[7\[SNCD3([XSUGLTMRVZ_9N$)=A>"#@6:O)"0;OEK M6X>691&I3QkN+V*28)E,%%I(]DSBHB2!O"0A6!%P3*ZJB T6>CJX!#+,14> MT 21001, DQ

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|:>(6\7@?8GKY6(=A, M\4K$9HJO-2#^=0-&DOAW&\L##&P7L-]! /X\4%-^3A3!KF+>L"<81Y($0Z 6 M_34:Q\C]Q/#Q[P_VE$11DO@1P/P.H@A#X&G$$,"0**K>@SOOHW#]G@HW M_\<;/0-02P,$% @ SH.+69>*NQS $P(L !?3T]M$MP>;4#M.*2VBZD8_1!2;5K5N %(MB6/:(7->=I3W;+T]l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|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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 162 216 1 true 48 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://alzamend.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://alzamend.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://alzamend.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://alzamend.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Stockholders' (Deficit) Equity (Unaudited) Sheet http://alzamend.com/role/StatementsOfStockholdersDeficitEquity Condensed Statements of Stockholders' (Deficit) Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://alzamend.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995612 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://alzamend.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 9 false false R10.htm 995613 - Disclosure - LIQUIDITY AND GOING CONCERN Sheet http://alzamend.com/role/LiquidityAndGoingConcern LIQUIDITY AND GOING CONCERN Notes 10 false false R11.htm 995614 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://alzamend.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 11 false false R12.htm 995615 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 12 false false R13.htm 995616 - Disclosure - STOCK-BASED COMPENSATION Sheet http://alzamend.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 13 false false R14.htm 995617 - Disclosure - WARRANTS Sheet http://alzamend.com/role/Warrants WARRANTS Notes 14 false false R15.htm 995618 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://alzamend.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 995619 - Disclosure - EQUITY TRANSACTIONS Sheet http://alzamend.com/role/EquityTransactions EQUITY TRANSACTIONS Notes 16 false false R17.htm 995620 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://alzamend.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 995621 - Disclosure - SUBSEQUENT EVENTS Sheet http://alzamend.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 995622 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://alzamend.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 995623 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://alzamend.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://alzamend.com/role/SignificantAccountingPolicies 20 false false R21.htm 995624 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets 21 false false R22.htm 995625 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://alzamend.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://alzamend.com/role/Stock-basedCompensation 22 false false R23.htm 995626 - Disclosure - WARRANTS (Tables) Sheet http://alzamend.com/role/WarrantsTables WARRANTS (Tables) Tables http://alzamend.com/role/Warrants 23 false false R24.htm 995627 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://alzamend.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://alzamend.com/role/CommitmentsAndContingencies 24 false false R25.htm 995628 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative DESCRIPTION OF BUSINESS (Details Narrative) Details http://alzamend.com/role/DescriptionOfBusiness 25 false false R26.htm 995629 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) Sheet http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative LIQUIDITY AND GOING CONCERN (Details Narrative) Details http://alzamend.com/role/LiquidityAndGoingConcern 26 false false R27.htm 995630 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://alzamend.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://alzamend.com/role/SignificantAccountingPoliciesTables 27 false false R28.htm 995631 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://alzamend.com/role/SignificantAccountingPoliciesTables 28 false false R29.htm 995632 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables 29 false false R30.htm 995633 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) Details http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables 30 false false R31.htm 995634 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://alzamend.com/role/Stock-basedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://alzamend.com/role/Stock-basedCompensationTables 31 false false R32.htm 995635 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://alzamend.com/role/Stock-basedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://alzamend.com/role/Stock-basedCompensationTables 32 false false R33.htm 995636 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://alzamend.com/role/Stock-basedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://alzamend.com/role/Stock-basedCompensationTables 33 false false R34.htm 995637 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://alzamend.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://alzamend.com/role/Stock-basedCompensationTables 34 false false R35.htm 995638 - Disclosure - WARRANTS (Details) Sheet http://alzamend.com/role/WarrantsDetails WARRANTS (Details) Details http://alzamend.com/role/WarrantsTables 35 false false R36.htm 995639 - Disclosure - WARRANTS (Details 1) Sheet http://alzamend.com/role/WarrantsDetails1 WARRANTS (Details 1) Details http://alzamend.com/role/WarrantsTables 36 false false R37.htm 995640 - Disclosure - WARRANTS (Details Narrative) Sheet http://alzamend.com/role/WarrantsDetailsNarrative WARRANTS (Details Narrative) Details http://alzamend.com/role/WarrantsTables 37 false false R38.htm 995641 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://alzamend.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://alzamend.com/role/CommitmentsAndContingenciesTables 38 false false R39.htm 995642 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://alzamend.com/role/CommitmentsAndContingencies 39 false false R40.htm 995643 - Disclosure - EQUITY TRANSACTIONS (Details Narrative) Sheet http://alzamend.com/role/EquityTransactionsDetailsNarrative EQUITY TRANSACTIONS (Details Narrative) Details http://alzamend.com/role/EquityTransactions 40 false false R41.htm 995644 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://alzamend.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://alzamend.com/role/RelatedPartyTransactions 41 false false R42.htm 995645 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://alzamend.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://alzamend.com/role/SubsequentEvents 42 false false All Reports Book All Reports alzm-20241031.xsd alzm-20241031_cal.xml alzm-20241031_def.xml alzm-20241031_lab.xml alzm-20241031_pre.xml p12624510q.htm http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "p12624510q.htm": { "nsprefix": "alzm", "nsuri": "http://alzamend.com/20241031", "dts": { "schema": { "local": ["alzm-20241031.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["alzm-20241031_cal.xml"] }, "definitionLink": { "local": ["alzm-20241031_def.xml"] }, "labelLink": { "local": ["alzm-20241031_lab.xml"] }, "presentationLink": { "local": ["alzm-20241031_pre.xml"] }, "inline": { "local": ["p12624510q.htm"] } }, "keyStandard": 174, "keyCustom": 42, "axisStandard": 14, "axisCustom": 1, "memberStandard": 13, "memberCustom": 33, "hidden": { "total": 150, "http://alzamend.com/20241031": 67, "http://fasb.org/us-gaap/2024": 78, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 162, "entityCount": 1, "segmentCount": 48, "elementCount": 440, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 451, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://alzamend.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "p", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "p", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R2": { "role": "http://alzamend.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R3": { "role":

"http://alzamend.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R4": { "role": "http://alzamend.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R5": { "role": "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity", "longName": "00000005 - Statement - Condensed Statements of Stockholders' (Deficit) Equity (Unaudited)", "shortName": "Condensed Statements of Stockholders' (Deficit) Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2023-04-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-04-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R6": { "role": "http://alzamend.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R9": { "role": "http://alzamend.com/role/DescriptionOfBusiness", "longName": "995612 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R10": { "role": "http://alzamend.com/role/LiquidityAndGoingConcern", "longName": "995613 - Disclosure - LIQUIDITY AND GOING CONCERN", "shortName": "LIQUIDITY AND GOING CONCERN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R11": { "role": "http://alzamend.com/role/SignificantAccountingPolicies", "longName": "995614 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R12": { "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets", "longName": "995615 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R13": { "role": "http://alzamend.com/role/Stock-basedCompensation", "longName": "995616 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R14": { "role": "http://alzamend.com/role/Warrants", "longName": "995617 - Disclosure - WARRANTS", "shortName": "WARRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R15": { "role": "http://alzamend.com/role/CommitmentsAndContingencies", "longName": "995618 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R16": { "role": "http://alzamend.com/role/EquityTransactions", "longName": "995619 - Disclosure - EQUITY TRANSACTIONS", "shortName": "EQUITY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R17": { "role": "http://alzamend.com/role/RelatedPartyTransactions", "longName": "995620 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R18": { "role": "http://alzamend.com/role/SubsequentEvents", "longName": "995621 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R19": { "role": "http://alzamend.com/role/SignificantAccountingPoliciesPolicies", "longName": "995622 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R20": { "role": "http://alzamend.com/role/SignificantAccountingPoliciesTables", "longName": "995623 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R21": { "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "longName": "995624 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R22": { "role": "http://alzamend.com/role/Stock-basedCompensationTables", "longName": "995625 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R23": { "role": "http://alzamend.com/role/WarrantsTables", "longName": "995626 - Disclosure - WARRANTS (Tables)", "shortName": "WARRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "alzm:ScheduleOfWarrantActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "alzm:ScheduleOfWarrantActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R24": { "role": "http://alzamend.com/role/CommitmentsAndContingenciesTables", "longName": "995627 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R25": { "role": "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative", "longName": "995628 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)", "shortName": "DESCRIPTION OF BUSINESS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative", "longName": "995629 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)", "shortName": "LIQUIDITY AND GOING CONCERN (Details Narrative)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R27": { "role": "http://alzamend.com/role/SignificantAccountingPoliciesDetails", "longName": "995630 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R28": { "role": "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative", "longName": "995631 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R29": { "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "995632 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "alzm:PrepaidClinicalTrialExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31", "name": "alzm:PrepaidClinicalTrialExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R30": { "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative", "longName": "995633 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-06-14_us-gaap_DirectorsAndOfficersLiabilityInsuranceMember", "name": "alzm:InsurancePurchased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-14_us-gaap_DirectorsAndOfficersLiabilityInsuranceMember", "name": "alzm:InsurancePurchased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R31": { "role": "http://alzamend.com/role/Stock-basedCompensationDetails", "longName": "995634 - Disclosure - STOCK-BASED COMPENSATION (Details)", "shortName": "STOCK-BASED COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-04-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R32": { "role": "http://alzamend.com/role/Stock-basedCompensationDetails1", "longName": "995635 - Disclosure - STOCK-BASED COMPENSATION (Details 1)", "shortName": "STOCK-BASED COMPENSATION (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-04-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R33": { "role": "http://alzamend.com/role/Stock-basedCompensationDetails2", "longName": "995636 - Disclosure - STOCK-BASED COMPENSATION (Details 2)", "shortName": "STOCK-BASED COMPENSATION (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R34": { "role": "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995637 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-10-31_custom_UnamortizedStockBasedCompensationMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31_custom_UnamortizedStockBasedCompensationMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R35": { "role": "http://alzamend.com/role/WarrantsDetails", "longName": "995638 - Disclosure - WARRANTS (Details)", "shortName": "WARRANTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2024-04-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "alzm:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-10-31", "name": "alzm:ClassOfWarrantOrRightOutstandingGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "alzm:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R36": { "role": "http://alzamend.com/role/WarrantsDetails1", "longName": "995639 - Disclosure - WARRANTS (Details 1)", "shortName": "WARRANTS (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "alzm:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31_custom_ExercisePrice1Member", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R37": { "role": "http://alzamend.com/role/WarrantsDetailsNarrative", "longName": "995640 - Disclosure - WARRANTS (Details Narrative)", "shortName": "WARRANTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "alzm:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-09-012024-09-11_custom_Warrant2024Member", "name": "alzm:AggregateNumberOfStockRepurchase", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R38": { "role": "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "longName": "995641 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember", "name": "us-gaap:ContractualObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember", "name": "us-gaap:ContractualObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R39": { "role": "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995642 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2018-07-012018-07-02_custom_AL001LicenseMember", "name": "alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2018-07-012018-07-02_custom_AL001LicenseMember", "name": "alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R40": { "role": "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "longName": "995643 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)", "shortName": "EQUITY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2024-10-31", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "us-gaap:ConversionOfStockSharesConverted1", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "unique": true } }, "R41": { "role": "http://alzamend.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995644 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "alzm:OriginationFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-08-012024-10-31", "name": "alzm:OriginationFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true, "unique": true } }, "R42": { "role": "http://alzamend.com/role/SubsequentEventsDetailsNarrative", "longName": "995645 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2024-11-012024-12-10", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "p12624510q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "alzm_AL001LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "AL001LicenseMember", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "A L001 License [Member]", "documentation": "The element represents a l001 license member." } } }, "auth_ref": [] }, "alzm_ALZN002LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ALZN002LicenseMember", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "ALZN002 License [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods

and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44", "r496"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } } }, "auth_ref": ["r560"] }, "alzm_AdditionalAL001LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "AdditionalAL001LicenseMember", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Additional A L001 License [Member]", "documentation": "The element represents additional a l001 license member." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r54", "r496", "r715"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://alzamend.com/role/StatementsOfStockholdersDeficitEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r380", "r614", "r615", "r616", "r617", "r666", "r716"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r566"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r566"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r566"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r566"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "alzm_AggregateNumberOfStockRepurchase": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "AggregateNumberOfStockRepurchase", "presentation": ["http://alzamend.com/role/WarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Aggregate number of stock repurchase", "documentation": "The element represents aggregate number of stock repurchase." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r531", "r542", "r552", "r577"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r534", "r545", "r555", "r580"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r566"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r573"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r535", "r546", "r556", "r573", "r581", "r585", "r593"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetails2"], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r262", "r271"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest expense - debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r5", "r63", "r207", "r671"] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r538"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive securities excluded from computation of earnings per share, amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r164"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r19"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r19"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r284"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r81", "r86", "r118", "r135", "r167", "r171", "r174", "r175", "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r286", "r290", "r306", "r336", "r416", "r476", "r477", "r496", "r512", "r635", "r636", "r674"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r116", "r122", "r135", "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r286", "r290", "r306", "r496", "r635", "r636", "r674"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r538"] }, "alzm_AultLendingMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "AultLendingMember", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Ault Lending [Member]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": ["r588"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": ["r589"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": ["r584"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r584"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": ["r584"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": ["r584"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r584"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": ["r584"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": ["r587"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r586"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r585"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r585"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://alzamend.com/role/DescriptionOfBusiness"], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r42", "r68", "r69"] }, "alzm_CancellationsOfCashAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "CancellationsOfCashAdvances", "crdr": "debit", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cancellations of cash advances" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash [Default Label]", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r91", "r339", "r391", "r411", "r496", "r512", "r604"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent",

```
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r14", "r117", "r471" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r15" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r14", "r65", "r132" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r65" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r604", "r683" ] }, "alzm_CashUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "CashUsedInOperatingActivities", "crdr": "credit", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash used in operating activities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r564" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r98", "r119", "r120", "r121", "r135", "r153", "r154", "r161", "r163", "r169", "r170", "r178", "r197", "r199", "r200", "r201", "r204", "r205", "r209", "r210", "r213", "r216", "r223", "r306", "r370", "r371", "r372", "r373", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r403", "r425", "r445", "r459", "r460", "r461", "r462", "r463", "r601", "r610", "r618" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r119", "r120", "r121", "r169", "r209", "r210", "r211", "r213", "r216", "r221", "r223", "r370", "r371", "r372", "r373", "r482", "r601", "r610" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/WarrantsDetails", "http://alzamend.com/role/WarrantsDetails1", "http://alzamend.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, beginning", "periodEndLabel": "Weighted average exercise price, ending", "label": "Exercse price (in dollars per share)", "verboseLabel": "Exercise price (in dollars per share)", "terseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r224" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://alzamend.com/role/WarrantsDetails", "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Class of warrant or right, outstanding, beginning", "periodEndLabel": "Class of warrant or right, outstanding, ending", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "alzm_ClassOfWarrantOrRightOutstandingCancelledexpired": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ClassOfWarrantOrRightOutstandingCancelledexpired", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of warrant or right, outstanding, cancelled/expired" } } }, "auth_ref": [] }, "alzm_ClassOfWarrantOrRightOutstandingGranted": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ClassOfWarrantOrRightOutstandingGranted", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of warrant or right, outstanding, granted" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r565" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r565" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r50", "r82", "r338", "r402" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r71", "r185", "r186", "r466", "r627", "r629" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r502", "r503", "r504", "r506", "r507", "r508", "r509", "r614", "r615", "r617", "r666", "r714", "r716" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r53" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r53", "r403" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r53", "r403", "r422", "r716", "r717" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 5,231,254 and 687,999\u00a0issued and outstanding as of October 31, 2024 and April 30, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r53", "r341", "r496" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r570" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r569" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r571" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r568" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Payment", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r612" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of contractual obligation, fiscal year maturity", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r602", "r613" ] }, "alzm_ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of note payable and accrued interest into Series B convertible preferred stock" } } }, "auth_ref": [] }, "alzm_ConversionOfNotePayableAndInterestToPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ConversionOfNotePayableAndInterestToPreferredStock", "crdr": "credit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of note payable and interest to preferred stock" } } }, "auth_ref": [] }, "alzm_ConversionOfPreferredStockToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ConversionOfPreferredStockToCommonStock", "crdr": "credit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock to common stock" } } }, "auth_ref": [] }, "alzm_ConversionOfPreferredStockToCommonStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ConversionOfPreferredStockToCommonStockShares", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock to common stock, shares" } } }, "auth_ref": [] }, "alzm_ConversionOfSeriesConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ConversionOfSeriesConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Series A convertible preferred stock" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Converted shares", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } },
```

```
"auth_ref": [ "r16", "r17", "r18" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r16", "r17", "r18" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r206", "r314", "r315", "r480", "r481", "r495" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal issued", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r370" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r24" ] }, "alzm_DescriptionOfLicensesAgreements": { "xbrltype": "stringItemType", "nsuri": "http://alzamend.com/20241031", "localname": "DescriptionOfLicensesAgreements", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of licenses agreements", "documentation": "The element represents description of licenses agreements." } } }, "auth_ref": [] }, "us-gaap_DirectorsAndOfficersLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectorsAndOfficersLiabilityInsuranceMember", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Directors and Officers Liability Insurance [Member]", "documentation": "Professional liability coverage for legal expenses and liability to shareholders, bondholders, creditors or others due to actions or omissions by a director or officer of a corporation or nonprofit organization." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://alzamend.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r229", "r232", "r263", "r264", "r266", "r485" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of stock-based compensation", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r7", "r33" ] }, "alzm_DividendsOnPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "DividendsOnPreferredShares", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends on preferred shares", "label": "DividendsOnPreferredShares" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r526" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r524", "r526", "r538" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r525" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r513" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r526" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r526" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r559" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r516" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic net loss per common share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r128", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r153", "r161", "r162", "r163", "r166", "r280", "r283", "r300", "r301", "r333", "r351", "r473" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted net loss per common share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r128", "r141", "r142", "r143", "r144", "r145", "r146", "r153", "r161", "r162", "r163", "r166", "r280", "r283", "r300", "r301", "r333", "r351", "r473" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Loss per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r19", "r20", "r165" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized stock-based compensation expense related to unvested employee and non-employee awards", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r265" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r265" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r519" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r515" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or
```

'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r515"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r600"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r515"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } }, "auth_ref": ["r597"] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r538"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r515"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r515"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r515"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r515"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r598"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity", "http://alzamend.com/role/WarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r113", "r125", "r126", "r127", "r136", "r137", "r138", "r140", "r145", "r147", "r149", "r168", "r179", "r180", "r181", "r225", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r307", "r308", "r309", "r310", "r311", "r312", "r316", "r318", "r320", "r350", "r363", "r364", "r365", "r380", "r445"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r567"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r531", "r542", "r552", "r577"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r528", "r539", "r549", "r574"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": ["r573"] }, "alzm_ExercisePrice1Member": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ExercisePrice1Member", "presentation": ["http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "label": "$12.00 [Member]", "documentation": "The element represents exercise price1 member." } } }, "auth_ref": [] }, "alzm_ExercisePrice3Member": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ExercisePrice3Member", "presentation": ["http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "label": "$450.00 [Member]", "documentation": "The element represents exercise price3 member." } } }, "auth_ref": [] }, "alzm_ExercisePrice4Member": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ExercisePrice4Member", "presentation": ["http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "label": "$937.50 [Member]", "documentation": "The element represents exercise price4 member." } } }, "auth_ref": [] }, "alzm_ExercisePrice5Member": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ExercisePrice5Member", "presentation": ["http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "label": "$12.00 - $937.50 [Member]" } } }, "auth_ref": [] }, "us-gaap_ExtendedProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExtendedProductWarrantyPolicy", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability." } } }, "auth_ref": ["r634"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://alzamend.com/role/WarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair value of warrant", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r5"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r8"] }, "alzm_FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock", "crdr": "credit", "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued in connection with Series A convertible preferred stock" } } }, "auth_ref": [] }, "alzm_FirstAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "FirstAnniversaryMember", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "First Anniversary [Member]" } } }, "auth_ref": [] }, "alzm_FirstCommercialSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "FirstCommercialSaleMember", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "First Commercial Sale [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r535", "r546", "r556", "r581"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r535", "r546", "r556", "r581"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r535", "r546", "r556", "r581"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r535", "r546", "r556", "r581"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r535", "r546", "r556", "r581"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r61", "r427"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetails2"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r61"] }, "us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteedInsuranceContractTypeOfGuaranteeAxis", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Guaranteed Insurance Contract, Type of Guarantee [Axis]", "documentation": "Information by guarantee for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders." } } }, "auth_ref": ["r87", "r88", "r89", "r90", "r709", "r710", "r711"] }, "us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteedInsuranceContractTypeOfGuaranteeDomain", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Guarantee for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders." } } }, "auth_ref": ["r87", "r88", "r89", "r90", "r709", "r710", "r711"] }, "us-gaap_GuaranteesAndProductWarrantiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteesAndProductWarrantiesAbstract", "lang": { "en-us": { "role": { "label": "Guarantees and Product Warranties [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetails2", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r182", "r183", "r184", "r303", "r304", "r305", "r360", "r362", "r430", "r469", "r490", "r685"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetails2", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r183", "r184", "r303", "r304", "r305", "r360", "r362", "r430", "r469", "r490", "r685"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "alzm_IncreaseDecreaseInPrepaidExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "IncreaseDecreaseInPrepaidExpensesRelatedParty", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses - related party", "label": "IncreaseDecreaseInPrepaidExpensesRelatedParty" } } }, "auth_ref": [] }, "alzm_IndApplicationFilingMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "IndApplicationFilingMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Ind Application Filing [Member]", "documentation": "The element represents ind application filing member." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r535", "r546", "r556", "r573", "r581", "r585", "r593" ] }, "alzm_InitialLicenseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "InitialLicenseFees", "crdr": "debit", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Initial license fees", "documentation": "Amount of initial license fees." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r591" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r527", "r596" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r527", "r596" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r527", "r596" ] }, "alzm_InsurancePurchased": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "InsurancePurchased", "crdr": "debit", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Insurance purchased" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r167", "r171", "r172", "r173", "r175", "r313", "r476", "r477" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46" ] }, "alzm_IssuanceOfCommonStockForCashNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "IssuanceOfCommonStockForCashNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash, net of issuance costs" } } }, "auth_ref": [] }, "alzm_IssuanceOfCommonStockForCashNetOfIssuanceCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "IssuanceOfCommonStockForCashNetOfIssuanceCostsShares", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash, net of issuance costs, shares" } } }, "auth_ref": [] }, "alzm_IssuanceOfPreferredStockForCashNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "IssuanceOfPreferredStockForCashNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock for cash, net of issuance costs" } } }, "auth_ref": [] }, "alzm_IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock for cash, net of issuance costs, shares" } } }, "auth_ref": [] }, "alzm_KeyEmployeesAndDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "KeyEmployeesAndDirectorMember", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Key Employees and Director [Member]", "documentation": "The element represents key employees and director member." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES, ALL CURRENT", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r13", "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r135", "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r287", "r290", "r291", "r306", "r401", "r474", "r512", "r635", "r674", "r675" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r59", "r83", "r344", "r496", "r611", "r625", "r670" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "alzm_LicenseEventsAxis": { "xbrltype": "stringItemType", "nsuri": "http://alzamend.com/20241031", "localname": "LicenseEventsAxis", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "License Events [Axis]", "documentation": "The element represents license events axis." } } }, "auth_ref": [] }, "alzm_LicenseEventsDomain": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "LicenseEventsDomain", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r99", "r100", "r101", "r102", "r103", "r111", "r112", "r187", "r188", "r189", "r190", "r228", "r272", "r302", "r331", "r359", "r361", "r368", "r393", "r394", "r454", "r455", "r456", "r457", "r458", "r467", "r468", "r478", "r482", "r484", "r491", "r492", "r493", "r494", "r498", "r637", "r676", "r677", "r678", "r679", "r680", "r681" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r565" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r565" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r99", "r100", "r101", "r102", "r103", "r111", "r112", "r187", "r188", "r189", "r190", "r228", "r272", "r302", "r331", "r359", "r361", "r368", "r393", "r394", "r454", "r455", "r456", "r457", "r458", "r467", "r468", "r478", "r482", "r484", "r491", "r492", "r493", "r498", "r637", "r676", "r677", "r678", "r679", "r680", "r681" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r584" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r592" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r566" ] }, "alzm_NetCash": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "NetCash", "crdr": "credit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net cash" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r131" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r131" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows", "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net loss", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r60", "r67", "r84", "r115", "r123", "r124", "r127", "r135", "r139", "r141", "r142", "r143", "r144", "r145", "r148", "r149", "r159", "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r280", "r283", "r301", "r306", "r349", "r424", "r443", "r444", "r510", "r635" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS AVAILABLE TO COMMON SHARES", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r129", "r141", "r142", "r143", "r144", "r150", "r151", "r160", "r163", "r283" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common
```

shareholders." } } }, "auth_ref": ["r129", "r152", "r155", "r156", "r157", "r158", "r160", "r163"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recent Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.org/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r565"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r563"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r562"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r592"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r592"] }, "alzm_NoncashFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://alzamend.com/20241031", "localname": "NoncashFinancingActivitiesAbstract", "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Non-cash financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r62"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE, NET" } } }, "auth_ref": [] }, "alzm_NoteRecievableForCommonStockRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "NoteRecievableForCommonStockRelatedPartyMember", "presentation": ["http://alzamend.com/role/StatementsOfStockholdersDeficitEquity"], "lang": { "en-us": { "role": { "label": "Note Recievable For Common Stock Related Party [Member]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r45", "r46"] }, "alzm_NumberOfSharesPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "NumberOfSharesPurchase", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares purchase", "documentation": "The element represents number of shares purchase." } } }, "auth_ref": [] }, "alzm_NumberOfWarrantExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "NumberOfWarrantExercisable", "presentation": ["http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "label": "Number of warrant exercisable" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r85", "r475", "r619", "r620", "r621", "r622", "r623"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "alzm_OriginationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "OriginationFees", "crdr": "debit", "presentation": ["http://alzamend.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Origination fees" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDescription", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Due date", "documentation": "Description of the nature and terms of commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": ["http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets"], "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r565"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r607", "r626"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r526"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r533", "r544", "r554", "r579"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r536", "r547", "r557", "r582"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r536", "r547", "r557", "r582"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r561"] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payments for royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": ["r3"] }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMachineryAndEquipment", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Machinery and Equipment", "documentation": "The cash outflow for acquisition of machinery and equipment." } } }, "auth_ref": ["r64"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r564"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r564"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r563"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r566"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r562"] }, "alzm_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.": { "xbrltype": "percentItemType", "nsuri": "http://alzamend.com/20241031", "localname": "PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Percentage of royalty payments on net sales of product", "documentation": "The element represents percentage of royalty payments on net sales of product.." } } }, "auth_ref": [] }, "alzm_PerformanceContingentStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "PerformanceContingentStockOptionsMember", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Perfromance Contingent Stock Options [Member]", "documentation": "The element represents perfromance contingent stock options member." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r563"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r520"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://alzamend.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r522"] }, "alzm_PreIndMeetingMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "PreIndMeetingMember", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Pre Ind Meeting [Member]", "documentation": "The element represents pre ind meeting member." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDiscountOnShares": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDiscountOnShares", "crdr": "debit", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Discount", "documentation": "Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require." } } }, "auth_ref": ["r77"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative", "http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r52", "r209"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r52", "r403"] }, "alzm_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "PreferredStockSharesDesignated", "presentation": ["http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock shares designated" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://alzamend.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r52", "r209"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://alzamend.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r52", "r403", "r422", "r716", "r717"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r52", "r340", "r496"] }, "alzm_PrepaidClinicalTrialExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "PrepaidClinicalTrialExpenses", "crdr": "debit", "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Prepaid clinical trial expenses" } } }, "auth_ref": [] }, "alzm_PrepaidClinicalTrialFees": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "PrepaidClinicalTrialFees", "crdr": "debit", "presentation": ["http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Prepaid clinical trial fees" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r608"] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r472", "r479", "r626"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net proceeds from the issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net proceeds from the issuance of preferred stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": ["r2"] }, "us-gaap_ProductLiabilityContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityContingencyLineItems", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r189", "r630", "r631", "r632"] }, "us-gaap_ProductLiabilityContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityContingencyTable", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Table]", "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product." } } }, "auth_ref": ["r189", "r630", "r631", "r632"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r104", "r105", "r106", "r107", "r108", "r109", "r110", "r176", "r332", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r470", "r483", "r497", "r498", "r499", "r500", "r501", "r603", "r632", "r633", "r639", "r684", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713"] }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyDisclosureTextBlock", "presentation": ["http://alzamend.com/role/Warrants"], "lang": { "en-us": { "role": { "label": "WARRANTS", "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period." } } }, "auth_ref": ["r191", "r192", "r193", "r194", "r195", "r196"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r104", "r105", "r106", "r107", "r108", "r109", "r110", "r176", "r332", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r470", "r483", "r497", "r498", "r499", "r500", "r501", "r603", "r632", "r633", "r639", "r684", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS", "label": "Net Income (Loss) Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r115", "r123", "r124", "r130", "r135", "r139", "r145", "r148", "r149", "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r280", "r283", "r285", "r288", "r289", "r301", "r306", "r334", "r348", "r379", "r424", "r443", "r444", "r488", "r489", "r511", "r609", "r635"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://alzamend.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r319", "r335", "r347", "r496"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r6", "r94", "r97", "r346"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Property and equipment estimated useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r561"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r561"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r99", "r100", "r101", "r102", "r103", "r111", "r112", "r187", "r188", "r189", "r190", "r226", "r228", "r258", "r259", "r260", "r272", "r302", "r329", "r330", "r331", "r359", "r361", "r368", "r393", "r394", "r454", "r455", "r456", "r457", "r458", "r467", "r468", "r478", "r482", "r484", "r491", "r492", "r493", "r494", "r498", "r504", "r628", "r637", "r668", "r677", "r678", "r679", "r680", "r681"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails1"], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r99", "r100", "r101", "r102", "r103", "r111", "r112", "r187", "r188", "r189", "r190", "r226", "r228", "r258", "r259", "r260", "r272", "r302", "r329", "r330", "r331", "r359", "r361", "r368", "r393", "r394", "r454", "r455", "r456", "r457", "r458", "r467", "r468", "r478", "r482", "r484", "r491", "r492", "r493", "r494", "r498", "r504", "r628", "r637", "r668", "r677", "r678", "r679", "r680", "r681"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": ["r528", "r539", "r549", "r574"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r177", "r227", "r324", "r325", "r337", "r345", "r396", "r397", "r398", "r399", "r400", "r421", "r423", "r453"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r177", "r227", "r324", "r325", "r337", "r345", "r396", "r397", "r398", "r399", "r400", "r421", "r423", "r453", "r673"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://alzamend.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r321", "r322", "r323", "r325", "r326", "r375", "r376", "r377", "r428", "r429", "r430", "r449", "r451"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://alzamend.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r274", "r469", "r476", "r682"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://alzamend.com/role/Stock-basedCompensationDetails2"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r273"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r529", "r540", "r550", "r575"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": ["r530", "r541", "r551", "r576"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": ["r537", "r548", "r558", "r583"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://alzamend.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } } }, "auth_ref": [ "r56", "r76", "r343", "r366", "r367", "r374", "r404", "r496" ] }, "us-gaap_RetainedEarningsAppropriated": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAppropriated", "crdr": "credit", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "Retained Earnings, Appropriated", "documentation": "Amount of accumulated undistributed earnings (deficit) not available for dividend distribution. Includes, but is not limited to, retained earnings appropriated for specific business purpose." } } }, "auth_ref": [ "r26", "r27", "r55", "r134", "r342" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r113", "r136", "r137", "r138", "r140", "r145", "r147", "r149", "r179", "r180", "r181", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r292", "r294", "r295", "r297", "r299", "r316", "r318", "r363", "r365", "r380", "r716" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r592" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r592" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/SubsequentEventsDetailsNarrative", "http://alzamend.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Value of common stock sold", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common stock sold", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of antidilutive securities excluded from computation of earnings per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://alzamend.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of common stock warrants outstanding", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of nonvested restricted stock units activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r79" ] }, "alzm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expenses and other current assets" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r230", "r231", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of share-based payment arrangement, option, activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r78" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r25", "r28", "r29", "r30", "r31", "r32", "r72", "r74", "r75", "r76", "r119", "r120", "r121", "r169", "r209", "r210", "r211", "r213", "r216", "r221", "r223", "r370", "r371", "r372", "r373", "r482", "r601", "r610" ] }, "alzm_ScheduleOfWarrantActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://alzamend.com/20241031", "localname": "ScheduleOfWarrantActivityTableTextBlock", "presentation": [ "http://alzamend.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrant activity" } } }, "auth_ref": [] }, "alzm_SecondAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SecondAnniversaryMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Second Anniversary [Member]" } } }, "auth_ref": [] }, "alzm_SecuritiesPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SecuritiesPurchaseAgreementsMember", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreements [Member]", "documentation": "The element represents securities purchase agreements member." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r514" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r518" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r517" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r523" ] }, "alzm_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r605", "r606", "r638" ] }, "alzm_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r605", "r606", "r638" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation to employees and consultants", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Unvested shares, Cancelled", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Unvested Weighted Average Grant Date Fair Value, Cancelled", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Unvested shares, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Unvested Weighted Average Grant Date Fair Value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested shares, Beginning balance", "periodEndLabel": "Unvested shares, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r245", "r246" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested Weighted Average Grant Date Fair Value, Beginning balance", "periodEndLabel": "Unvested Weighted Average Grant Date Fair Value, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r245", "r246" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [
```

```
"http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Unvested shares, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r249" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Unvested Weighted Average Grant Date Fair Value, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r249" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r230", "r231", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares, Options exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award, number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r487" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares available for grant begining (in shares)", "periodEndLabel": "Shares available for grant end (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares, Options exercisable at end", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r239" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options exercisable at end", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r239" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, Options expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r244" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares, Options granted", "verboseLabel": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate intrinsic value begining", "periodEndLabel": "Aggregate intrinsic value end", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares begining (in shares)", "periodEndLabel": "Number of shares end (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r237", "r238" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price begining (in dollars per share)", "periodEndLabel": "Weighted average exercise price end (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r237", "r238" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Options vested and expected to vest at end", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r253" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares, Options vested and expected to vest at end", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r253" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options vested and expected to vest at end", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r253" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Terms of award", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r242" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r244" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r229", "r236", "r255", "r256", "r257", "r258", "r261", "r267", "r268", "r269", "r270" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award, expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r486" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Options exercisable at end", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r33" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, Options exercisable at end", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r33" ] },
"alzm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life end (years)", "documentation": "The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life begining (years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r80" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, Options vested and expected to vest at end", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r253" ] }, "alzm_SharesAvailableForGrantOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SharesAvailableForGrantOptionsExercised", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant, Options exercised" } } }, "auth_ref": [] }, "alzm_SharesAvailableForGrantOptionsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SharesAvailableForGrantOptionsExpired", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant, Options expired" } } }, "auth_ref": [] }, "alzm_SharesAvailableForGrantOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SharesAvailableForGrantOptionsGranted", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Shares available for grant, Options granted" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "alzm_SharesPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "SharesPurchasePrice", "crdr": "debit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares purchase price", "documentation": "The element represents shares purchase price." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://alzamend.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r68", "r133" ] },
"dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r521" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/BalanceSheetsParenthetical",
"http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r98", "r119", "r120", "r121", "r135", "r153", "r154", "r161", "r163", "r169", "r170", "r178", "r197", "r199", "r200", "r201", "r204", "r205", "r209", "r210", "r213", "r216", "r223", "r306", "r370", "r371", "r372", "r373", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r403", "r425", "r445", "r459", "r460", "r461", "r462", "r463", "r601", "r610", "r618" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementEquityComponentsAxis", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity",
"http://alzamend.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } },
"auth_ref": [ "r9", "r53", "r57", "r58", "r113", "r125", "r126", "r127", "r136", "r137", "r138", "r140", "r145", "r147", "r149", "r168", "r179", "r180", "r181", "r225", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r307", "r308", "r309", "r310", "r311", "r312", "r316", "r318", "r320", "r350", "r363", "r364", "r365", "r380", "r445" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative",
"http://alzamend.com/role/StatementsOfStockholdersDeficitEquity", "http://alzamend.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r136", "r137", "r138", "r168", "r318", "r332", "r369", "r392", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r406", "r407", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r505" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label":
"STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementTable", "presentation": [ "http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/BalanceSheetsParenthetical",
"http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity",
"http://alzamend.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r136", "r137", "r138", "r168", "r177", "r318", "r332", "r369", "r392", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r406", "r407", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r505" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r532", "r543", "r553", "r578" ] }, "alzm_StockBasedCompensationMember": { "xbrltype": "domainItemType", "nsuri":
"http://alzamend.com/20241031", "localname": "StockBasedCompensationMember", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Based Compensation [Member]" } } }, "auth_ref": [] }, "alzm_StockIncentivePlan2016Member": { "xbrltype": "domainItemType", "nsuri":
"http://alzamend.com/20241031", "localname": "StockIncentivePlan2016Member", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Incentive Plan2016 [Member]", "documentation": "The element represents stock incentive plan2016 member." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for restricted stock awards, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r52", "r53", "r76", "r370", "r445", "r460" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for restricted stock awards", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r52", "r53", "r76", "r380", "r445", "r460", "r511" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [
"http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r504" ] },
"alzm_StockbasedCompensationToEmployeesAndConsultants": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname":
"StockbasedCompensationToEmployeesAndConsultants", "crdr": "credit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation to employees and consultants" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://alzamend.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } },
"auth_ref": [ "r53", "r57", "r58", "r70", "r405", "r422", "r446", "r447", "r496", "r512", "r611", "r625", "r670", "r716" ] }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityBeforeTreasuryStock", "crdr": "credit", "presentation": [
"http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stockholders' deficit", "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r38", "r39", "r40", "r113", "r114", "r126", "r136", "r137", "r138", "r140", "r145", "r147", "r179", "r180", "r181", "r225", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r307", "r308", "r312", "r317", "r320", "r364", "r365", "r378", "r405", "r422", "r446", "r447", "r464", "r511", "r611", "r625", "r670", "r716" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://alzamend.com/role/EquityTransactions" ], "lang": { "en-us": { "role": { "label": "EQUITY TRANSACTIONS", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r73", "r134", "r208", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r222", "r225", "r298", "r448", "r450", "r465" ] }, "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteSubscriptionsReceivable", "crdr": "debit", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Subscription receivable", "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital." } } },
"auth_ref": [ "r25", "r52", "r53", "r57", "r452" ] }, "alzm_SubscriptionReceivablePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname":
"SubscriptionReceivablePaymentReceived", "crdr": "debit", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label":
"Subscription receivable payment received" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://alzamend.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r327", "r328" ] },
"us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcern" ], "lang": { "en-us": { "role": { "label": "LIQUIDITY AND GOING CONCERN", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } },
"auth_ref": [ "r43" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowInformationAbstract", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r572" ] }, "us-gaap_TerminationLoansDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TerminationLoansDescription", "presentation": [
"http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Termination loans description", "documentation": "General description of liabilities to third parties under a termination loan agreement, whether or not guaranteed by the government, including a cross reference to the related termination claim or claims recorded or disclosed at the latest balance sheet date." } } }, "auth_ref": [ "r41" ] }, "alzm_ThirdAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname":
```

```
"ThirdAnniversaryMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Third Anniversary [Member]" } } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r624", "r672" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r564" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r571" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r594" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r595" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r595" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r593" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r593" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r594" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r284" ] }, "alzm_UnamortizedStockBasedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UnamortizedStockBasedCompensationMember", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized Stock Based Compensation [Member]", "documentation": "The element represents unamortized stock based compensation member." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r590" ] }, "alzm_UponCompletionOfFirstClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponCompletionOfFirstClinicalTrialMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon Completion of First Clinical Trial [Member]", "documentation": "The element represents upon completion of first clinical trial member." } } }, "auth_ref": [] }, "alzm_UponCompletionOfFirstPhaseIIClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponCompletionOfFirstPhaseIIClinicalTrialMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon Completion Of First Phase II Clinical Trial [Member]" } } }, "auth_ref": [] }, "alzm_UponFDABLAApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponFDABLAApprovalMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon FDA BLA Approval [Member]" } } }, "auth_ref": [] }, "alzm_UponFdaApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponFdaApprovalMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon Fda Approval [Member]", "documentation": "The element represents upon fda approval member." } } }, "auth_ref": [] }, "alzm_UponFirstDosingOfPatientInClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponFirstDosingOfPatientInClinicalTrialMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon First Dosing of Patient in Clinical Trial [Member]", "documentation": "The element represents upon first dosing of patient in clinical trial member." } } }, "auth_ref": [] }, "alzm_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon First Dosing Of Patient In First Phase I Clinical Trial [Member]" } } }, "auth_ref": [] }, "alzm_UponFirstPatientTreatedInAPhaseIIIClinicalMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponFirstPatientTreatedInAPhaseIIIClinicalMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon First Patient Treated In A Phase III Clinical [Member]" } } }, "auth_ref": [] }, "alzm_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponFirstPatientTreatedInPhaseIIIClinicalTrialMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon First Patient Treated In Phase III Clinical [Member]" } } }, "auth_ref": [] }, "alzm_UponINDApplicationFilingMember": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "UponINDApplicationFilingMember", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Upon IND Application Filing [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r21", "r22", "r23", "r92", "r93", "r95", "r96" ] }, "alzm_Warrant2024Member": { "xbrltype": "domainItemType", "nsuri": "http://alzamend.com/20241031", "localname": "Warrant2024Member", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant 2024 [Member]" } } }, "auth_ref": [] }, "alzm_WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://alzamend.com/20241031", "localname": "WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant exercisable, weighted average exercise price (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r502", "r503", "r506", "r507", "r508", "r509" ] }, "alzm_WarrantOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://alzamend.com/20241031", "localname": "WarrantOutstandingWeightedAverageExercisePrice", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant outstanding, weighted average exercise price (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life (years)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r667", "r668", "r669" ] }, "alzm_WeightedAverageExercisePriceCancelledexpired": { "xbrltype": "perShareItemType", "nsuri": "http://alzamend.com/20241031", "localname": "WeightedAverageExercisePriceCancelledexpired", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, cancelled/expired" } } }, "auth_ref": [] }, "alzm_WeightedAverageExercisesPriceGranted": { "xbrltype": "perShareItemType", "nsuri": "http://alzamend.com/20241031", "localname": "WeightedAverageExercisesPriceGranted", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted weighted average common shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r152", "r163" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic weighted average common shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r150", "r163" ] }, "alzm_WorkingCapitalDeficiency": { "xbrltype": "monetaryItemType", "nsuri": "http://alzamend.com/20241031", "localname": "WorkingCapitalDeficiency", "crdr": "credit", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital deficiency" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://alzamend.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r599" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "405", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478788/912-405-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.4-07)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479808/944-20-55-15" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17",

"Paragraph": "Column D", "Publisher": "SEC" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r490": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",

"Subparagraph": "B" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r601": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Subparagraph": "(a)", "Publisher": "SEC" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } ZIP 60 0001214659-24-002764-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001214659-24-020264-xbrl.zip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|V[<.]@UR+"&O]UR"B@,@8 M,=!YB04!%3+@B9/FD2EB>*6*YW]KMR!C>:MW1L-N?#!MT:WNV.[H!5]*E K(G261&T_Z8]WH:?TOX_YPVI]ZAC:: .L_T;KWDTE? M CJ=|F<-AKFK"5B/M60*S)+92H#'DSM<3V07*B#U,65CLU'WE]:U/NWWP ?> M2;AT.64UP&0#|QDO!AXN,*#HDT+7?Y_L^L_Z9 *NK:&!W'S<:D6$M\0%SP03 MOIO0L+,9<8H(% #Y(0D(C\[8W8'WLEW6+ FD!-.?]C.-ODH^1'B#.R (W.K M Y'O7@&3\R0F?5BJP4)M!I8RU:O2.S5(Y" OP2 HML:(9>&16UJ.RO%1$I5) M? Z#/8.88ZY,&'+4)W7W@^ \75.T_XFC^2+U5 *.3FL+OKZ=@)G)1U?.4;R:4 MW8*8"L%,A:#F.)46* E]M)A[4WV9A<89^C!5@(Q(%2 ,)4 *(70KJL!<(\ M=1O'"O0* <*;2#,K!:@/L;E%KS"8+213@2^4:\B+8!BW%4'8;GL0[!3Q2&84P MK&WZ?_?X=AN2[5I4?8-CQ4VG;"B5J1703"4Z"C:E&D1?*3@(NE$A.@@IRY$\225' M2L.#H/(&PSTP3)AF-18%5--9%D54&QM]E? @O9JI5&!2P3>5D*D2 C>V^&K8) M$]Z)4P'M5/JF.MJ-3>|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|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|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|\XZ^S@O$F&WY*<]@(21BY9",^. MVB@(;2]\C)'9@O_4WC5K\X_:W5[!K'ORPIS6SOBA!7WJXBE>&/Q?8._M]*]!8U6(+UWWCW=ROY[K%'PN@;'9(3[5LZ/FIC2O_4$^]H(E#HB-W%*@4GL>!R$?,A@^"MAX,5[S_M80Y^5&BR_% ['1S8+]/US25T'HLP0+XA- O./#0E>RP M%'\W /$EC_!Q:R[=#X.SHF/UX@XYLL:>PPSL,D8 M H8_V/@\|=/094PB$960<;ZS D&SSA./PJ00\-HPDQ:,EM]MQL/V&?!^(*[1: MLMUQG@YZK4@01@3@ 5R;NPL.YO2\3]'K<3!NH^<'0QP@XK(1MU- GO!>\|\4L_M(=7.'\M"+RNGAF@6/?[@<):041][97.Y15@*73(K/:5H%&FL:A? MY7.V12K5]=2%6- G$>XBJJHY0%K]ZA&KK#&5OEY5331VB=$A5I)^'UD:NO7'# M4'P'\=ZX)< \&)G)X>#5MUD"DC &T?[?EVCS3<)-]RIX;]1R\]0I.\DO1#U M ,9:L3^$!/)ACN4846=CV]OX<.^A#2Q'L/- OM_NV0^O2.X;2Y=M_-+'/MMM* M#3?Y%H@]A#M&]9^1&C=X7QVL!NPW2>+3-8:9 MPL3EI1+/X0-\S?/(".>.C;Q>>@R*S-%0K+!.!-T1}$!<$@A['C(?L48-#==M MF8U-T"LO)!? G^(SV30_G%'LGQW2NICKYSH@&6)F0U,9-#^5B-G)TU(D*\:!0 M_(20S$1:\)8F4 L,-G5"2 4SWM3&30_G;+O+LZ0L577R(UY0H9X*'7++I@>S M,A=92NI$1-^!A32HC-P)3*XM;X#6)'@_29F2\+(ZJ- %RUCPM!2KKQ.Z4EX\| M]C(]V"%RB!G;U:;L# 6'=/.)DJEKQIGY\USIFX(G>@3TCY.T362*P2'8V'NO!RYA=946$WB/O Y-#Z<#:2A23RF$UIO:+O>F=6RU M^DEQM2J* 0=;4 ;%^!")_VAL'Q!;QM;S%I=?UXXI]UE1.2[&".4TOQ0'[^5P M(IP%W2N7^\!K^6]);6^#6N&@FWN,C(T2!***4"+ %^2FV0B3U-;I^0]Q&L? MVR3V2K=,2[R5!O'^,%;2E- ;)E/Z*^@'Y$VW?![OBAV!(6'BV I+3BFQ6V4PI M=&UZ6^U@^J3-HQ.GX6SB.NL6A92S#AGMF]Y@.YB]?$/H1!E$;A\#T"'">_FMY MT8G1831#3#TYFE? =V$^>&N6?]*7\,$,>LWB2L1S*!+@K#8KOCF2LD$K*4"/U MLX:D[[&LAE4P68/$\45>MK=M?X_=I9.F^\I3\K-?-/2# O77+]YGF,+RGC [M<'66*I.A\]BZ#=?! <]JW81GOXV_(7A(/^Z_BH>^.BS# _/D5!F-;638&#OL!JBW&-OP8R/CA5URJW?*.JJJ?_F<'C7 ME=7.HU,.3@<==/X.,PV_[>8GCO8ANEB>IC6.0]E7-:1,+L'MD'C%<@HAW"(Y[*9- 5<++"=D_C]QM%T &K& M[G(!M>ST5.LM7YV-F3 M7G4IV_B8_V#.!E-K,K?&(V-!8US?SZR1.9M5N %8>/FP /Y9*EQ$+N, ^3N&?6[I3-'MQ0+ ^SQ(%|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|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|U(44ME1_0<5*$,-:TTX=!R"%SA M?H_9QYO9U>QB>;)6/E8GX]NYA-_? LGEWB%"<'11987^46PB8L@ MB?^)V2BS">*(CC?|\!OE)GN,BWY_O-'@F!Y?]DLA'^@1MAA]8)!CJ'Z<>@]]> ME8IXL=0'V1=|AJJBS[@OPDM'9?'MP^Z W \.\16)+ZT/- P=J,N9:#:?.N!EZ MQ\56BX,AK!FC<&/M(70QF5VBZ7\NIC=WTSON.LR7?VW>HM@!=39K?O[]G+ M*;ZX?]\U<[Q<(L3%IS!.]/=8T#P?9#3+&KL,:0AO;JU% ?Y0-TI/(3@N3.'-.=- E4HG+ B0#;:N WF[_B8[?7"I(/N& ,.ZASR(E]>[]#6 M0^@>R G%W]Z<3^ZFEW2.^8D-'A.V^NB],WSUB%VRVTP1#U$%P^WS<*!=|ADP=[?4A&>ONY7;['FJRR3:*+KEI M7Y$V+\U:8#AI#;7/QU\FM[>3&P!N,S7YZ[@H/9Z46GN^?(-3MGACO9XOL R7 M#!Q5O3T9M2 AI=CA$LN2JC+X#;S4PK0Y0:K>INLZ-!"P/%9:UV'E0#ES/A! MZ 5FSS]IFBT_3;G]Y>L9%W.^[#R] ;'F//W'-BYVI/;%W+)03G -L>Z$F"L MHA26$+C/A2 9-7X)^F.61CD);J;K.#V]FR OM.=LJ'5ZFR2V2]#(=|0Q (O M_^,SV[I=4K?O:G+!YM+^356U1K (2+%:4@\X9_>T9:EI&FU6<\E#VTJTZ6?2 M<,Z22#B/45<#?$]U%;$9!A5E:,WC8-*@$!*2_.X0!T\5>U-Y.WT>K*<7J+% MY!:.I63!._@?6^]W3\L]IW4XIY#K'2@^P%5,EDP]#(%!:P&W%4RD,R?/VZ MV,3P*>1]\LD8H2<5!LLHXYI(Y_ [ZL6O/?ISU,(BW]5)'DO;FM7_M=X>L!2 MV>F]@4$5ZIP2L-($P[U!+D=$.S.R=C)S[%]+)R)>4S>@?UA9)>22 M7'* ;1)U)<'0110I+<^BI$?7.B8L@?V3K?|0/-F=^"A)F:.WLDZ6NT]7:(=7I M+-K:* (+AVQ"TPMHL52]W&]A?6NK>N=@D8&|=*YFEU"7EV07VD M>D:;G_]^3YAU0OU0]4QI52VC:67]97@P8)H_'+JS9L%V[*LR[799W0D^? M"YQ&N!<(N=-2UZ4?C-(:.!GXGI$"G (9X-BB%4.!2R+^-G 8DI=/_?(${)[T!V M]11RRFM[*K0(99>!0ZUK' *9[ZS/$?4/V3&;YVEB*MZ9]H- M):N2192O\: MXM:$(YZPXMQR<6QE6R3]%?.C)CS'6 M!.D_U[SOO7O[X1WO? ^R7UB>]3L7.\WZT'WWE+/N=O4CE.>B-OVMXJS3*%R8 M|?I12OBR5+V]D/.E"6!:._EXRH+%//O7ET]AR_1M/0MJEXV*G M[13'+-C/6'/HAY"/+6-+]=Y? CEX57@.@#G23I4\X+W!T2_]+XI#^C7^3SVEJX%DF*]'28A5923S#:\) M=U:,. *NCVI=2'5WWXO>M7!0N7;YMP;*+LO3ZMUF27&6$=ZEA?L[@\OSX."K M+?=O!A;FG=W'JH&.\F&YV5!Z,A7_(__=>>^_0?O['3XNS| MQC9(YO=)_,-_A4=>H+D[S@@GX**K'7MZHIHN7^$\EQP_VC59MP_N##OW#]6 M#?3<;\!'6?."_[3BKT [^@ZTKE[B?2A@0;::(% [WT=&]X&=P>2CVF&01S"=R M(W_)R\LWW>9$?82KUB2Y52()S#(.G.A37 ;SU EZ-U@V*3XCE*<126BAJ M%+QW)UM9000Q^0[H[']'GZO\43M=OQE*--719R>1*HW:F/0_M2N.C:*IW_"8:'-[B8I702@EGXT^0IB!/NO66MF4Z%^9+M<'N-WXARW$88C:QF M-\1H8"'0;.?8"@B7O.,");2($_ENS"W\G.-HELXWF%T1G#Y42TJQ<-K51L&9 M%V<%O''EM-+>39XU1.FOQ"U:+8Y3E-5/]9I>#.&$P]&"A%CW.7DD4OF2EQF& MUOY IPE!8V_PWEE.6BW!G6V'FU5E[\Y073:;:+N|019"$S.-EP6:_\L+\IV(Y M\)-<*RYG/W[Q3]^0/?)'Z5PX>Z2RP72O(U?(IF.Q.,Y!)X[SHAO'6;\$T;>4 M9P9.=|&\AUXW6;-P\M.T1UWV"^IOW<|OQ,Y6%OQ:>E)G-MIN-CY<'<@P%_'W> M>U@O<>>DN @(V5&P/!^"9ES5P'#.]LV//06NU1"N4DO%;%)-2"J +>)$ M*R_5V8 +*2U7!(:D<9#4!P5DZP-Z>62K+C;PFV47G:!W%MDB%+E3GK\(*QU4 M.*7F. 8 &\;QS=)!2X(T5!NLOIA;ZR0'V35%71GOC#$ 4Q$EKN6\4X.?/NN> M2]K.(BE]JE-P?NNI%KAPZ:E4&@R%C!#[9"IOU>V?_? +.J&X5NG<+ZWN/0L6# M$=*"EQ@DJ:O39A59$22ZW2<+I'V"+5F9[@X7#O"*KK"]1U3*>O6&VG"UGA 3 M]&Z0:-!9>D K?+A!4M"B&6H7M,Z/['R$K!HR*6=44$-L2""*P&A^):Y^PS>" M:%-+>A^:C"=S5:K;K>TR]HSW]+2]KC'ODD>&];:>3O57\T5%*(TN(/FR0#^:OO M?K_@^.&OP-'D"9/@ 4^?,0GC'"]{K%OP[O>N 5[UUG&V) MR?]KAU=(W%N'OO\):L%4N(7A?6;KO^Y&NT'J CK',]F>8\N&L*.9K\MWF-&Z MQFD>A[]@C1.^[X7Z[+/=B*/H/NR5^X#2"LKA%(]/!#$\!08Q;4X>N*WL-1] M]5196N1+ E4U^-_ ERZ&6BNXRM RIR#X_BXV6]]%9,%3[19PS5!50_O,E+[FV MOT0^2Q>\|W\D6:[:*SS)FUZ2_==\|F-:,?LEKO'>IT]?-M(KS GN>,@V9]&.< M8A7GF A_]=3C?]I\/?AXKW\Y/?OH=1ZXE'-T S#*Q:LK,L+);ZD"HV>=_:, #O&V:N9^ (&'>6F9GVI59F_H7 5!I8K2;EX):E@YPL<[SFZ[^7W> MNY[#2MK[AD^HHYK&T_HC>'40!X(U9E^H&/ZB8.0O!R.OP]CW:63R:11CI M+FYB,LY9K!3!N([=BE@[BES+.W4'0QWG)/(2X(|\ONY)Z\%UF@YZHM4Z9M MC2'C/]4O5P0EKW'3I7XLNU3*]UJB4^X]:LXQ/E[(1W0/$ *'\./\S<0!]BN M>Z*/?&0'8W6/TU<RC/X M2SF& [_$SO[N5I4-[WF!V=^LR8S^Y.CMK_WI02S=']C'I,V\[8^OGBJL/UJ M;76M,4 Z5Q6-BHS_C(+B#]+[/1S=/134Z[(4KN>FAR'Z UF54RX'OQ33<\#, M8/ '5DT8WND8 3@2SI%/?R&.>;AXN.A@V6]('V2 ^;>+\^$G72,.:.,3DXO M'X#G=]E,AL_NUEU2@(%E?cO^ >OUEC^&,<QP-'D"9/@ 4^?,0GC'"]{K%OP[O>N 5[UUG&V) MR?]KAU=(W%N'OO\):L%4N(7A?6;KO^Y&NT'J CK',]F>8\N&L*.9K\MWF-&Z MQFD>A[]@C1.^[X7Z[+/=B*/H/NR5^X#2"LKA%(]/!#$\!08Q;4X>N*WL-1] M]5196N1+ E4U^-_ ERZ&6BNXRM RIR#X_BXV6]]%9,%3[19PS5!50_O,E+[FV MOT0^2Q>\|W\D6:[:*SS)FUZ2_==\|F-:,?LEKO'>IT]?-M(KS GN>,@V9]&.< M8A7GF A_]=3C?]I\/?AXKW\Y/?OH=1ZXE'-T S#*Q:LK,L+);ZD"HV>=_:, #O&V:N9^ (&'>6F9GVI59F_H7 5!I8K2;EX):E@YPL<[SFZ[^7W> MNY[#2MK[AD^HHYK&T_HC>'40!X(U9E^H&/ZB8.0O!R.OP]CW:63R:11CI M+FYB,LY9K!3!N([=BE@[BES+.W4'0QWG)/(2X(|\ONY)Z\%UF@YZHM4Z9M MC2'C/]4O5P0EKW'3I7XLNU3*]UJB4^X]:LXQ/E[(1W0/$ *'\./\S<0!]BN M>Z*/?&0'8W6/TU<RC/X M2SF& [_$SO[N5I4-[WF!V=^LR8S^Y.CMK_WI02S=']C'I,V\[8^OGBJL/UJ M;76M,4 Z5Q6-BHS_C(+B#]+[/1S=/134Z[(4KN>FAR'Z UF54RX'OQ33<\#, M8/ '5DT8WND8 3@2SI%/?R&.>;AXN.A@V6](

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|\%7;C?]M,5[@,I'I!A)&VEW M9!\06'96KE ,'VZX<5=KT&@(0*WWA7@>SY43$3_'5>S]<.EX@YL_,UY#-H)K92O;-Z- R=2#'N|+"N)$-VMA;<9:[E69"B1O39>]=>^|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|H7!C-"@)O.5$L\N AWO^Z',:TU\ZW5&_|WD\'WN|.:CWN!VA-.]QW3A!-X?"3),D8@1Z#H9(7DF MQO-KML4)9I[CWVVS]@!]M.'FD=(6U@\|Q31F0O7#]4/CI=[XB2!):@[@\Q%5UIP_%[GXW_#P:7@]IW=&TT^WUQO>C M*>_QD_'-L#<+4ES&Y'8PZ0[!G<%_3P:CN\%=.,L6.I_\8W'9Z][>W]X' M[^X&4Z1NU\].H7MA%$<]9^7%CN_]0=Q,_ZW>J<)[Q=1]\^B&<3IPF65 KY56 M0NZJ#1%Q9GX MH*4QM#Y.!SX4: -[IBBK#*F+W WUR"MT-S@V%O0H-AXLO3@=10(V%"3K>A* (_MM])_+78R-K-~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| M-:/^FADTG]'7V|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|-5RL,A<[5YE3BJO MI*B#G9UC;,X'867!3DL:BIQMCBIV6>]+U\XH8Y&SQI[^*2N"D2BVN'M=6'#)WN0;97+)PV

$%G29K)K;'I<-7FO)+8&:5+ #-GD?*6*O%Q%IL26X)\,88 :T[$A17 MC8L\TUC[A[N>Y8:LS2]12ZBE[Q"=#4SF!0Y-U1!(G(EXL]\FFF9+R8ZA62E M)_#-2X@C"[PNR^H 12/N#%EX4'O8-6!H U&T"\\/T] 5B>(4XNQW"/":O0D M=P)3\;OQ(.)48F^NQ9.*9W5>A*G@Q!6HA]RRAR&:V#)BU,WO4=/:8]WL1@S' M(,%7|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|S@F("O M?)]L740:H>'QZX5/IGR?G(&E\'VRZ/OD!$1%MCK7V>H\0*QPK|/E7F<+-AM= M6HH<=:9SU+OMW5+$63F(L_8!B2)..D!A%W%.1N*>[@S$!3N85[=PYW;B<(|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|'JQ62 Q M,22^0I"P!4@P0<(>+DA>@[>]&Y#LVTW?(CTCPUV/#!N^<--WA\W"3<\4-@_ = M3><+)*",Q+R!9'%0NEJ8'F96?%7<+'/]N2\=N)%B(8@P]7!;9*E56H5!A_W-MA:3I1EU1T">@Z8*6XQO>D\=.&/-V.150%AX <7GG$#J4KPD# QW;OQDN'W#0 MY,|\ M,Q,7T'X#AB >K]@-J#^P6J8Z*Z,Y*T M1[K4[\PM,>]XTQ:|A^D^; MHIC7[YUN3W-O" (EXS1.?'80:16!GS4]]/<@^($\U MB\#,F*^:25R;E_F9\9?YU^J(R;H;Y&%D5'VFNS?$+(03"C$+,68,,8?GP\:! MTZ'YLJ\/YP?DTV8;Z%GS;5\?T@,'Q\TTT#/FZV8+Y^Z%)1T-M!3Q&@_TT8_@Z MJ%^'NV1*8S&+YM&#;2F7V2=6M939RH5,7%E=X,[@<)>[*Y>@B.H3Q!:$..U" MD@\1JMY,>/NV(S82E+%!XX"C,G=V\GR 1:.IQKNI03C?##10:G'%4'Y01G* M74T2Y(,#<2B^O'Y<9|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|^4S$%T#2.NXO$:4G*+@MAJ?MJ=CH F&NIW2 MQI_()GDN8SK>> X4=2PI >\,Y,?F2UV&M;IV3C^8C1WX"G\I3>"26#+Z)+T< M:T VK]?31!*8&$+5OO5#'2]Q,#"@>I7+M2("4!>?]:]AJ 9 GU>YHX^80U3H MN$/4*KSK$+5:&7(IXF$&:+*QA^B$G,(&CDOQ T15<70WPTQJ#5]38 .OS$ M_& $!!$9Q4\?(=I.W!QV\VE'Z,9,AM9U+&@/DG),0 /]O__29>KDT\?)]?.! M(;1)QP3-30RB"U<_G6B#9^)6'0L*:7U $FA]&YX0RZ'@H]0)@2Q929"E! _C1 M !I@M,Q_Z]^^HC^SWS'?THEXD("LGA,W$YE4.H(#X HE4X_02K7Z2L9Z@02 MP4P_^S6EOFH8ZOB88-%GSY)HC. #%/7V:.WG?56#,I=^2B8+@T<"CD'HJBR) M)\3B2WLDZWMZ|3V:>DF7YN 8?:IB$&+BXO\[IO!Q;0YILO"^W>HVSXF[;KW; MO/O4UZ#D[YJ-^]M6M]6\(^KM6)HZ[8W0,L]Q5-TKX?^HBF6[LW+K:?[?R+X_G##P>&@^BFJ M8]XZTH!8K/!0@3=+,PUU=>KDR'*RA=!>K?/|1Z?P|\>^FBJ_>M ;F-2#]-C_&&I)"-'[.L1|OIB@?QDB/9#]M!OUY6:0EIM"=I;6DHC'5Y M=DS\A%-:T]'MAU9H*&^@X? L4.H9 DV>W8*)JACLPFC^;]5O*Z%ZVV,C &*K: M6# ^'TDOQG%?564 _79M"C80P[DA9H/&H],73^0L_F.(7IRLU5Q9V3_]?E^_ M[39OKWX3M\W.S6V7Z-S?WMW7VUVB>T-*]6/IHB@6>+FEJ#Y=^)[XN:"Z'YI M$@X#MC1>]487?4W76,X",Z0'_C_-6NA,%)XF#>X$M,7;KJ@:88P |<|6!&$% M 00,$8"XH"(:!WS%TTKIG"'V=08J4^_N!NA'=W^.&$FH@ 7_FXD"K,9@#ZO MLH$VW@UM:X0>G=X,#!4&MPIf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|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|V55;6H57[NK0F->;T_^U.C^M|>4:V+9 MLHLN;%&)6Q/[NF,*?01=TN4:]@["V'3MK=H\?|_Y_0<"AG1!@[6M|@[M1)>O:?UY/?GS_2LO5(>)GFIQPY-+<:R3/N3;)!<%IX"X! :KFW'>.1A8%Q+0 ME'6< H%" \0S_'_N:8UU!\=Q@:]U*/MF:IB6#+*@)[4L0=,,,3?7FBLC_?>]S MSP_07! &VO?X?&0-0JQO?U@#*8Z1EG"X,%,6\-&M;)\/'4=KZ%EUI#-O$UC' M16T=0C5OOBB$#GG\TA[>/H/,FQ#%FI56SLV.2N M@\16OO#+\96*S0 W>"2$)=3?&#B;$$4)&.=0Q[/I=.U.9YKG=D-<3[7 M68*I.L&*$>&Z3=BI!&OC/M%/FK)DPY08->,M+ (JA'^B) MO5"!OD.K4GC>4U8(IV%]RS(_)[<@/6@Z4,81ZFK|$K'5MQ9WZ[==HO7!NVS(M;XC%&&O6R9PQ=+06IPJ.K8HQ&08P1Z<7K7:]W6C5KPCH?]W<7M>[YG44 6=% M_++)'L5,;'SN_D2OQ411RP!C@OZ #Z.+90)A>6F83KR;*L)4A$^+[K6)V !+ M8/:1L!5>G:#Y%5%;6)XV3($0!C!P"0.=[S_,-(/_JD'<*';]'-!%@Z$W/Z M7 [%O\X).PPG8,ANA;O/6'=POB/1WP^(=(0!$Z6_(<$R*U MW$'DH1K0#3)48L42-^,9CQWHBKZ=@_B/7B6E $JRW,L@+]7-('4^LH.I|[MKRN"/-,E$R4K!B&F6? EM],PMT*=RLK;&8?;&))_): @F?D>I> E"!I4K(7[M#V3[WXB=LHKNR-.)>E^=&HN"2^)6TA]C+D?E/:"+"\$8% 1[]JR;3.EHZ@"(M4_, ^PUBSKN3&QF3)J0\CZ*7['LY_#^>SWW2_-&]C^^NN"-G?*A3:83?[8EFZ M8=8CQE6.!*8>/D"IAY@P,GL$2]NK6@;F&D?,8=;9>\5QU.E.D*TLO^5P.BO$ MD:&\U\T.T@(3&6!2:$"$63RA]RV8SL/]!&WT $52-0='JC_[..!)LUA>0ZL(MH3$$$!$.IV'_# @M?OX#@3_M&W._NJ58NVMQP=C_A.-(O!Q"XLV7D=27XL88 MW(YCC+!.T!U\MV#$AS)'YZ/\"&?/CCF|@9(9)1VC41FM;WQ0F*3,"_; MA+O9VI-"(O,P DV? $!Y[#NEO]V$(.^)VGQ-VE OL,%0;+B+;FD*Y;K)S_,)> MR5:W>6T&3?TM57.M?4/WW"Z9:UY1?MUL=^_6]_*6ZT/N#[$Z(%B7Y]!JP1BA M#:::2D*W:?!A%^_UWD[9P? V"]X[=JP2U*Y1>V55N+,7W:!I5>XOM7[5OW\9_ M'Z#23<=P|)GYO/$]=TR4""^^$8Y)15|:O&49;X\>PQW<6(3)/,#M=7UC ;<9 MR=7*RP+/([=?NRRF^*|)B$3*))'B6"II$DTG-H5:@\T+]9X!HA&-)T,/<8'P M5>7+F;F)U<_?Z5%SH=AG[%3"B M/MS>DF6"IY-C@B]7GN$97GBP:AY5*=5V'!G>1!6F Z,GG?7F2'L\ZFA?O[] M',6V'9Y"@).]NVNB53L!EU=B7"HB@;AB)?LN=+G/0FT:$ M>:2"Z+?N[L/F4VYZ^_^\QN3=TTON!U[L1]!83/0Z[])00A7P3SW0CE.O9AM M)#F2]K$D56%=CKQX\-"-.[[YO]?!=HHKL1O'C;AJ5+;SE3()?YXY-MWY%[-0=]P=/5-UFHZ_]E7*9K'!,(%+VY+_&YY>;6G&1 M^<7S)!.;6ZXIQ*VMU.H$*L.L@Z[7AS8$>2H3E*EN |<2;2I236$4_6+P1>?W ML41;9)+$1#;;",$5&MBDDH1B7U;Z*L\MX1"*&XY*A 9CB)KE7*Q"*S M$3G$HJ6OWA2 LS!X;27HMUV%I_7WY24C41_'R(DOU*9/W=-BK,!W.CV5J6 MUY=C+PXM? A(6E,;/"%&=[F6 %7.&''"7$ZA7"6N!>;;&%/YZDJ I9H8.C35?^ M1K<8KU8|+N:A'#W"8FF2KZ8DG")_FHG\:<-ADJ\DH2_)9M4T7(R<1QVM.G/ M'M_^@J.K5OVL=67U@]VWSXF[DWCVY>;[_/F[9U|(K/Y_;[5_4V\.V]>M!JM M[OL,"B-3Q+@BH^Z.#/==]X2*_>_ZY=7W>25*W)S$K14#%QGD<*:(2:>T/:OS MS10QKKI&.1UCZ^)&O2/,4&795@9<[>4&U'^5I?;T44HOO#;O/C9I@2ZQ M28P92@N#@38%(B&OC$(T/F^Y2^%](5=>X;NNY&K'&:H=||S- MGXSL[C-DC8$N/Q^GL:5*_R(CM*Z<+LC%U|P*$WG3 MEZ)@&+Z[?1G>W;=T,H@+1T+5_6[YGP^X7KSB|'SU9TLW!0FPDX=3 _%M7)! M#I^3).I7RSV;W<,3+ ,_0!YD,,>&OKY7(QKXZVO<6).-F*_C(MH)DX"I> MP:C+B6_-; M_WGGU:LWU]>MKGF.R\P+-6I:W5;[LMEN%!F!(B.0$^:OU*[F4+OE@;";H5]2 ME]*CI&7CZ%R1>RU4[V"9CYU$0V9G/XCY^EW9> MSA)9ZVGSX8Z@W6BF41#-LN .T.P^ 8N6"*CC16_;>)@]OA<6I/XBZ;E%T79D^CYS&'=GZ_BUM]M]Y> 'GW'[C&1XJ3, "3"I'"#%.)65TN M7$(5]S8:B_^82]V;T]MNCN'2K'@PA= 9;R+:HN$[DD/8NHRA6O(PU+PC&BZ=6F M8$^V5(KU7^6LU[=T?;I[?2)MTB7S]=O*1 60|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|$; 76@=+WBLD|++!?(!SXKA QE,?,0L ,]^Q/(C## MC(PV2(QF?6T2>9)AS7-*H5&&'.%->7.XL, (S*EZP:H;"%=Z[4H.5FVV(M@=E M!BL7$KEX!K9KHQY4WW2&0WA5D2^>Y)G@8VU[JF]/ MA%EN3EWD,YH8E^]&B(><.YIUT6H2+|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|S:69FY9K61M4JR)/ U1-\%%>_N;;O[/L'7+:TA M'I9M_YNEFCV:9GOS\^[=O|H(SI ;*%,X'% M9RB/DK!Q!^NJK!1*[|C:6<_^,I9?.53Y*OIV 9]C$OO8Z0O)60Z #H/_ZP)$T]? 8OO1A4/C5"SW& A[M)UKW/A^5C\(-YVYF+U2-@$XNT1UI !#7\$7 GO:3/ =QCPK$ YC)QI.S?DKG,ID_NF<&+PWQG7;OOL@P;6?F:/'O(DR\D M'W? R@=TA%OZF\K!HAJP[^EKUYO7+'Q=?_]Z|S+]'Z0P1QT6\Z31OZ^C.8J+Y MJ]-LWQ77%A?$I-;K[1:H0- &H[HBGH,G(*MFW]&%1]"[A,U"$(&^[LTK%__N MJXQ:+9=3V:A=A&8<[=9ME\3\1$*!HV&GM6S=%<46)1X;(?NMNWC:?PD]1 MVT\$IEFGH&(]'YZO)\(O-'5L)<*K>8KVW.(]W[)'I6F2PDB%+W'+-RV89I:S M2|:S;FR/WE&3)FNU,EFI!I?6'";C(=YYR'A#]4)\.<0^WF:=784L8[2>.DS& MLQ:C/1$?N3*4(]DRZOL5W.<%F_&N:UO%L;9= @5Z>#*SQ@;;^$)T,? 0N8($.4<2Z]7E5BB&KZ72A*\2'MW-9O;JN? >/5_UT M0MDHRSYC+OM=U8"+OFK/@P"+B;Q:]&Z)+-(R'SG^I4F6KT+,%@7&28HK8&&O M1(Z;801!T62%2<6\'*RX A? S2N1HFR%9= XEG2:1!RNP@.4[>O ?,LDQ*#VR MN^6;=5N^6|I `8,K58<+N+5\HV4;A>KR[PW9O?G-]\:|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|^4S$%T#2.NXO$:4G*+@MAJ?MJ=CH F&NIW2 MQI_()GDN8SK>> X4=2PI >\,Y,?F2UV&M;IV3C^8C1WX"G\I3>"26#+Z)+T< M:T VK]?31!*8&$+5OO5#'2]Q,#"@>I7+M2("4!>?]:]AJ 9 GU>YHX^80U3H MN$/4*KSK$+5:&7(IXF$&:+*QA^B$G,(&CDOQ T15<70WPTQJ#5]38 .OS$ M_& $!!$9Q4\?(=I.W!QV\VE'Z,9,AM9U+&@/DG),0 /]O__29>KDT\?)]?.! M(;1)QP3-30RB"U<_G6B#9^)6'0L*:7U $FA]&YX0RZ'@H]0)@2Q929"E! _C1 M !I@M,Q_Z]^^HC^SWS'?THEXD("LGA,W$YE4.H(#X HE4X_02K7Z2L9Z@02 MP4P_^S6EOFH8ZOB88-%GSY)HC. #%/7V:.WG?56#,I=^2B8+@T<"CD'HJBR) M)\3B2WLDZWMZ|3V:>DF7YN 8?:IB$&+BXO\[IO!Q;0YILO"^W>HVSXF[;KW; MO/O4UZ#D[YJ-^]M6M]6\(^KM6)HZ[8W0,L]Q5-TKX?^HBF6[LW+K:?[?R+X_G##P>&@^BFJ M8]XZTH!8K/!0@3=+,PUU=>KDR'*RA=!>K?/|1Z?P|\>^FBJ_>M ;F-2#]-C_&&I)"-'[.L1|OIB@?QDB/9#]M!OUY6:0EIM"=I;6DHC'5Y M=DS\A%-:T]'MAU9H*&^@X? L4.H9 DV>W8*)JACLPFC^;]5O*Z%ZVV,C &*K: M6# ^'TDOQG%?564 _79M"C80P[DA9H/&H],73^0L_F.(7IRLU5Q9V3_]?E^_ M[39OKWX3M\W.S6V7Z-S?WMW7VUVB>T-*]6/IHB@6>+FEJ#Y=^)[XN:"Z'YI M$@X#MC1>]487?4W76,X",Z0'_C_-6NA,%)XF#>X$M,7;KJ@:88P |<|6!&$% M 00,$8"XH"(:!WS%TTKIG"'V=08J4^_N!NA'=W^.&$FH@ 7_FXD"K,9@#ZO MLH$VW@UM:X0>G=X,#!4&MPIf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|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|V55;6H57[NK0F->;T_^U.C^M|>4:V+9 MLHLN;%&)6Q/[NF,*?01=TN4:]@["V'3MK=H\?|_Y_0<"AG1!@[6M|@[M1)>O:?UY/?GS_2LO5(>)GFIQPY-+<:R3/N3;)!<%IX"X! :KFW'>.1A8%Q+0 ME'6< H%" \0S_'_N:8UU!\=Q@:]U*/MF:IB6#+*@)[4L0=,,,3?7FBLC_?>]S MSP_07! &VO?X?&0-0JQO?U@#*8Z1EG"X,%,6\-&M;)\/'4=KZ%EUI#-O$UC' M16T=0C5OOBB$#GG\TA[>/H/,FQ#%FI56SLV.2N M@\16OO#+\96*S0 W>"2$)=3?&#B;$$4)&.=0Q[/I=.U.9YKG=D-<3[7 M68*I.L&*$>&Z3=BI!&OC/M%/FK)DPY08->,M+ (JA'^B) MO5"!OD.K4GC>4U8(IV%]RS(_)[<@/6@Z4,81ZFK|$K'5MQ9WZ[==HO7!NVS(M;XC%&&O6R9PQ=+06IPJ.K8HQ&08P1Z<7K7:]W6C5KPCH?]W<7M>[YG44 6=% M_++)'L5,;'SN_D2OQ411RP!C@OZ #Z.+90)A>6F83KR;*L)4A$^+[K6)V !+ M8/:1L!5>G:#Y%5%;6)XV3($0!C!P"0.=[S_,-(/_JD'<*';]'-!%@Z$W/Z M7 [%O\X).PPG8,ANA;O/6'=POB/1WP^(=(0!$Z6_(<$R*U MW$'DH1K0#3)48L42-^,9CQWHBKZ=@_B/7B6E $JRW,L@+]7-('4^LH.I|[MKRN"/-,E$R4K!B&F6? EM],PMT*=RLK;&8?;&))_): @F?D>I> E"!I4K(7[M#V3[WXB=LHKNR-.)>E^=&HN"2^)6TA]C+D?E/:"+"\$8% 1[]JR;3.EHZ@"(M4_, ^PUBSKN3&QF3)J0\CZ*7['LY_#^>SWW2_-&]C^^NN"-G?*A3:83?[8EFZ M8=8CQE6.!*8>/D"IAY@P,GL$2]NK6@;F&D?,8=;9>\5QU.E.D*TLO^5P.BO$ MD:&\U\T.T@(3&6!2:$"$63RA]RV8SL/]!&WT $52-0='JC_[..!)LUA>0ZL(MH3$$$!$.IV'_# @M?OX#@3_M&W._NJ58NVMQP=C_A.-(O!Q"XLV7D=27XL88 MW(YCC+!.T!U\MV#$AS)'YZ/\"&?/CCF|@9(9)1VC41FM;WQ0F*3,"_; MA+O9VI-"(O,P DV? $!Y[#NEO]V$(.^)VGQ-VE OL,%0;+B+;FD*Y;K)S_,)> MR5:W>6T&3?TM57.M?4/WW"Z9:UY1?MUL=^_6]_*6ZT/N#[$Z(%B7Y]!JP1BA M#:::2D*W:?!A%^_UWD[9P? V"]X[=JP2U*Y1>V55N+,7W:!I5>XOM7[5OW\9_ M'Z#23<=P|)GYO/$]=TR4""^^$8Y)15|:O&49;X\>PQW<6(3)/,#M=7UC ;<9 MR=7*RP+/([=?NRRF^*|)B$3*))'B6"II$DTG-H5:@\T+]9X!HA&-)T,/<8'P M5>7+F;F)U<_?Z5%SH=AG[%3"B M/MS>DF6"IY-C@B]7GN$97GBP:AY5*=5V'!G>1!6F Z,GG?7F2'L\ZFA?O[] M',6V'9Y"@).]NVNB53L!EU=B7"HB@;AB)?LN=+G/0FT:$ M>:2"Z+?N[L/F4VYZ^_^\QN3=TTON!U[L1]!83/0Z[])00A7P3SW0CE.O9AM M)#F2]K$D56%=CKQX\-"-.[[YO]?!=HHKL1O'C;AJ5+;SE3()?YXY-MWY%[-0=]P=/5-UFHZ_]E7*9K'!,(%+VY+_&YY>;6G&1 M^<7S)!.;6ZXIQ*VMU.H$*L.L@Z[7AS8$>2H3E*EN |<2;2I236$4_6+P1>?W ML41;9)+$1#;;",$5&MB

*([JYA:!,125.3,;!FF2J52R&G9BPH:E?"Y#/1#8; B^O6320"B MB,T*8@IB"F(*8M**S:J.0Y)M8+04&/> *U77>W/ G7>?_@R:HXJXD_C+HW4)*

MI(J0(4&;D\7N<I)X/JBW":XTPHSCY3V[MCW!)2!'$\?VNWRV:P^%5P5(@D#B MLR%]*+PJ0!($$I_T4\&K#5[YY)EB\W.#G_>;?!=_&^5T[J#;7%J8#SQ:U%>]2V\&A@]J%<_V

*MI1X#A/4*S)\1HCJ%# G56([U;RS7W.V)AEGEI7_U5&ZT9OUEC7'3),6SU5Q(M=B3:@B[NB066B=>S$>/.<%=\10_]4H+G5D.EB%+%#*1H%C_ZRR;#//6YL4-]*

M#FZW6A:;%;YS2:=:'3$[U.50/5I:)=Q\(7@_62"!TURK-O5J5IE)5:;|\C/|; MYYSX12_Y#^$Z+^]+=\:$9>*=Z>&A4TA#IS!\]B&;Z$M??2?Z3"4]&E'Z$^Z+OXR1=)EAN0[J;O>V#L)Z_#*

*72|W-XNR[*E] M-DR-L/<0_^P<7R;ALDU2;(*V)7#[H3 K?A#8D'$M\HE4LL(S9*VOGGS:6*/-X1S.R9H"O*Y*XV!3K3!,W&KC@6%M#X@"13C#$^(L:]2'!X M]"BU&G^2Q'#K$Q@*

*Q/]CT^X($,('301E!GR)Q750.=+-/BQ0DCPH0=-D*&I MT]!MDF^,$= !9*P)6R8)U04:-#0696AI$ _5(+/ZK:?]W](B/2$.0$Q;0WT MGU*)N)" +!X3'>$!PO\,_)L"Z$T?*

$SQ1*BW44)2>_#5H\FOX%FO*1G[Y)BH M(LPL/K\ 4$9Z_LE$")2) +"~09[5_1NN @/IW^NOA(N0+$QT2)GIUZIA_D6] M/2$0+T]Z- <60]!K//?-

('UN<':HP&)HEGWKM2K:3W!OW8'E9[-UA.B.YM M NN:T6)<&)T0;FA*+]6T5\9MW_NBC_2OTC=?;6?=&WYN*:6OEIX]0F"YBUB#P*

*M6.H#:%@@/1,3"DY1EEU$60TO2H>\3/'X9>_7I+L1?3M$774N'(Z8VVO23OXB MOILHSYR">B"]?UJ7YQ RB@C'F6HJ2<"U!MJ8_FG:[VTLS=PRB-?111O.U>]_*

*M_ZTR=.7DS3D82@/)V 59%ZI&0(M,=$<: ,0U''VD$TU(JKBYW<'N@IQW]_:Z M\#[!URVM=2A=PW\9GH$]*DH1,/-DW!F%F_,*F\]7^,WYI?GNZY:ZZ%;^[:W*_*

M69N8)]XDO!+/G:EH:?;)6I,8L$S&N+Z:*!MZHKY)MO<5L9?OC]O#AYS.RD MS\/J61OZIK*N?AQ]%3=Z(>&A4TA#IS!\]B&;Z$M*???7Z3"4]&E'Z$^Z+OXR1=)EAN0[J;O>V#L)Z_#*

*&Y(L$@E\]UT[DS7X^*A_YO&01]3B']= MB8F% .@:EEK*84W;*6X"[I#7JYE[?3"8C]>F)YSLQ./,,H1U#7I-CFP\LQ/: M9I619!KD:4Z_/E:GBG&PTR^D?\C27Z1\#G;^BY0/8>9\#I8+R_V:*

YU_5TU(M!UR/&%E%L>RR)9-Z8C176[>KXG]_E6G\2VENV(6NT%,]:WS7-'7]3QS[+*Y M;E/3;]TEO?E4J&KDIG\U\ITKXU,[8*#_^SEY_L)<=R[I987R&7B0%,6O2'DQ M\[+*

[+CVN"1WK4W(>aK?)"6VK]"J9B3(^%TOL9Z>Z*RGBDZ_2]Q\7X?QX=I?OS7]PO#%[?O[5_YO.#3O;L)5[2]W_DE .C9$2/\3 T1KRL+(99U0EMU7JQ77-LOA8.?*

H=9I,H<; MW'+B["^GM<1E,B^ M_]>=5%H +[3T0%GTL'(MD1_(B61C29Z+=^%M< X_ZJ]0O0:WV*1G, K&))VG M\DMZ?]-(/G(4600\!3$%,04Q>27&-*

>"IK78[[J9]?:!)$^3!K,Y[=X09\BFM M#X#8DSIL6+=:U_M3DKVK#T:^6O*OM,.=E MXYY(SQT+!Q59>I/N43ME]:S'4?KTMF/X^-?45DB*8B)$8, _3!LQNF)Y E2@?

*MN>@W*N\SI;'E _,9AY*/I4-04$E@\WQ/Z'V^-'6'SWL*9Q)9,&E&"?4DD M8:@$L,DD!,6\6=PFM/"VUQ= EZ9I1<'"'OT(NEJZ2*

*M+%O.O=NJ#H.-6_7R;_7QGW%=:'NTDV/"X<0E21+7!*Y\"HH)7&[P*T=/^ MM?(JX.:*-<\@9+H"YQJ1"FYQJ_<.*T/6]'*D/J >,@WL GI0XMR05XB\TH[E*

*M543I!3$%,04Q>27&]5+>LQU=RMOLS47AV^!['^[YV]B65H-^CE?;]>M[M/IC^_MJT%*O;@W1+FJST9=I#;=.Y=\4EW8<:,/GVV>?##,4U7.4U45OZ."'^F^ZT;RE_O"_^BFK M12+W#*

*(.(C.'I60 //0N D4*OQ[V'F M*9*GRB17[@L,9 4#&T*.?Y\S0Y:K#.FEH.=VWN*C.=G3-V\^3>RA4!NB8X*F M(+.[TACH1!L\$[?]6%![ZP,20/'N\(08"]]#!$=&CU{K6$R2&,ZCF=((($,(*

M538+R@S%!PJTQ#H!?64"AF\2?.A!$V1B HTOH0[?&",@ \A3 4K9,$NB%1C0 MH>+HH:3 N$"S^IVW*)_2(CTA#D!O1]KH//^42L2%!&3QF.@(#U 'I[",*5!0*

*M3ZHR42HM=%&4GOS5:/)B;T58KRD9ZN28["*X+#ZP?U!&ROI)1 B4@"PO0&8B M%OT;-<2R_[W^R@%4&F&B0\KLOTX(^])QBGJ[Z'6E2W-@,02]QG,' -+GAF0' M^A=#L^Q;+T?'?H)[ZPXL)W-MMIX0W=D$$EC7A+XT."':T)Q8K&^KB-]EYX|^ MVK]"WMBG[7&>] 8'XSH6AKY:>(4)@NW8 \%C] VA<(#T3$PI.499=1%D-+T]'*

MO$SQ^'5%UZ2[D4UQB+KJ7#T<.12O23OYB_ANHCQS"NJ!J/YI79Y#R"@B'&>] MJ20!UQMH8_JG:;^WL31SRZ2,C]Y<ZN8 MZ4_N[(WE;F>]|')OU%*

*[;MZ_O>G]]O\U^\.LIQOA24F"2]:)(*W7\!<8QI7 MX,_3K5)(D<255O)^&7W.I0R_T)=,_'FHUS+&I=5$V= 3}4T$]N8S=O)O3M#2'G@Y\+*]\&&72+#\PLPR8:7XKL3$0@!T#TLMY;*

F71\,IN.IN1&:[,3CS#$IOUZ M38[L/:,3 ;;JE3(-\C2G7Q^K4\4XV.D7TB^D?[#3/W#I+Q)?!SO_Q<;9PC-%;5.4?OBZIS+J6C-'>]N?R]P[!__E85-IT+-.Q]N=I;YP&:^D23 M9(*E[U/U*

(!^]VJ]#>?2K+>_\Z5\Q&/Q@3ODIU_GZL/#]SNB\H 3L%)AXV;VL O=,1XWW/M,1AK7)R6RK("Z9B59]>O+L9Z>X.1W",,[@C<.*

*MORKBP^.X\?"]GQPZ$SB+PI4HKL12=EDRWG36]Q1KE5CG4QB2I]C ZL3?I44^ M[:$RID6U5+7(;]-7?OS"\C=WXHSF,ZDQF"=X:KAG.#Q.;U4K9*U6>R7ZL:_] MZK*

*RB]R.NUQ(*EE)A3@M50MQ)&+C) 1-Q;$84QKC=F0G>9MV[, MY$+=Z0*#E%@9H0K/D]5J<*"S+W5)BO4),SU$'+/133*[//'VQ&K]G Q'A;CG M=^.&$I*NP*B1RR[0<=*

<%G[IW!UPP<0UU!9P,4N!>:>8"""88+S=-A^;Y%$(@I MB"F(*8A)-(EPOEEAA=8-0)Y/-92!!IJDBC\$>0K:X<G\1N_-YTSM!\N+6KOG_M_F8A>8#R9)HT0)?*

*^6!*SX(F%HF#=> ^&SEZ;\MRQ<%^YEU7BH!ZLK5;XN5+7 MU'(%WS10E;!^UUYFF+D"#T6-GB=8VVL+Y$2R<2H=KYBJ&GS/6]:U85]IM 1(MSU!;9VS2N?R2'CF^+J+*

*@IB"F(*8@IBTHL"ZVX;4>D6YSV[RU;?1P^_=Y?4 M&;N'@'"RO'=A=QO**X^\$H-S2>SFA3U\\W/*WM_U W^F^CJM8?D9F*;?*%8 MANG^KYV5"&+-*

*NGO/Q.OE4<4X*9%U=|WG[$.1,/B(5/D7&*S, 'OU+DF:L 0V M=)D0Q=H;^ ^2@D5:V292[NWMW^L9/!, ']'V/'>TV4B; 0GA8LBFB^(*8@IB"F(*

M22N:OUC%I%:0HT,KO;FN=%7'#D=O_O)C].UK]?['=+BK3=T5:6YQIZ&N;2 E M'+53H3FTCUC[IG45Z=/#^.'U4T9H;B&$YU[G&,S?9)0O$D_*&=QFIN;0?GV

M;=E92[-1/!AW]>L_MANK<_5'D54B4V7(\ [- "^>WG-P?M:?_|*WTA M_$W/VNS8V&|NYK/Q-O-9LE*MD$PUNQ%S;*XGS,_(IS:PEPD*:7#F+C MMZ&,OQJLK)IL?*

LM5V,AYK'+54A!3$%,04Q"35[J%=G?C4=?PCC!#5[O4%=&^ MS:6KKJ_|/:G#1@L"YN.K_LO5GZL;MKVKDHOU4 UXR4FU@P)01'-AKQHCB@H MV(@3BN!S?3DO-M;CLI K-

M9CLS!7&^OA;6MZH107>6>=I6F2Y;-[3!T7.KG: M5T\6.MX;ZUSDC?5D8%'$>@4Q!3$%,04Q:<5ZW"K6,]>)OJ #$>VP $47D,7N MJLWQ1%9G .AP>8$+CSZ5#4%)!?)U[:9_*]]?

*E'EY1_&:26+)I!'MTBR)1 $: ML,DT0[?!BM#"25[W=,J9|W1RQ)*P<*X+,S>AK^/OQW2-*88I^%>Z+]]>U&9*

*M(7E,.I&SCAL^>UF2W>#&,TCC(U\GPPFBB"M(*8@IB"F(":M(*WAN"&G#8R6 M_F,?<*7], ;CFX+>^3]\GT]/.XG!/!HY0JH(&1*T.5GLKH^+YX,Z/>)*(\PX M7AZT:Q-(7)R-*

*'%LU\LG17XHO"I $@02K@!) 9(@D/CAPI3I5K.P Q2G3TH$M\O![B56 M9$L*8@IB"F(*8E+*E]#CN"['"3?N&(I=Q:(G-7OSA^_CH2ZQ/ZXOJJED7S:7*

*M%N8#CY;UL_I5O=UHWI'$S;/"%&=0H:$ZN!=_M\>_@W=SMV2.*S [_*C<7\I6T/ W:-$GQ;.D=DAUX5SMCMOJ.?;\'/,^Y^"S M<:[XBAZ#1 3/K2ZX$:6*&;*5??*

8H|\$P3WWF=]C/9X'Z_&3>/I3TRY&/T_!,"9NU;&@D-8')("'DN$),1:T!PD.CQZE5N-/DAAN?0(# M@%A_=-H= 4(8H$,=@C)#+B ZC:\3T!TBH(>.3N(_:(),3 0-W=C_QA@!'4#&

M"E#"AGD:1($^,SH7,I04Z#I*\%G==DWU#ZF2GBAW(,CM@2Y3*A7I#%8Z(C M\'5N / I@ ZQ<=$A2B5%JHI2D_^6C5YL7?BX>4#'5R3%01CA8?V#\H(]W_M9

(&3DV6%^@S$8S^#8.?@?WO[5<.H!()$QU29O|U0CQ+HC%"\Z?>GA"(%R5= MF@.+(>@UGMM?D#XWB#O48CS[R[[U6MSL)[BW[A)S,M=FZPG1G4T@@75-Z$N# M$Z(-

S8O%^K:^%UQ_NBC_2OTC=?;V;>N=FQ366U-_?01"M-%K!H0'DM] (T- MI&=B0L$IRK*+**OA1>F0ERD>OR3\FG0W@FB'J*O.Q<01.GM-VLE?Q'<3Y3DQ M7Y_ZIW5Y#B&CB'"*

*M6"LC\>X<#*6!9+S?!7T7]D9 L+L@YM7]O63L M9.Z,=X321GPZ\$P45%$Q)D0X]KVH.16V'1UM_ S&\6?_BA + K1', %M9*

M)]XDO#+,CX(C_3/NXO[O_5]QKB^FB@:>[*^V8C>_,MEI3;|V:C?_WC(I*3/ MP^H9NNGD%L95X F94M1#9"7M6R##(<0.#]F-A:/:^[U3NW/I/^#SRP3^-"2 M=T]],:7-*

*W>MI_;S7Z:>-->OB-*WSCO)%":?'[.-E/VDRS<@W<)';KK)X1DM< M":W"9Y8AK&O0:W)DXYF= MV#:K7B33($]S^O6Q.E6,@YU^(?U#EOXBY7.P\U^D? @SYW.P7%CLY!SL_+MJ*

*M0CK@>I:H85:_LLO]5S:ELT1WO?DDP-F7:/V\U-?MSB\JK/>9POU.:%56\E,M.)S@\Q^)NJ>SEIJZ/3;KQI> M5V^,IUEG=LTFA\0$"N#9$L656]W!+]*6P+M7@!?*

YLHD@U$BEP_]V%?E8DB9 M52)?]U\.OB:AD\08286H-J]$KD0M,R1%T21;>R72VU^5N"V^Q>&^<#O5&^(L MQRX>ISFR6F5))]Y"CZ@6TEBUN "F(*8@IB\DJ,ZS7%*

*[*J73$O7IRA.O1DZ/!_D M!PGZJ V,FZ']0$/542N9YZ?6G|H9_V.B[JB3C/U^5"@_L':,S;Z>:(D@!I!* MDE .FE$2/:.3 T1]RK+(6QN/*K>G=@RK3 T5%76+MK.I)7(:7YD?G/&US??_*

M+A,Y46&WE>_!+Z\R[O$B3#7[(:+AC2"X2E+52NY1D[U64]BDQVBG*4Q[WX!R|-Y-24"Y"#D+ M8@IB"F+R2HOKR'F^68N!K#00SZ<:2B,"35+%'X(\!6WP;'X#0\T?*

RMGSX,=% MJSFH9"'61$E,31J@0B;KO^%9T.0BSESW)6K[:L^^BC/98*A9T<=$'' 3!LQNF!Z_VI.G M(A?O1N5]MC0VMS$53T6,J8K I'"'F(*8@]J_$! 8F:.'K"SH044X;+J EJ:N*

MVAQ/9'4&@%Y7X#>/I4-04'5?[6]VFFQ3YS*';N*41"))9-&E"Q?$DD8*@%L M,@E!,2|6MPDMO.WU!;"6N;4[;RRD?4[^[HMT']A6R M0I?S[C;3VO1A]UY#?*

*'/T0[>)@+F(1@IB"F(*8O)*C<0CF*==K M:"G0R0=7]II'WI-YD0DVHG<09'K#G: MKC :W1M5[<[5,XZ*KG]U1UC<9#>7FV[6F2XGGY:<1^XIC>-.NS M21>10_?.)9]4*

W9,AC$^6SSY8)BGJERDJBI^1_Z^<^/Q66UTV59!RFJ1R%W! MH0[TL?'O"JZ5@_?!\H&I])1U?Y!8"*X,;_RYEGB)YJDQR M9;K 0%8PL"'D$)PB9(?)O90])?0,4%3D-E=

*M;0QTH@V>B5MU+"BDJ0%)H'AW>$*,!>U!@B.C1RGW%D8V5*;IO:([H0P0)7. M@C)#,8,"K;-.0/^9@"&=!!]ZT 29F$"#3*C#-\8(Z #R68"2-\P2:04&>;A8 M>B@L-*

*:0X+.Z'JI*E$H+;16EW]%FI$8NQ76VTJ&.H$C($ M/K[.4$;FX).)(2@/65[M^C?]>V7_>_V5 ZA6PD2'E-E_G1#V%>,4]7:1TDJ7YL#B"MJ-YR8!I,\- MZP[|6 S-*

*LF^]7"'[">ZM.\RD)T9Q-(8%T3^M+@A&A#@V.QOJTB?E>= M/_IH_P]|X_5VUOVZ^0OXKN)\]RJJP>P^]=U>0Z1HXAP MG*FFD@1U;9F|T=,*

*<2NAB2N)#59WT75+R[MXWQ^V1MHS40']3M M/!A+57HTS?3F9^S-^8^;Y[_UT0@"?CJ&@\,_1XY7S")*1# +"*

M'B6UC>]MO^8G$IJM89OD!/=EEMLGM3.47>26>4;.S#/.+VDP;%3.&/:[Y'>C MUQYVE%:4LSV7#.DBH M$7?2"W$-?S+2B29$GDA\ZFL?3YV[3N'HQ2XX.)0FVTC!L$HX7F-_59P-

RZCM %5:GR>IDV6@\ZFOHD012?S>[A@M%2;B9 $PSXMCH.ZIXD0P)ZO:\;,K26>] M^;*6)<,4![ME^K#[\9"8][^\K4W'S\'*%??.]1XGLX98;N5U69HX[FN>U7Q[IAGB^8C-4D+*

M+H[CK.(X0S7_=LG3L/&3<0S)5FMDFL. MQ:V+?Z>Z83KV"4(C64+^OEZ5[T%L7?5=L<$T1T!FCTMLUT+,@/H4_0WFCLQ1;&.I!2K1&*KQ)D#;.=@ ODO*

MF4=Q(3"8U2)1D1Z[,WYP)MUP.SK@Y0(5)WD$>$&GAD';/:W1TZ"HIE_CHVZ M3/A[? LPX%[FT(1&NN>H1[S3:8[2E,S?G=S,\!WWC7-('4"., MC@;&TG2\KER-1N>;V!*

*[(7^LI>MJN&F7O*X]G:1)0@_H&(2[(W2M* KD84>4B M-SZJD4PU]S=<<$@GZL_SHB M@$7)F,/]9Z#[?U89SK\:OWZ=M4<[6X$84Q4;(7+PX)YX&%_7 M5]LOHKBBR'&//9W5$0&3")D%,PGY*

1^M3:87' MU>E?O(FT!$#E 0PP!)1W!RCA$G+/YUJX'NBC)("L714]'=V! 5OPT< 8#L?T MCBCING!Q9(@<X+W @C-T5E"E&_AY7BR6_#M0]$5N(+@ %[!?%6#;4]LO&\-E MPEFB-

N28P/ML6AOOCKLN7C,H>^9$@?]1#: V,@ 62(>1/.I.W\6;8RB':,/Y MIN"+^#PB^BP7H4\[ND'QJ<>:+H?H7KV#&P/S7+TE%O8% BR"3Q6QD@,OLL8$ M;Q[7F_TIL]"1R)%#L-

9"P##$#V!+!(@#, ,XC*))VO?C?VR'/K72:S<)/Y0B MUVO6T% `>'! A/669K$I9T4%E7V7NG/A4 6Z3QW.E\2A ;<[OFFG%\Q5G!]6 MSQK=2;^%>7V>X2%""":\^]T!8@NM9O7D?

W=%AJ!A/=]!EW-2H M<3LI/]3K9TW3W]1EV)F8:5_IR2SS894Y$:FF94U$:CH_"7OY+NE;WEU:UG@ MN,"&LX8"DC=%XL:/SWS -6;ZG^"&?`6\JXQ]64C!0,(:)=_[#"E4ER2%

M8]5<[$Q_EQZM8NOFXG#:S8T4RLN3 MO4YR(INZV#TO=_>MM("K,9I34M:]7! MLY!"S(9+6>N9UT<(>&B8"_F'AO&A6 MP=@#K?@%: S,_+PBJ(<2QAK4]@B4MA=BA<9%*

[1Y9U.]"4L2 VU]H&<*6))#X MV,%B9P\1@6]PH).#0LXL\U"%IQ=CV5 ?<6>;8):YS$YR1X2ZV(:$>+P^0GX(M-5BB"&UG8)A4.5*!4495+[Z-0 3=#$!1][CB@F/PG)'M!+-<:(,&+_6]4:%*

*MMTE?!#N VZ2656B?#A08>Z@CHK-*D24%GA76Q%?A*K9%]H 2]@;&P"/$ M"AD@)X8#IJ"/3/CBP"!%RHMY .S8/M4.=7H$NDO@#' K"EH-'S(@RD/H#,_ MI=T5HH)+92.-#0?*

56;1O- $"OBVQ@I9+8853;P1X8O974(C>PVPR=MSX723 M$553W(Z=M+CZ2!PB8KDLV&LCA+G@CKQE7TF"89?TD))A6('YBR+\FMJ I9GVWX>S258L)CRIT.K^@B,.:C/E7H 2-4-

"M8 MQCW5)EQF:E+<&"*]XW925Y<- ^>L(U,ZM,83!NM2"^KDC>',NCT&6L\AT7Y M,G.76)0784[MG+C93^-/<4]D,R@.,+&^80<5ML* BAU*\U:A3I-$78T\(0B5V*

MG87X$\/W&L/WA9F3BLQ)68XYQ>U=<*<_0_&P|[F'QTHSX;%VX+0YLL==K]6% MR_M@XV@KV^H1)S$L5@FEZV==I#/5>_4;9_+CBU4IOX;#LH?#2BN%P[3.]-&L M-^ZNN_]?_

*_E].O-Z='I]0^U=7ZD?K@X/?^@'EZ<'QY?G:_)/99P4E\,2,4^0D4C6)#H:15;;*G?Y0=KJ=GO_Z_73<\HROI<#] M_<]G*0K+]G"'"I[_\|U6K7X]]/KB^1U[9]U=)S5%,>O4"4,WJ*

*MS4N#:GD_KMU#!*JH8?5ZX^&8S8AB)_1B@2N/ ;HBGFY8T'^L.UB.[[9&H!"" MG,=%DB!\],`3[=-J_@1"W0YA%NS[YZ'GVFO7@#"6;U::1"NUO;C.H*%0,S" M>Y*>RQ5.VNF\7#P*

MN^%[P_V0%>J9=9(=^.:N++AV_XWH/4. K'/CIZ@G3@C$L0WBHU7A209?T M[EPLWP:\2^7%*O)BR4<7=UWE<#?7HJ>CD/Z5N:#_R"9$..:DWU%4%&

*M6IH[A$A!!#5IYF)K4C4&K) \BRG]#AO.Y&/]H'KZH6]&E*#4':47(*3M9LE; MS$/:5^9+^WWUHX$YB-F),HFPL"X$HD ["%33C$?[(#V^+7]6N&-H!HHR% M\[M80N*"X;G-*>X+VRAU.)$_]F9;NFWU&I0NL0TP+)WJ<]+Y" Q==X".&,< ME.4IN.,!4PVI;VLP%A%24[K0@8LP]F K5B$ *-G MG_JI+PGY=^G7V;$CN.'1(SWX@#M^6@G34,W77 M9;Y@GER'#SDHB-*

B@Z@)W@OHNO=E?N2PGSQ]XR/!QB'428/D#"(''N;HS4=T[MA!*O8Q8X8.>)NENXHS](,_=9HGUB>P_*Y7KG>F]?E6IGQ_^TIZ2/%UA5!*(M=^99$20?):4Z2"N^E@=MOCQ(*

[[6!SU#25#^Q+8%TDB-25U1_*05:@P/,'>= MS5BAC-:BI>TQ[]$:(-WQ@I'C8OX1=Z@!3S8P1Y2FW3.&ZF=OBH1-GL<<;$- M@MXD9Y)2/@^V%G&HU E^O*]FT^>RJ4@*4Y%L*

$DVE8@C&6CB]B-&?PHJ2W<. MR^.9#/8N+SJBNB&F[@ME4Q7*IA)U10=KT%YU%O('*3C@-JQ_HHP/Y2HP1]0\BW,4L1UB,QSYU;P]^L\=2^'G04[$' YX8#]N0 MDJ+]I-

B@P0, ^X1>?2X7;:I QQV-T?"T" :BPR3X2,P3U&\=0BIM DP;/!KO M+ sU'=)1 G'V'2\QBL!@0+2(73X&U=EQO1XU-'T2,P' !:Q3P22/&&,F,O M6T+)4 I'$Y\XII1GP4B@42^CG4'I*

.885=D9#L;BQF6FS,Q0V F5(6R/#Y% M&LY "5(<(.DFQ0N/9;=FI@4ZT &3_?VI]7%DU6Y8Z98X7EE6%Q<[T9' R M:%D_R-T_=V_>MT_G)^>G!ZVSJ_5UN'AQ'C]O"5W>N%[1*

M9LI'66UG!$TG['\3<+TBSZ3(MD!G>EK]>&-.C@ _.>NOBNL+%P9&4"F=:;D MZ>//T]4[_73?>/.>G@&YE5SBZE_\BTCA7#P\',XDBHL6&S2\!C8(9?94I.H^*

*M&@C'F@EG85H/>MC@>S+R!-<GQ5L>E7I8!(.YBBV*ZKJ?:G^SWIY7/|1:EZ%< M>VHRCTWB2BD]0D#BJZ+M.4VM 7&$!K18L7U\&*PU&@&:"N6.=HDQAHI#Y8_+ MAXW!Z7'9*

*6A *.11ZW&'VE=/V2NQ1I1[*P(]CCECXW%/ #U52<#$(T5V MGP2."_1RTP).6EIYG^@ME%=%QPQ@A0FP]|T[+$,,WKGDFD3HB WRQ"<%'76X*

M@M@#UDP!J5&/RX.O\XCUL!R4<'N#9U%1E6@,"AJ%.7H1@;QLJI9R^X]:I]F M |*-BGNVPX>+)UNJ*C]2_ H5K($:1W&=.U3E#!\SB).*>.((0ZQ81979\F G*

MZ+GG'E"7T\5BB!CP%WMW>![WY"9A35Y ;D47$]+"PO_&)1>#8Y 90Y2_$2$O1Q_# M#W:F'[K-AQO+-5K% ^K,+\U9G>O:Y>(C/D!7[_XQK5 M0=)@LG-?N!:$Q>?

*YK=@J42 D?54 ^MN.!*A&SV4 MTNL3/G=)T^H#ZJRF/Y4]T32>YC,A?@"|->KA2/B-%T16.)^=%U5ARH(2W1@- M[%3IJ7DDH$;2'3!@^-_VY@WX4T'F[A,; 8UH,-*

*QK+\L/)KW+_U73@!6(68 MHYDTO$8L\S:2-+V9?X1+ ^/_$_2%#\&@P7G5TY^(NZ^V,%_<] 42 M#:0H?0.!%H(KVJYTR:O*W:I1[L9[O$<'YF2V;#+]OC,]_/BS_O'"/FK^OG!V*

M7GCO0FXG%\;/JU!WS=]&.4 B$+_D$[Q8AABC'.7-;E)@I1F@-MX9MW>@_9@& M'+[/)]TSWL ,%B",(SIH_;R^'3V>U<.9(M*^9^N!H\2PR!M90?#%9=D8#_N?3^QRVGOGINPFOSE[*

*M6EZE'DI$P3Z0F(SR".8#V/S1*58L$66FR>4:MAI3Y%MIYK!5RUZXQ'<&E_?&]5A3 M%%1GO%Q2)V, 8=MID,?#>'I$%+0D[,_T\ZTY@RLVC?+^%Z_>W91@/EAQ>'M MIY%W,?*

IPS]M2?Q-MJ?U3-(Q7II0"'KS239!&PNWL%.+#[MA>*>!Q;=#](Q_$96[<':U"@!2X>KD$!]1C.(J3**B"W0E&0+W4E^EW#L1(02 M@ B?%8B('I'M>.HGZA%FQU)_ 5.042Z-=(,*

(@_40Q=5.MW7F"?]6WB2/!D> M6_*=,,?]E#=<@)KQ>O\!M$O0^^VQJ_ .5<+.]U\5K(N./^YWP:PY?#7GAUWB M/:+9S=? SK$TLD15;O:V80

*2W]OFFZ_%THY3(*F]JXRYA.6/2P!3AW#I\(8G M8VA,F3<#'J:>FZY+G ?]SC.LT9CK_T.0M$GQ);.LTS5EUYS9Q '_E,%..5 M(YFH&)@8CJ5BGK^()=;H$YH_D[CU FT)?V?*

T[GA@#.MXL2.0[A!?:\'W!)L3 M[DY3=SWTO]>O81DN-XBS:1HK.RAT93G&G'/Z4MKSB MIJ$G\;::)B-0Z/TEWK*\(OY!P'++(4#BAO?:#O[6%!0B4$?[(,MW_. .*D#*

*M4_RKP!Q9M,V<#&.$] LT8E+W70P_X[\ "Y%W(;_"UK=2V^*-B%D&Y:I(]Q5 MVA1/MZ@&;3N.W;595ZON1'Z(\Q'@$SK;95QZ4=E]VFNVVC-DJVFOV6JOV6HK_ ^R[&W]2[V1!+X29:WN>,1] MG%UT=W@>X[%6T'*457),N$HA?B;Y,GF$;1":8)/(4X.\;D7^E#D:475FZ5/# M+NGW:06D W8ER@<7U[-[M*B1>6%Z/-#E3\N!G?B)3]'V"#LOV,-*IBO/'**A MQ3Y!848#3ZR[*,*?LN>]=N_.QIAWX/4=VGUB%D#G%\U+&=:(7L"RSAQHW9&T M/.'X["ZE:,R"2Z(&PY0+5 $\NBBSGWB,U30&)+S)P,6'S@5T?HSU ML-+@(YZ?76"X]X# A/BS8Q2:MQE:UQB.3 /^.4$VI.JB$@Z_I[5444 JIR=P MKZ/O:Es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}H$]BR^C$TB3>;;^)Z9ER+36"E#N0 MGT! <@;[XB?I3$>Ul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

*MN'(4X,H1F ..00W2BX$@Y0!+<|0-'R^D5^+A?+FI^V]-=7FO?(U^KS2*4G, MP.92"M*|TV&;)@BN/B*R >8U@!5NUZ ^>Y^GX;%F@MU2R>LI^PE_VPDPP5QI M<%0<%7UHG|YNSTVEL=G-Y4M&E:S>]J)/1,6P-0YF>#&I%9-$10$5]"V4KBK: M>_B8;BJ!(HK7A4_*8HE+*<;Z?;HR4%2E4'-"(0JGWV/JU2:%3+S)5"R58> M4+JO\MP+S@AA,7QMLGB 169Q2*Z;$HSOQ';NQ))YHE'@W_H 2A0J6:1_:H&= MC@/0A75I'/1D!*_8?'"]*%;J6Q11VT,-B\5,<@UZ"#YMYP=ZXPZ^*IN*;^&U' MD#BK*RD%B2L9P)WI;$>3)]H.F M((^617AR|/&HZ9>5\;"|V_#D1,7. GP0=*4!6*T%(6,5FMH0$K"SPF|_,9W@ M!5]!*%Y:"G@WNV$@Q^_5,'K?Y\5B*<;:EAOXSQ7<-L*?XV|LXT%3? @;;7 MP8$F_&?*7/^9>CH=?VU49!:S0*Q4IMUF?5 M&DY,&]3[^+IRB4!ZZ#/'31GQ+NS^U2]NW%)@8.%.Z=:(\8K&IAKU3 M$[74I+=;HKZIUO6@6$$75&L*5-M\UI?@>F, !$[HC[IJ:L!VDNVYC_%)I]W[2 M+>I)*VL%)8,K+>(QRK(RJ3[|),^$PD[6?>E'22%=V MP/@I<^@3.9I8*M<[4ZM_?7]AGGVZMGIY!@6IL!'OS$6\Q!SE_IO; Q0#3O87 ML*!;\C? \\O>86#CI1ZNK>WL\^:%O/*3'$6=/HI9-#C(V8H*,-19D7"3Z M2/F=28>6X8N 9[#-F]BV3I=C7O\$IBK<_FZ(KP,K1:]_9F?_X6K_EQ3FI2 M2ZU6K&;VU.B)=L[=7]LK5O9*3?97-62(S1XH8FPUHNY^> M)L'A7UW,X9\7?N3L\E_A*JO:\SC]M;E,_QH<2-N_U7NH+Q1QS^CAQG7O^J; MQ$]"ZY_ --77#]8*6'*+^?I]33G6M5_*XF++#5E>AG-_(61:!JEF\ M;$HN[OVC'4.>K7#P+X4]F5S\U?I&HT.S+O]Y7MK4:9F[@$+;X.1?"H.RN/FK M637//% 1*G%8TRW|R]_*K82]_@BWTKW3SG]L/W,/7G)^5F$N"+:XBZ3^P5Z/' MDID5]NW$I]_*N;3^GD,!FWQ" B*G5EDXIY;J79@A:V'R:)_<$HLX.GHXU;[A M$AU_QSP-"(_9Z(&?O"KEG2K^+_';ODA"I2[[!=W)\|I7W!J(=93#A86X#4M'!=1>5.9HL!6 ,UL M5_!6]DB2_2"+CZ,Y_H^\D>NC?A \L"/7'PAV5PA>/?Q\G]?B7=4S.=,L2Z, M5A83(O<[?QFNC*5P:&A8/71BT'E\8F,Q:+,XL6^:6 F:,KDX:CFX.+)E,2]Y MN3@:,XI2V^#6 FCLK@\:CFX/#:1V:AD\GG,E: OV[9QB2*4KB#$I]I#X0I MD'TR0"T2;H$X0U8!UZ,] <8$KM0#&Y@"5/=8MQ;1Q_^H5IVH,6.6"8?2_*C M.LYH!%_2' G_I0KKKP4*BSHBM(N0>(S% (ATPJ^'^>H3^C"W)3&."]C^^$]Y/ MM5^ EDWS$ %@I\3S4QBQ$EEX.+KHV+B%NW+9%\)A8F>V.@"BI8=^GY=F^PV<(>\6;-2P\I6S6 M2WM"$]C_Q2.-L;]V#TFX+WQR1-TY--$&=Z+WF$'LC@%H(O@&*(+DJ**Q#':(= ^(*)/&#[YB1<_VSX?@OJK@&-&.C(H(&//LRW-M3O2Y3\.\A'^3$L03(^./])$R#5\ MOT]/I-RQ4QIB%HO/0%UA[!AR!#%AYQVO9W?&##,P,3?H3B&-^AWY! MF_\1/>W\!X+&=M50BZT81B+W]Q/F))<.[*1NV-*\=,BIU3\#?0\ '&INOF(5 M.L?"F>QD+3ZE>DZGY[B39FD1%W>\C%7K]1P/=`8_>_U_@ M9^-1ZN\K33^?,_"#G$A8#S;0?_WI3Z]K7R MN:CW?O9J058IUQ8SY(X*_2)?G*A&^^6E0//-^T.N"8<:+16U9EKOY!2FD,+< M1,%" QZ#|^V=@DHR9"=D91ZBL1C-"_')<[\C&++B+ MP26L H^=6H=P:WB(:\?OS9?!6A<[;$9*:V3-7$F+PS07T'178[<':V:W&T$H MGP,/2:UT=/6Y_G?+R9<#KP=5RLDR9; *?27&C&?BT;H^/,!4>0+GPG0F7>WQ MLZD>'NZ59>?"LBMK8-D<-6@Y'D73%\]M,YTS*_7ED-!330R8Y\ZHJQM@U.M$ M(Y'5QKDI/+S]T'W(7\6G2M^U)?DSKR3% [TRZ'4PZ,8Z&'1? M;XU&COWHPKCPS*&RDE0.X3F-\MGU\|K2)GAM3MBQ!H:Z]!4O%FUKT-0/-^B< M0P8#5OSHIW720$F1D+@;;$TY:]D6>53[SCB<8:KSL\;/^'H1TZ@$9I\4&YWI MO3O|]>VQ|$A^=Z/!_B:^Y_.C. <[T:3.]*Y\0HXNOK8O:JL.PP:VI5DVW!-% M 2X/B@:U-^K3T/S+U!$XQ-J[:8.(]%-3AYBJ:05%9B&?H>M@X[7KX&O7P1C:E0^2EE,;;;;!.WS7 MV#8C8VILDA*JME+BZ1)YD]V\|B973#C,O(^9=,@,I@M]R?K2#DMKL&=.SX]6 MRVN8VQO(O*0>QMM$6(E+9? ;I?@G MTA(C,S+M!5U%R_#;#7N+8F/_S+E)?9G+1\H6YKO;D" SY^39Z6C3:>%9$?A9 MG$Z;1+)-YPK[C??L9K_|J7U\"7FYM(?,&111?+CA-(%EJ[787!%E#3QSM=M>+#=;XHN1 MOG29.-\+S3:I=*:_KZSFMW'[9\WH9\XVJ7:FWWIG ,Z3AEYNI!:P$4UUI%M MLF7AYIC63HOS!U>8$II_ZF=C4ZOV!?I?OF>?JZ-+-R89]U!\MI.5&5D[Z:^ M'2U\EL)S]B:72N6BCFT9E]9$9-BZUE:O<3V^=E8S&=3&+DEY1W94:FT7*%' M;;TM@=ACZZX)V1&K.L>*D7RM[Z.K)_7-!QR$LAE!L3GAD'S$Q4FWDH,] M7MN0/5Y>,Z-?'^KDR|'SO/_:0]R[-;Z%-Z@:G0V6J:-;"K\YB;?T8TWZF3=% M_IUOXUV 2R,*ES:.O+VS39R3=DP:8I^#X1NTQY4;I0:E%8VBW/HG\QJ=:?VV M5>[__BSVL^S&D-Y&NHL1^81O'2-3#[N]&NO*5Z9VI?#NY/ M;WY\^6E7WKP__GIS>OU#O:YJG:=;A]>G%^=M'\6[N^OR6&*&F]3T7!][=[9C M3%G;<]IN7DUSG%XZ9$:C7 M?M/-,,DD#MU#5@"/=$=]P!^];T:$M]J/KQW%Q&@3;W[O%X)VTFP7@7EH*[]"0 M7 K8%_3W_](C@&2!D0-;P"[B GY$Zp-BJ;IXX5Q=ZHE7:;_ J. Q!_O[72S=CZK'J3=+Z-J:HB!#!,01E&__K+8&@P911[4=Q1B.;)P2-48O%VIH M;'=]S.[V=80Y86EG.D3 MM4&-\TIXJC:BT873NS. BS$:(?*<;5T>[C0:PX.Z/,4]-"6=+|. ^;(EQV?X< M(O%+)(IQ"%$TQC[0 O:<-_-7(D6<&3[%1A"T'R.F6KC@S MWY+#0^PL&&H7PW_/(W3N@R)5-,>#(&XP8<@9A'|ULG!=X0^:?Y@P?ZZL9O24 M"M5,O#F.AF/5M$<=KXD-8/>QDZ_#\,R/1$G+HQ,+X,V6.2S%Q<&&U+VO6SW M5G2Z@(3?^1F%2/DJ4CX8FI.DK%GB[16OM>*"-.WN\B52.H!" M4/+L(9>EW^6,9T&_Z0-KDRCLT? #N<.PE>4)W+N):#$I*@IFW!ARX3._|.\. MTRZ<*U2(COD:E[B$_Z7+OW4U@5%;C$?'(3#.C04M X4$I7Q=2+6<[2Y[9+32 M?C41K]B$61U8#0X4];D-!9\:AT42WPF3'8579V25K7*G/|QZ[C.]G7YP+L;# MXM.WDH|^[3#S2<K&V"O|(<5:S-AQ?UD%C0T3!/^O:]FTXRO M)=V4(Q1.8AWI!IUE2R=OCT'TX? A8.EBSAT.K35,7Y5$ZF^#+DZYU:8-&-$7ZG=#6X+;MGC'23QO9CGH&P.*/?/|'K2=4[MM ^;D@^!;X(?<1[/2CU(1M1;%L&R.A!2PM9E32N4J[5D=@0'< W7XT7),W=: M3[Q3V"5I#0$//703AFXT[WI\.S@DU^.Q>5#IQMRC3C>QV#T&FT\5+TM>7#6' MK+.REJZ?4-^'#P*@YIFKD!=:G5([&+.C)AC$.Z1\8/T7-SJQ:A^K7[ZVI@'/ M;_5ZSIB9Y'1+|RXN? NMKN;:L"F5]%5P*M5$FRXY/&?#8HLQ90"(F%*8E.E\Q MGH[X>V$QD;CVNVP:3\S(E[|ODY*/E9 MQ .!ZM[%6S_I/9EMQR6-]E$YL/KX'M.-/+;!M5Q*5HTIK;2_ MT2C4*I6D2]E?:X7"9KT=;-Q9-=G=45V?NZ,>OCS['GZI/Q_7-^#O6S8]6=7C=']'1=/*L.BBD].VL "XOL9U0:1OMQ. M5!Q*:XR3M#(J#@V? HP[MNV9K/8.=O$!9Y)WC=|HC>P3QS[$XB/6(\D/Z%=0VG=-F[HQ(X=S]>VM^Z]U]] M_M.6")KFU^)!>@RO>8H@,+-Y=[_0X?*E]:P*>YJ\+&TF/F!8RK]=7I:T9'FY M1D-;6UQ>EF+S*W=)7I:TC#147S%')W-5PK+RLI*CO,SG7]>?6_=:U[FXO?C> MV YYF?VV5R^6)>\/%R#O,SIOJ_M]_+MCY\#4C>V45YFO_VLNG&ZO)QK7ZHF M<5WU#^[=[[WXRXA1Y=7L],5HFXP|>JN]DM2OZINI1EZQ8R2M.E38%/24G: MI*FKN:=EIJI5BE:RR993DAEL+3!!FM.U3DVLT\OI#IY<.ZW09 NG3S MZ_?/PZIAG/16I1FPE%S->_K<(@4RB|V$;+[.A'R&F9#-UYF0+V FY ZHW)EY MK*AFDG;SK8J-A#0X2G;/N:!B,@_:+EJT$Z'JNZ\$0Q\KZ!?+9O*#[^%HZ($ M9I6IX^$8TY0?*$NQ EP <6KU81.8? 7_WQJ#]N'P4=!:]3\%%;02V$^UB/T1 MI"V]Y?5]1WP)A66!BB*_@MK5L=*4%TB'3N@OL]^>VQZJMO"UA01#GT7"N[7A M7UPE]D7]9;'^#B#=%:[SG!1]_& II6:[A*U)SHR7?#? N2BXL5T"G&U MD;?2)ZBN'5PRH#'LT\#N @.LB\9;>]N_"^X\0&HT81/AV"5X^WS[\.EH#+>- M9<\\Q[4[]D22IX^S!?XG3:Y_VV4OO:6UU]1N?&N\4_] Y3L&:T],VW:4R&&0 MRMX:!EL(?1M\G1:LHU41_>D3!^_41O$_8E2Z;3[_8Y@\O@.,#?9W|O@.8|>. MP'#OSB$$"PL1)Y6^/G%58S@D?0.V;DYP#:R090@BCV4/;HK5GT?0!2_"'7=_ MD9Z'/|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e.]DC&QN]DXG5L_7FBB4FWPQM28072V:WS9+ MXIY(A-TL2.T/0JI@'SZ\TW+8_(NN#W'O6A/=#Q7K3'1F.IJJK/KGO$I5NV-NZ#F5>5 O'$) MM4U28+6Z8AIE M]R6G4=(J2)!\B$!RS5?M??FW1M\48S-]X'=P(IN>;W=2C5MM^LFS/7^77+> M6$S8$(J160^KP(PEA3;6I5 '=3L@3W;\V5QU2THLT$F-+/]A:^TIX0S149SY$ MAM/BF;0M4]Z9)('M1I3DDU=;R\@['TWI#,[$(]\O:*JI?!5L1F858+Z#6:'4 M8-Q?--^B?C^C*1"@^ORPJ:P2TBH*,D^+/ M"L&ZBGSNG@4DRR/N#PG1K5Q112F]=C')HZKMCA<@PAVX4=6K4-U355R66OX8 M9%$N_O1S,OZY,|10F._,|1|\,*NO|<@ Q^Z&LOH>CP$\(R3C?E?^N&JWW:7H MC,6G?I]D@#5R[AZ+]7^K_^/T-W\P_=PYOGF:C+F'\N[C]D:1Y]8.OL3E +2SSX@A$BM66&^R^)R/ ZK!)!'MPS? MY+S!)FD#LRHC_>AA#$";.!9[4"D*L "HM_*7T:-;+9&O8<(Z'O^W M_H^X? O[I2PZ;-F=BY^M;J3JLLZP-RY*JZN.2DAJ'2WtS.K;[7:&99?NV3F5+ MZ?W#5.*FYI_-1N=E6DI-S4>;![#&]4G]8:KRX='3VTF-1R:*7;63%I#*8CL) MU(L"OXCFTGUS<'7-\L OG6FWE_=Y-NOGW]O;H/)=*^[I];O%WYX/)-I59D2 M0V]Y+-;^[4OO/^*OAG?SX5_NT]A+#^3@;KVJ)KQ,65F>B;*I:/QN:"E=.-[M;BRN]#%+MNV'";26)N56HS39_[ZD/+P5V>6[? UQF=YUMD5$M3>RM UCL^L3^ MO.?N.LT%-J2N+"@*L3']V%5U90$I+%-7'NC6?>RT]?<;\NINE@ULB5?W?O?= MW3:O[G%U%>71^/H7+PZ^7F7_ >OB:324AS)MMZ]>>? ^RL1O64+9$&;EO-LIR MR;71;!2=`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|28>5V*Q^O!D5V*Y=&D|K\O2D5V*Y=&D|K\O2(7K HKV\N>BBM+V!)=BQMJ/"C=OC5'^_!9^^>M+LS$^>_ ^Y M^5# //__6@/$;16Y?,"DE-.*07:#[>6V[3Z? L>=.]6RIQX%;PDK_ZQ9KW M.==?_5CBB396>USCE18|UB4[Q@[+PET_;K3__'9Q^>'X*+S\1^LR>/7+Y>F' M[O7IB?VI>WG|;OZLGM^U7UW?79Q?[55MUZ)TW<#VMUZ="6^V_M_:"BBP2=L]@.5/:???=TH)H\>5(44S"/J1]JI%I%.:)DOZ$0D[MIM7]A9BV) M/0^#E.MJ"/[3@NEBYKM+T7@SP]]'*6M658:7 MH.P:A^VE&%G<\KE=(G-R/0?S"=*WC;W#L5Y_? 7IW^_/I^;5]^CO_T<7O<_G1\%+E*?A MJXQI(X\Q)_P-TLZWN_CBGY8?K*KZSNX#;>^1:YH5U=GV\3$&HDBBXP]SBHQ=Z7,R1RMX) M#I+X3YL!9);,0>?5V%6YO+"/"+L\)$D*I7? K^0&)):#:GI"N'1D5U'!S0@A3 M#)*1?CTL'!)&$E+*'^:'5 4^B_YU%V7 HF*0TGXL3+ >?"S*8NK!Q_9SHB+/ M0#2P7*SW7S+G9)$CP=_1@- Z_7:0G)]'IY*;Q]IXF(7*;1,4M0|*Y>R3<,R#A MW#T2[AF0<)O7W%Z>ENU*%?OL^O2CW5A+S?[8/>_^>OH1%&B)7[FR3\ZNWGV^ MNCJ[.+>[YR? P?]T/_IXZN](OWMOOS\JZ^_NA_L=Q?GV)?7ZIG+TZO/'ZI MD8M/IY==Z0M[<9KX_-_^7>4@8(GY98WD"U^@B"ZP[#.6 M?#0=/$98EE '# MF!XOF"9^P@XI) <%0JOFI>@;$71:D]$@TD3H4'4!X[+]9:'C14$AFH9?!RV*0 MRT:K3#:R9JER:F(!,M8/"6%*#6K1>6V?.?89/&Z[[!J#:?XS@]]%$SM2S&) M8HU4@GT^^">GD*N)|&GHCULS'X_933XS"?S+Q_E].RGN6]?8M_=Z=>]*^W:9 M[]N%N6^\2(N:)\4P$G6%FE_./YPY2%1>]Q_'_W:'V&E;-+K?9H;-9222"BJ MN?SW#+;J*>VQ&F-=MS^.KP5C[Y?SB^M3N_OVXO.U_?[B\H_NYOB5=<[3I^5\+^EM"W1?0M$78)6AUW7CPX"*+H"Z5ZY92-U'*5TI'P M*(^-/,)\31N'W;P[CZ:F;I]R4-SC9L@JJ!K4 38Q+/FCUOP>+&ODQ[=/2T9 M7=-I_IG6PL^8#YLIGIA(([_"_ Z[U!#+6X,1E2KI);R@ B.*Z7AJUK7]Q<5C MY1A(.@/] ()L;F+>#*7]@>R,^%_Z<1C$*6OK+0P[5*C_4!8=C;O).8YH47C8I M' (?)F@MUC!+LU@HDP]X(Q*&_#&G!6#.9,;'V#SK#VDT>BD,-TDY1(/94#B! M96?44W7?HR"ZF4H:PFK? U2OB*]\YW|N MP|!-_@2[[(>9F/=\KLK#]P8D\%F?AY!T[F?)H$7SCTW@3L5 M8K[PL^'ZK9^'0Y.\(>S9^!>Q<=*1B3(P)&\@ CX!/FHQ|&BO' M|#'(#X=2|8HT0|5OL 5,!51@NM!:Z/.S0Z\(-3:A]1]_+,_]& M&D<_I0:/+/<=L$UN14#R'YTZMWXZ=4Q:PUEZ_1&>/,^!?1IX,K%/?00&_I"2 M4%.+8GZ$O&?BG?M&7/$;<,0Q-M\;X%_||00(3Q7=39:QH)K=#=(110O*

*% M"%9[6FRF'*GBQ&(8P+|4$US*V3Q:C)=$(1Z2@W%.(&]DDC<@"N'.'+%@S5;5 M?=U]#G<6EFN_#A HME)4KBA|5_FO$B;5.S\1&#V3R]&*JO\R%:-T. M:7=E!\T(8V[MZ=WEC2)3&0Y21$!BF+Z%EYIEL->7?MEP8&$L /.=86W?L+,L M"AC.Z1(!LAYDPY,8K=5T2FS[2QC='8RP66:$'%XVXL-VIO1G+:+@:O61U]"% MBGVL8T$ #O0O>P/X*ZQ])&#/8[,5K4#FBE!&GL9M;L!FHDI7W_V MM4_75_J]FG7Z%51=7-#7Q9,%*O@$NEV W5%C.R M8*C&>? :#"S M+8S@OSDI#=$U6+P?=? \"F0(PQ^/LY"8KC>9Q2AL&6L@#O8.#04T/KK| MK9'QFWZ% 6@I'H'@](37P:/H]3?2U!SJ&@V+O*$#QRI#TAT@C9B@CZ26HZ% M*#P_R)\'\6+?8Q(OF0)[#A:%TP6 5U'/3=$;(* MWPV\'B=7^K@)1B$'>H*:)]0ZMH5U9GS5:0[M7N(PK,.B E4^):E&X8O SGL" M+M"0W'U9;$GAOJ6B>(WSUX8=RQ&.&I(^VTGRQ RNAL9*4QRK^B-HN@)Q5T) M(Y?)MB, ![GX)*AML+%<'R2;P%]CPB3?5*K_Z)%P\)"/'4N,!)^,I%$[=, +& M/BA_*7;^4^,Y1)!F&9]8]*.;$*9*Y+F0 B0-YP67+".(Z]/4 :$"JF?(YI:< M0);HSKMRL]"I292X|$OP 2R'\@*TZALOV6A <]6M(IO#M!F19Z"]_J6E"$;Q&,0307./XS" M_5/D&9PU&24,I42(%TH3 >& ,#B:5:MVH\9 */,. BFLBR6?B1OT"? OZ$ MB1C%/(II[%/IA[[<-$6-:RA'9XT- ;4%55&]6[P0LX_#]$?K46'JC,8:>'^?%"M7DE0,) MWDD4A)@"_ =7_5&$A1/X22I/0&U.HX$(@!#))H1=24GJA-/"IO!W>4:4VFY4 M3L(O]^51,FUN0C=EJX(D"G0 3Q;) (,V.1'P&GDB&*>O&0R .!>)?7(MF<1_D_O%)0[PZL#_)$,)1I*,T71,Z+@:'93BG&3*<\-SZO;X,%*>C_(2;_X) MJ7L^[%N&;=C,E7KX/"I 3QI[Z,DS0$\;>^C)CD%/MH4IW*\8RC+18I%HL;/4 M1WT<=%)A$*HR)DFO$"PVF2I90H4=0>|:3O-+D#=<@)6695?$$YH7V&(K(M_V:#&Q03*F9@OBWCA#\]CC:ST\B@VB$>WU(0_MQ=&7H@;*? B*;C7A30;APU MBQ>F E(?;'P_^7+P'C.:SJC8$YC9E[*1,NGBO,O79+7 DT-|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|/ZP_']/IO'.62@#G6329Z#.G.)|EB MQ(>O4 ZAG(K.-"#YIB'JW<:+- ZJCLVS.N$0_^9GXQPA ^^UT-]"('(*%;C M=FLX/8=C;5*RH;.6Y$79Q&3.0'^V)6&AQW$3.?Z4* (G&YG@$D&OQ6?E"X0R M'(8$62CX >B(DM'T8Y^HBZ!I,H]4PM8&8]R<$:K#B6/V&-%QDGXVS@*-5!SC M'K*6[W\UF%3B()BD'PM\"_$T.>_3!]YBG.WR@#/#2T0&B@*? ^]W7[V//C!QA M#LI=]EI#" 6\,6 VN@,&::0*^42U]$W^;($V"63-CP5 NER?.B2B!&40!AH. M P[^]4] 48[]]L2Q/YZ M&83**8L;8!][MUN)^O<|WXOU ,]T/];J[*|V1R0YI98$ M!C97L^IPW0HI>QIY9!KYSWFJWBBGDCU-$B: %.2@"*HW_D302 (((7)R .% MK$\R#L5,GAE]X\:2AF?W!/ #TWT?] MC(QZZNW&;?HP$PY.<"B3^>?? H!"1RXK(0"@G$QIZ4D6:1]_C&/LSWP;S_P" M#**Q5&-S6%%^=944\$.)3!]S>Y67Y;!98@5<9+&E>:'$"#-2Z"Z2F'3# K ' M<79C4/Y>(]X2.F>*/K"]1FY*%|+ NQ|/DY1/WIVCL4|(5L$"BE[R6$D:TXVB*L:Z#GO!H:.K?13D>=+U$<#& 7 M-.98 Y:%_9F;'60]O=(N30MF;]E>8D<'^ZLF<[]0?ZH MO$)[WKS%-,N\MT"U,E;#?D#/'F<(*;8G O@X C3A;$$?0W!Y7\'3Z;^DM!:D M9>FG8%QY(L07DN@(N8@DWE||0C;">1EUM_@Y!]X+F0\)"'Q+A25HZW^">!M*<'=\E3"2C\/W3%R>N9)',8H@T]Y M80+4"/<7_6];, <30)U)UHE".R]=&014^0(HR1%&3FYXBQ+F!C1+-O^8MH5X$"@?4'4853UT=KE(D%.MX5'LBMQX7: MNL*@K MJ7.@P-Q@=?!TGBP1]]D?<0]EC3Z<>2(== M,J5F7S#9N&WX*HSGR.2VOBP9*;,;6#R3*\&FRH^F'Y7 RY2O8I62)ED#>8(* M4RC8#;IH),NJ-),LM]1MHGVX*?]*CE, /GF6BBBPB@OSXQF1S_-\Q#[XO| M.XN0_P@,;U%Y2\T980[85#3O3IJ+2]*<G*YTS."$%KOA1]TK0(%R\$)66AU#46TG\OB>'>$%C%Z]$H142%&G DO+8T+VBIBA6OU13#8#L5"Y$2<1499WYKI MZ^-D!A'; (ARQX2;E&(R"-5Y9F4&C#A,8HHSJZ8#2 U<"KQ&5 Z+" 7B6]%_P M5Z!33/G>=::]1$5Y:V9ZJ"K$1(AH/.9ZXL?N"2L/I!Y3I0.*&;..S(VVBKID M4D0:G2@1N/^QCDA<L|H^SR75 R8^![M-V&4*%I:K3^3E6>9UK23PP(I32<9H<O R)*&_(|<#2(N<8-, !4D M5(UCTH,XGFXH1R9OZP&9#_V469-6.&@)=&=K6*[6%E\|5.DY)PDQ7G@%22V" MT^E+=Z]I%%30]ZNS%)3[A:YHI*VZD2#]07G)_#R.'(5S#V6*GR:R458 >H* M=2/S)VVP:I@QHCV"&7!XF7A@/I%X91"K&\V2:;]$9!;##S7HE\&0K&$6^'(/M/BKPLW)AZ\,K!C01S7A+&]X3_US$!L?,\;SUT;%3=DQ85.8 M,2ZEY1.'-] VFZT=9B6D:&@.#U?VBO@ZD3U'5-8.D3?Y>N9)',8H@T]Y M80+4"/<7_6],<30)U)UHE".R]=&014^0(HR1%&3FYXBQ+F!C1+-O^8MH5X$"@?4'4853UT=KE(D%.MX5'LBMQX7: MNL*@K MJ7.@P-Q@=?!TGBP1]]D?<0]EC3Z<>2(== M,J5F7S#9N&WX*HSGR.2VOBP9*;,;6#R3*\&FRH^F'Y7 RY2O8I62)ED#>8(* M4RC8#;IH),NJ-),LM]1MHGVX*?]*CE, /GF6BBBPB@OSXQF1S_-\Q#[XO| M.XN0_P@,;U%Y2\T980[85#3O3IJ+2]*<G*YTS."$%KOA1]TK0(%R\$)66AU#46TG\OB>'>$%C%Z]$H142%&G DO+8T+VBIBA6OU13#8#L5"Y$2<1499WYKI MZ^-D!A'; (ARQX2;E&(R"-5Y9F4&C#A,8HHSJZ8#2 U<"KQ&5 Z+" 7B6]%_P M5Z!33/G>=::]1$5Y:V9ZJ"K$1(AH/.9ZXL?N"2L/I!Y3I0.*&;..S(VVBKID M4D0:G2@1N/^QCDA<L|H^SR75 R8^!|

M17@OBI\Q1^$YUA#UT$\U[]@NCH%=]-0PX5)5#%Z20EN69Q3^@DTNB"5I8!B M,4*0Z2T'C]S.SS+8@^W3WJ)^)P60=@?/N;-DW3;^EV.X$\B3&TA/@FX=5>I* MLY4KS>'EP?5$Q3I)+ ^3M,EJZ$%9L,,#O;^]6GT9INJI\K)W77F] M"*TK,4G9>]3>Z0U9H'D.RH>QXK#854"AJ N:'+>QF".A :7_ M^YZ*F9:X!4$]U2R=8\.' ,.;@_TA=<-)@HO2EC[F]-&XX\?]!EC7?I>%"2I+ QM MX.3)[%]VK\L@\DY>2)!"-#U!/#D'*N=O$=2'(C!1KHE;AL]#8D^HW&; #@2? MP[62M<_-A"PVD?M\]9QQ^0=R+]3^:4N.K4T?S&*%YY^31H92+0@:P,@YA MP<72IX#5[>AF6N:-{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|"6HMSK.\5&]DJBK.I$=VH!CX,S'S>/O=?ENJP$4X'ZWR^_<<^4;X$:K M]8)*C&G&T\$^VNN(*HJQ\X)[.E*C\&27C\IIMH^<>F=.V_A>;+7A'-==Y[#1 M^%XW #2>=]OI=-K5_H5=)\=6OQ!NYJ7X2D5IQ76-'_^0Y2HJA*&LWV)L;: M^2W:RW)"6< KEM#$8\UEX;5]^KDLO#^KQGRD^BZE>7/]V>]E\@(Y]?GJ]A9NSG|Q.3&8+;)A7OYRAXUTDJ;)4=EA3>]-T M6O-.N>] 17W3)CMP['LZ>U:S9 $7DFX30BQ*1N38 MH9@+M>S0 >VYT?>V\#TWVC9_[O;]?OO)[,LDGLO,1+O2_G!QM1QDLLAR_7<=U MVIT*_J G|==UG'IS"^;"_KJ6TZKBQMS[Z_;L8C^9YV"D%4V+$|SH%N& 6O). M8C$4,6;E)B,OWNFP]LV1A2^1SW[@$>]K#2_2(W[F8]_T]MG-M7OW4O<[S[HKLH M1U[76[)KLJ-;)73NFJ/DED[+;3L-=R6$A8:Z%|_<\AU8:%]|+SL)'!<=XY6 MNZH6;D U<;9Z%QIC@Z5+7JT@+/STW|[<3V9)[-E\O.ME_A]SA/R@PQ+GX4" MRWHG"9;VEQW[V.;<;1[ZIEYKK4O9>*D"Y$VKUOINI6>K5K__VG=.<*XT/2M] M>2\||Y/9PLELO>#@d;#4'TP.:|JP .4UL.>62MIB8RP8\)D8ZQJ^O)7FT MFZYS6%^98_+H+/;9MZ+3[CC-PY791B['UMS[_1U=[V9EJRR)M3.U?@HUWA8U M75 [4:'N&_!B8ROEZ/57/_XR_^OQQ-S]7\ZCE"J;PU*&69#OZN-MZ:8]7E94<@&FW] I_>1?-%]A/'Z%LH"_VJNNVZWC>U M650UMW6O"X\;?YLU+ZFIMUVCM#R>X5Q2896-3\UA?*G%,) B:+J:))86C6+:82+(>RGOJP^6'MR+A]NUK$MNQ^_M*|SG$LMLZ[=&<G3)'-DP'@4B#Y]73=2E2FJ/^]/R@+HJ&]T^$(%[%]3IWN4AG M9U^D\QF*=';V13IS(V6WBG2R/%0SV:@X+)5?N00V:B.=&*+B5!<|>"&R>5$5 M*%W:P;I/?4KNZ/N:ZCC5Z_3SZT;-Q?+_@1282F!AR]$NUD(?!D+U=Z+/T1WH MP7SN'%T#WUHT2]DXP ^FNBOK@&K]Q|$0I*$L 2U$,E-JF]LQP.|_;5@:/(6N MO:^KN:^KN:^KN:^K6;K.?5W-Q[WFCU&2|=.LM%]@H#YI.<,C%|:SH\4,L0P= MP]+F ,Z[,?TW1YVF9 MXF]'QRVG)SWQ M@OS:|2HG1 7%;ELS6=K.8?.[+:WH H<[_FY7_^;(:7?N6P%YIU/8[KW]+:E _M:X;HE<.T853 ?3##VFXPY(+Z^[L!UME8.1G",O[?U2XL[@:[<#@38*V21R" M^V:;[$]6PWHF0DW/F]HT2\Z_-X+%5?<]6ZBR3*PB+4$+'*'@!T" 0U*(G?1 MT'ZWD=471K]?*(HH.8(1#.%(4T(X-C^$=*D4&K)#*8IK'?(X1N&MFW\ YV M|\4>Z_3MI(]=PQ'%@UV7;WWJ;)NW^'U_TJ70(_9.AW^?1[BM^4#T8X&=Q&,1 M('P)/Q!$,+V2:>@=X&>Y7;H?PB*"V<"EA^NE7KQ;BHI93/G: 7=-*IG3ODG(M)?%IOY&*Z?^P^,V_F,VEE[BV2QM,6DM",'3G<$7L$TE-Q\/@)K3@VRB?_XT M0EH^,^O:O=CS0QMH\X:('D%RC#+[Z"6)UQ]E\&::V++'3>GLU@ 8-(NSRZ"##"'<3O^C"\/>O[?D_7MG>O].E?=O?WL4WUQ@G"4K*AX MQT(_D,*EU9R_7HYBRA8P91K.CB8TQ$WLA1+*B?6&8Y^P+/R(_!NV-_]^AD.M!5LEQI.@FFI("HL.?'!&9/CAPHE;:N+K8'~JJ//BB[$>+*QX*N%2%Q23V@=,> MMPW8YP1.-N+/>S%3V+}>)YJ[T>Q-84-ET]LZ1U:+(G8!5D1);4S2W0$ ^1$U;+50MZA@*6:OLRJS4Q4S5:@RW"]ER8DDP]D"S^R+?WC65AW"%9]^W;]'7V\M#%B[N M\=IU-X#L(6&\L_$5Z|=KXTOM"2^\&;A7%@R\-_33YN6#@6'B;?H:I)1G("L0TKY)5/QMY!/PRL/4[,/;Q?WN1 M%]/D!G"!8! YMM;L]RNWVRJY^]R^? R*'GZLRE8A6SAJYGSAN%24+H)L>E-D MO*P7#OU K1_F GN3#($FO!ODS/I'&(XS,A -E,(\=58'LZIH")PEGYYZCAU%(MPEYR)M@Q.T$#Z\B+F25> +3SF+#0)\DY.-SG'#Q#SL'A/N=@5W,.ILCM/7)[MI]"O~3^VRUKG'KF]>\CM*!3QIP4-?POPP\U&VSGLK=,,|S]WN!MUOK;?Q38K<79DD\&ICTR.ETYD#XSP0R;8!AW3Z:@V,\ M&^2UV7*.YSL#/0-RNU6AG<7C5OT\4^Z;1UYIPYZWQ9Z/#IRCN>A8L]%CHTC MY[!586L>G1KG,;_/RS2?.7DD\@.#[>$2MQ#!&5O3=; <!@U9IX/U, MN2\?"\[N1]Z(9IWB6%M"']N8=[-=.[1]V2ZO?GE;&H)YY(UH-9W#]K:<2O/0 M:6|-B72 TVS+7-P*2_(=[4'F&]>;]V_"]B/2L)\($7YF0O; OUB GR"Z3V[&EK$R$-$,,P,1!HC(D7I_R;1N=O#F:\|:F%VXQFW)($P]:Q0=E')8#VFKWT]W-(VIFK<\PW M!TC>RP:.^0K&^;K;5SX&XD1-R%**>,,O>5^SO#!3*?GM^@>*>IGC'R#QGPRS.U M*F97SN_]B&'@A]\:Z MY(IE75EX\,J+>UXHDH.+KX'@M(+ OQB0&3_8+<%L],#U >W^3_^Y^CAGOX M,XDT*9KT;_J#6TI%^YS#M>AGB=.A2M;AZT):^V&9/F49Z>" [F7GH[%,/9QAR M'M7<605MQ?V9(P*K_/X4DYGH2L@8[%HZ >S2EC!@"C8"?E8(.SA!HSMP,O" M_H@I!WX;1ZFPR'Y B@JG.DN<*7&|7B M.I10T?SV);!]U3*G?]IW-IG1'+EE5Z12"'>?(;>):=!=J!=>5XSV[86I\C0ZY" M_^Q7OUQ\.KWL7I^=_VJ?_NO3Z?G5Z=52W%S)#[U0,.>8S'|>R|*8|5\[?#^934[FN9C]Q?5OIY?* MK>?8Y2?76[@Y^\GLQ&2VP%IY]3V9;)/+MAL:#T M6FYOV-W?NV=W.ZZ6FCI'!T[G7F5 MOG)9J94|<\MW8*%]];WL %AUK9;CSAN[3UY=[3$^6 [V60ESJEI%;2_]Y-Y M[LELK_Q\ZR5^GU,H_"##:AVA2.T D4P3054)QF!]DLVYVSSTC5M;76+VI0J0 M-|>U!Y1HW?'%']7F&R:]7,&YTO2L].6]\-Q/9ELFLTO"DP>" _!@CEA[@P4H M+X<]MW:4I4D*+|&S\18U_#EK>2N#<=MMYS#^72[IZ_R>_OIIRW#E-T+6Y%F(D74S6H4'9I7OS>L2KXA["HMEZ8!E-[MY&%U;"IO>T!'8N_,C\6%]Q!A G6PC1>S 93+.EW MZ\/VX!OBU@LRRM_!GV^RP$NC>&H^X4U@+O"48R>P2?X0!H*OY=7^Q' 8Q;(2 M9I+U4-ZG/GR+"_GBU"PN168+GY!Y48Q:S CG#_\>85QJ$@?I]D211 M#'M$B\(Y^ -A9PG\.OWJYXG":K8L4/6' .4$K'JX,EP8-!7FC,6FO|&F!)7 !7K?=H[S@;*O6LL= .?+NF54V MNPG_P$U925MY|%70|F/TORM17,T"B-CI5D_P9'@QLV77Z=BM(I!!+$O M?_]IPT+A* <3VOG;9OG;9OG;9OG99R3KWM]YH_1MFK3[.R:G9!SU!SJ=EI M.|WC|>H6E=/.,TR^X;AN"\O][.;TW[C89=YIU>%P!P/\D\WF#U9C:3N=PSM&\A+@?:2X' M57;EF;K37ZUH\?'86[.XOQ.I(.M*3OU:;E8;RI/YI')>/MZU2_M^AVOU"XOK*S\EGO#)00XEY9CO"T3? MQ_NW.M[_&"V1:51CO&7MCH@W!H1W9\;X=6:IT|$0|LFWJ8;[S8?V3Q>"/MA_4NQY! WKN\Y18'I7738@0"F,'Y,?PCH>"\51*<3]/8[V6R >TMO!-EB9W" M1:=O)WT?EHB8'#L1\:W?QWV"Z089WA;[_4G7;$ZN'IGI-\L=;A/=@KMD&GH' MC&ZXV/Y@# __8<|7*^?^CO8J%O[P*I])7O*S|^]!"!"M(^.?(/VZXL +>]* MWC=0--9R% W=&7P<>_'!0(0O2T1ZD$WTSY]&2,MG9UV[%WM^: -MWA#1(^2- M,6,?O23Q^],,WDP36S;SF)V;-3NWI0B?9G%N^21F-PP>R+%^QJ_ EC|L*3C@ M=A+?=]FF_+YW9ZA_I$]+\M8'/9'GR5K.D;/EBR-9VMB=?#9#;]R8ORB#V_U<$ M6^[,TA[M;G&M3RV.&@:\LM,INR\KE23[MQ&#U:)PN"4QU0/-Z8LL>]=T'4+T MFMVLNH5N5B\/T[NXE$;/W1O6ZM2.E]ZPP I8@>RV)[+U9.-.5V-ZTT-=8 M|>(^$/%-%(-" I.=>(&' T6C]^'!+0S]-?B[8-:3__Q32S(0$^A66"6F?C:2 M ?AEX.EW8*3C__8B+Z;)#>#ZP#[R9:W9[U=LME5R\;DQ\QBT._Q4E8TB%:5E MF&?NX6$95U@$EO:FR'49\#WT [5"F KL33($F@ K'\BR_A&&X[0*]-.D,%.= MFL&<*AH"7\DGZ-AA%)*8[1W"O>XQ MVR]KG7O.]NYAM]_*-(PMP ZWVTVGO:M]BIN'QW 8.PHZ=P];3G.^@0\'S3/Y> MN.U69VMAVPM3)!X)1]D\|=)WZ|=Q^/!.^M-7$@1Z;%1#@3\DU MQSPGQP.TT0!?9%C)IM[I..]\<^[F(MGG4*%/4GH%]#RMV11U]5K@U3\EFWY;Z?A]Y$XX.G?;6$.MA>XMN MCMO8HIUQYY(DMH2Y+LW+]A!SJ.# V=;L'(R4M.:33K^7Y'3WL..TY]NH?R_+ M?]-T';=^W\2|'3F^LG9&V *VUW(HZ+-2N<(_?YFT(\YRXTG'JG MY1PV5W;.?-&[*;1P?((]T]5VJF4K'F[?.M2LAX/"U>();W5L:0|\@V!:*_ ; M;0-ZC1&B$ER+'VI8YX&"[BN1P+!.&"^'=1K[;-G8'6%2!IE B*4'TBW,$A!0 M/D$N"0@W\L4P!Y)*A$M,2"0BD@Y>'61 _K,MV9]G_F6:Y?[S+UX0U>PE'S=%A*5%!"[GW#8//#P+*RP:^ EN^=NO'ZO= W,@)P>]''?4S M5Z".8DZ2H%O"^4RCH9Y)O;_8 Z &+4;S]&2.%CL&K%5=3)K7=PWKY M:F1E8&/:UMRT.^4K;APO70T\T%(/*"4 A>S46)BCX+'JP2LO[GFA2 XNO@9B M:F&4+/QH"NW8#8E9)XTE-Z >%VL@"ZS"WG93LGA. MG1Y-;/B-ZQT><+&H@ MB4CMWM0> =>&+^:;M6,P?3^/H^^3JHH72>/3S62IUV|SV$A'K)=BO7.D=8[Z M5@&*Y/_[GZ.&>_@S,0"IR:K?\D|N*17MD_+6H)\E/K,J:7FOW4XSI[1VJT3H M.9:1++V+N7G,/CEOAAOG8?>];CA[H8HY0*P8MEHKN/&,#Z+@:L@'!-T"KL78M"KPL[(^8H."W<90*=D$@H853G5K-!+I.LX\-.AAZ^A WF#8'HW[P_|\T)QX MF> ^|B8^N_TN1P(K[2(PO($L/B<'KR^/$PP-.-T"F-;"&?@BBU^?F-ZF@M"SN MK],3(1*+S:C2Y)LS.=N|&:|<8"2@+*(H=U$-FOOQ$D&6C7"N?F*AT/L-J5_\HP|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ÆE##YC&]"?[:CKN10'MQ5&S&,X]CY-I MDU]VH1QF ;"P. H"H@@_E#0\G@1"2:]9>C E,<+]>3[[>?/CP0&'(6"',KRB<*=C+A*3MU/-)A,0++.']_+"?8*YTF M]4#[$9\!]<_TS%F:"DQ'G/Z1 KR@"L(L"K03+5+]|K2TC;04BILH]=D%>-5 M8)MORHHBJ(]$/8X=-*":)>2%11. /+9>'&,=)S8F0.1$NN0H;,Z4"P,2O 3(M!PF1?"#HM ()Z;QZ1/ "' +A5'^4164 M5-00B[Y R$D6#H2T(8+@NB]22A<"(SQ\|^^$A0]0Y&PF1D8FR5B(U+1')%R (@AE$:+9E9 B.#.E MS44F)=;G?QINH]TX5I7AS8R;C<'*RE+B"6-4,HM*R"2>*WY*)-9;^U,,+)GP M6^\5.")?P281-VLLY'FN[AH3O BMOWMAAH"(@: S!02>X3%-) KDRSN4^L: M'3.QWR 2H5' N?O!OOK4I7^X/__Y-M%Z/)2H_?'BT/VW\1;V#\=U8]*:% MU^@"ZL_"3+$XS2<9>;'LA46$8+_%R+#)1'U$TT4# I5'[]2#[\S'M84 M9!&*7B^$KCFIXNQET.1'Y?S]==G9B112^-(HK(9[=?3RQ#2E4_C>RT"/\5*$H%BI?%5@I(^$@Q]25S3:;MI?A$5%?9U# MYR- AF7B['?]I*M.Z!@- @\M>^W6W+9YU0B,Y0UN M&1HU|@:"GF7$L!59 M*76B980^3KD-2(P)&$]!Z#E!YFD:3K%"<)4|3[,"|L/Z'=\H2--|))@M>OU^#*-1EQ.@LJ166,RP|!ZMBC^&XL>2&U;MPVKTPA;Q M7F#>+6P%W/N"Y%IG68IFEHZ.VYMDO?]*LR[']RK+B%QA;-YIG.43&X98@&VOS.4T0.8CV4X1!F[Y@|BK()/-6'E< 51V0P33*9!#XBCF4R MD2)0 NKTL,PF&& "%FC@22]@4K-08Y (7=64J9K0B4GM]M- -6Q@]"9MS!8W MD*XC4!TZJEW6NRB>*% T!W@%[^ZYEPR|OYP<7CZ"DX-0.]S)HH0#432)&#O,>=]4 MS$-KX;>5_X33OF6^ASHOH@QG=B!;W3MUV?A.XU]PIUB+Y7VOK#CZ26''01@! M80Y(A(V(KRX096OCV]'S8+6^'O$N8!!!%,MW#Z591R+"4:628T8:1W2;<%BCP' 8 [XX[$8H%<@F!8UR('4$+P?IA_Z>'>1 M=|+$-=N_[]1G./F9[/>KEV ::!RMYPRB(>6U'\6ELL?F?F_53"=^?9377#8#7>MK'VSX#WK;QO]ON)M[V MN2II?<(==O?IPAW/%X"LMB\7H?41-).CPQ.(2L%%W!_Y:G-$,?3 ?U,ZA-PN M9\V@AZ'=\'B6&?Q055;FXQ94A7_>(]E=:AS.N%:6/ES0[E;'+6@^,Y&+@KZ M:#0T"BYR<,*''DP8>=I["*TD7K<.4>R6W#S5CJDA?M]M'1_EWN-VW7'6N$U M=FOU/.NWLL=P=]19AW%"&'DTISE6G;N/T8_FD9*-9K*]:X#O9;1N>?4H(=EU MG6:[XZB^RA(^ ;_SEF"3996B*TO0X?.DPI)K<$" 9B'-S*<+BD;Z;Y=IUAKX M29]0=ZIFAD[":A|=.9U62WN7X;3_GH7";K3GCKJ]]GV<.>K<^>XV'G;6JR($ MKI$+7?VL%P8'M L>=]>;W!W,"M->;5#;'5#:F^'U=BDG)DQYW;DMJ)DMVOVV M9 %7W-2.N!5)X;'"4%OGBGKURZJC?DQI M,IO*AU^PAPOW:P%VTC2+9LVFAV$G%UK%U9T'6'09'DGW*-* 7+93(;]BQ]M|.CX;Z6|B,TOYTF"+RE7TN7J;WBMX<)UZNA.U($'1@OYMX(_]Y+&X MD;4924S(>C,%BKDT'IE2CQ1\A/05TT?N4<784,3)R)\8>CWS'3N4<+T 0?IA M=!=273"9)#:$\Z>\0F9!Q=$_PLS>1X@NM*]9U8SFL'[FNT9]C2^S33N+]9Q M-Z=Q+!6*D6MRCP?3$I?S/0C>+%P[$/V JMI98?";?_@6UIYDW7B@]# M]ME M? #LOHTVCWWVB#?TG0TBBWR06GC/ EUF$2?:'W0P4MO5F' M0C'X*O["7 DL1Q3;-U363X5B40%$#PW#3DQ^6Q:+I>@#K48'P*WB!WN""P2) M05DY-5F\%A:.8&Z)EV3,-C)5PHK(>0 YT &#OU_[AK(C M&;;$ WWPQW[]2)8M;[F?V.YQ[?CX;WHS%R] ^@FC+%6"5T7]|?9:Y=O+]7^% M>8BV<8B% U3DHF,-6, ^7YHJB@H%,A1=4>2?ZBSH3ZWG/1%|*J\J9U.29;*=3 MI%(P M@0>@"QDH)+Z/>;Q;??PYSF+L6:78NJ7[^ R3+UM8NJM@A#;%)R^N,?%86>1 M&;WIS 6B_WDS_8'L3F5$PIS?^#^PDF|@8O'4WOCR#QA$D8]V?\ N9#79R>+- MVQ_LH_K?E,Q$X%QNXN0&\FSRGS20K04&\DJ KZ$$T_8;Y;!?V^\9=>NDDO0 M\3SUH:V;0F!M&,/XX/E:3XM=M!=.&O2QRPGBQOP%Z=.&]5>) M&4;A>|_;R;$?7_PO^9FY;A_UD_B(NB?F)FV41^*IU<#/41TJ,E;3YM[MM9L MK05; ;1B0YOTLX>*[)U41L*$$&-'$O-+QDRP.Q"NEH;K-5 M=& L\D"\RX+"JG;30|@K0?<,\Z^@-V,"QC=7>5D#6!-:*E>A'E'C_G*(19; M":%=W(8S=2^O/*P3U"V&W;M)'\,@"!12#<[XO43B=PU^V+W^J#QA;FZ3X*5;7)/#02XG R]FX0 >.!>QC)4E?]Y7?|QB]'7' %U1I(4B1BA7 MI3M0MP*RS.D2R*IL[*A0>51K#TDE9PB7FC2TBK27#TW5P['9HQ-WF138=* M9FP59NR'2Q" E5)HSGGW"?:Z=)OP<.0V4Y6/GN#:|Q.)E+X(U>9E>Q0$FR M$L%0>:P7\$;XQ_LH'O.2KPZ:+'C#8I.['F/2U)%;V!S%(X.8^#(DG-EK1-*2P[4*L*S#M@Q:;%@:M/@>68JNLJ$*:L"H)Z(O M?UM=_Z3N.NU6\SYSM5;,M<$SBTE"R6&WZ&_[#WV8MQ|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|#).|$0|=1U,O@_ UA$=74^@U MWD5Q,"&+&2G5U*7QG[*.&O&/F+F(%!]-_@V$G @L'$O,_ M<?? \RBI40K"L7,$%G@;LY'0R=,ACIU.O>D< M=8(G)RFG!1,Z>,[8#$>'_CI8.5XA)Z-9+TY3A9ME@[X3>GWJ1;SWZ#ZQQB=8.K8MBRZ <1EUZ@;U(ZCXF7$T\(&B.6TTUC6\IC(@:2'<0P"W1D_(%-VNP-!^5928&MMRCMK-)3C+FOT1ICL&#L8[MAII&+A=*A DBF5^W9)5(LYB$ 317E1IDE0G=?9=VW0\UJ/!ZPI>WI!I/Z?M2 MU:D7QN!R%,4AK.5#8(K+E%M7$9Z/2N@QI8/9_9[?C-V_X*I,JO,VTN PI54 MC!4:QG_.Z_5&B8Y15!CX*3FVUABL1](8[,H*@WTV'F^\R91$R(GOW801M;&M_E3I1 S'C'ATY|59G7DAWQ],@ I;Q5]2>_0GT .H|B[X*-)1Q'"^SXF8 MD<;48LTZQ".K'|^@#35#/#;11*AQXIW:%,ULWUXEP&%4[$455A#A-E@Q99DK"FLE.1+!M0|SEB1:M07+)=+OU5<[VK=XSVEV>CAK"7#<7,\|W"9 MYG'E?ZTP.UMJ,KEZZ,X:A[+=57763GL,H6F^*2^_,5DU+(O665?^LYUF@6;MJ92:1)9L1IVF5)79E")#\|"JC"U5&6L]548.LKXR(U]UBCQ=:2\67&3@9/?2 M7GA_25EI+%=6EBH;CM)UK(JHV EGD+@C;*DI+S<2Q_2$G!GD|%M<+$H(2O'%|"U5%-8"Q:2,Q0.$3+=G',,.\W)VXV97)NZ ,80|<3$^WBIE+EI;-8V#[M9:500TEGBL$?L0P[=7%&"IC_4*ZX8VKMEM|<2B4+VWL M2|AVM0Z&"CT6#(|SVN 6E6D;3P*1%IJ?H(XR]KZ8NC?K.H@0E07ZN88LYF6%=)' M>[/Y+538Z 7!Q\.H[O8F]".?V(RY9TM2|\K>Z]ZSD/E>9QDW%KYV2=R>FNM QOR-GFQDIDJ^79D?6RX51.T_BJ[!?.3W"]_[OLN^U6EHZOY-,KH RJ;O'RY,Y MJZ1\ME %^!2+@[/S$U66>^,)4U6S%N>E^WT)\#Z_/1*9+2"]DG5WVNL0TBSU MS)$*-V.L-]S5NX":)B)&)_W)Y'G(1'85WAB92 Q@O=&H2"-2]985354GFCUI/#IN//F MFL11MB1-$>VUN(;B%2E5 Q\PS_A$&51G9V=[$MD.$JFK?GH/6_L1Q0&2/"R3 M%[LS^|%HCVA%2GI_TK5#L.@&<59P8>M&/.5YT8]5 ZM@0YJNHWJZZB"?^X5 M3G56%gZ^_^K'$!W;,H_U?70!$MYG#KG+DC)!.#JJJ..|=VC'/PPSJ8:<]#IV]MPV%=A\.VF/H+2AL]EJE_E#OBB?O-VF,'VLTYT&A+K:B]'.'Y(S)Q$TK3*O.) M_R35H9>M#&W!>6]J0,ML'\72OMV?XB-;,QO15/<6RI8]O@M9=H&.1YO'Y=|3C/A26./WWU\L;$NNRS8'>M)#_VJ$7S47L#.TME7#S<:AL[W M*8XWJ6!\?I'>V8A(K_"\2H2DK{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|+Y@IR QQC9$)>I4D2V^"YP>S^7.F8-@REU^,/:B] 0& M6|-BPB#EF/IXMX9400W(\I)(TFUZ!V[[C>#VU&Y[(/|%-\0R;PC6A/T!,UGD MU# Y5*6SF9K^ENMC4GIC:>VJNZ-C"@VG* ME94OSL=;9 M@W_]/:BD$55W4B#S@W\"ZV++PI@A+0"_-Q6I$>'W*6.>N\DS#=#A8(M9=(_! MC_.^(.%@[N@M)K7"%[&9=G%6MB[EQ.)14 MK]M*SATGQ3&D$KMW>LRHI70>9:IIO=:@HW)KE312T \&$=TY8LM)AJS$Y\SY M!/@1J &]IX27.]:&6=AGUE7MT#G+'4;$\BJ8?HC#:+>)*:6VBUA5@^+7;WUQ M)M02(@C@)_3/?TOC(<#!ZE&M*3*?#WGS1F LJ\&-9)N4&&3 C C./&>:>0|FZI(AQ95LKJ'W#5@)-@>)/8)_ M"RN-O3#Q^K*X,]'ZS_C.4U@"+YO\&]7('PFQ&@ES"Q86=/$;,5 #('F8 TJJ_\%0_XGXX4W$#GM9.HI M%)I*Q'<>EFJ1H,L+X!P%V78GGD NBQWCU?7S^(OLBXQ,R%=6DF2-;T6@*X"*

M=)U,X?)(_7W@I9[N]BYG![//!?$4;<[_.S\"[?MCV5L>=&NM4P13 M*D8S\ ?&.W-OF,Q!{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|HY5MUAXY .O'4<@QC2%<5|YM"DLN MH_0"F2Z#O9:QO31T9AHCF'1M"AW6):1$8EL6O30!&RI$1_G):^(A^B#B0$@O MZ:) !N&--;O#)B]-[Y &GNP/#/P<%0[6$"RE<]"6(I^'48]:?5&,Y2*=9;;0 MDBVA.G,8YN'A? AE]1@E*0A) M/B_+F)?IVR#/]4#D,7^MQ0R,!7K;#896]6.P8R]2FZH'V%MI"X@C6A M$!9!(8:>CW^:@$B0<"?$*.7B"GX'_37%MI&9*91P;C['8=G[SK)'@66D[8?= M?(=8? U4C&1142WZ0&HS@8&BQ84B6M)C/M:N:BH//"Y%!_G:2B$,Z46)0)-EN MEG9]1ZHZ1;C/E (@48DO H5X^A4/C50CD7K49$T:SH.*[2$*DEHRWQ+:&II M(*% RKB1D(U'/%T7C&12-H[VBL5+Y^ZE]?VV1FU47(;/]L7U[^=7MIGY^|O M+C]VK\|NSI\B[7[W/#D5TBCA A]H^W?J#C$1RA $;6^ZA MGQ3T;:=,C(7)U5ZBR=9 ;T9T?B#I*]2<)4O[$6R*%<" [$@/5!Q[%_1Y#_7U_ M#-:>#OI|E&G6,8"DQU/W7$I&F@8J.):AI#ZC]DXPX&)X0#8N4@1]"OP_A U'| M6+V;7OK%[ZYU\S'1UG[???=]Q:MKE5U= M3@X]N;M\42BB%WL#:3?*W!$8]1VW;W"MJ=R,0.)2Z$*GHXMC&$)\\#4:PJ8I[(^T#Y7 VM?/@XO+6-8_YB E@AKRMG!T4=^ @_((B)@^"5V M,](=DL-E"?N:/9@79IL04EJ>;:Q>05RE'AX="ASP-JG14NG@?-A,N4B2LGK% MX]P+U89+;O1"G\B>Y|Z'YS:68KF?SRI/?SV|NCZ]#VQK[H?3]_LB_?VZ3_MGUW_&U/\/E^>79^=]K]U&K5UW9"0HC:|:H1XU?ZI1]V,KJ0 N,5_OF6?0 M+T1]1-&%Z"6CVF9S=M8XEUVAAX8[1P_MS=&#:F# ^>/305O1@DS:N^Z=BO!,] MPWLR>1B9Y"V-W#E*<3?(.8Z6$8I%,8"'$(JI%8QCV>&_I>/+Q[/P4M,;WIZ L&N6S7B1%/4'!MJQ=..6^VU;&N!^_U%414K#O[@?UJ]!'7S]\[A^]*<0 <'! 1:Q<.N]MMN-X^X@ MPN#\ ^\"[^7/0>_]G']6&>KON_ODG_I=:;|I_?FM\.OK7[_\Z_G?##*X!@ BJ) M>,C)*$S_O/PU^/;OQM?;?O/WZ7^NNNG9:9#U&\&7__SK[.;WW_X^^L^O0?:? MZ=NW_?#OH]YX$/3^^#T;_:Q.S^_4SD_X*]K3_'";:^+A\&70<-[S"F^+=G" MZW@[X*_D[>CKZ-A]S.D=E^]@E1G>I4=GGR^:?_PUW.P&^E]_"J/P M/!L#+?BF&__L*HQ3X_8-Z^Z#NIA']MUL_:,(6<0K_[|ROZ8_]:(H M$%XX](}$O*+%HH^H7G?=YO$K,_3&<)E@U3\MH)E'GD.K;LYA,>D^]C3<15N1M'_YC3Z&Q9"?,6:#^]/]^+$SEE_7_+77^DO]A?EM>4,@:^+%@ORU%8;@ #B9Q MT$DY]C@:4)$1A_R5(AYC#C/"7ZCVSXWK.7"U0YK,(QG@(:1&BS2L>I A-)8QMN_^3J'(ORS$U]ANJ^.,5:A*A9]]NU8_0>+H4-U@9"VWLJX-_&"6[KD0?ODII M*69M(BR)XQXW6X2"AK/#K_ZPR^B7XSWZY1G0+\=[],NNHE] %U;3T/B3%VXI M=-:R%$[_]=O9V|(K)S,[=ZM)AMKF)1T0#O_&?4?,FT";/<"RD22L?F))A;%; MQ)Z._)Z?_K]>_.,OUGF4N_>]]!C3WV|?/G3B@&/^%R&\7Y5V@R M0(Q^WM7[/^_>G9Z^?UIQ^TL)NEES2W>B],&*_1SRV^+9HQB5R5&:3G[Z\<>[MN[M:(QJUF^CVQV[<'_FW(OE1#&Z\^$>L_2CVSD\K!\>_E@'];'CM@\/6_"]M>N>X[OZ(M4=1F6S61BG0VSO*+C2]8|OX;;ZK2/&TW8JG:]_]/XVORS47IV7=0R59DETH&7G*TS>T(G(F#\ M&2BTL4BQL!;&,U)Z.;3_GH6H>O.152,,&_94(<.6%YXL)Q;=%-YMDY+>W BE M;.2J-W>'5LKO^:/2BCZX1H,.KEZ97IK;1R\;X"RMK:<6,'(I1"WNTU.+,L4; MAWQJE8G%U:6-)2!IAE2.L%)L*;5HZ[^^;8REO=VDTJK76PW)6"2I=-FW04Z? M2T%Y>(-9^CBA*BH2]P?__]1/%-3H2S10V6GTP1_[:?Z8#*;_719,7Y?:N%68 M]OH\.JGQ]YBT6]O"D,K;I&T3E;7KS<8Z#.G_;^]*>U7%EO;W_A4[G;Q)=_/V M84:X-_R'UT221*W:.)[E,JFC#>]>@X->]$[7O7)ZM,_M4']5=^Z'T>_1(9!^IQ;U]QC@Q[%EY ^]03!TU2 8(E 21L#Z@$ HA:%80/PQ M:M/OR'MVSWD_2K_Z]"#K'.Z3JK['[L]N-XE:_P.?UBN\(]B&V#HFQVH_&7C M_]@#!Z- PP]>4/U[V8<_CZ:VRRL'\2J:JX ?\.;NEO0^W-X[I@17&7ZY(<^ M@0HGP="5/RI%,M5#9KPRF-VY2B,!^1%Q/_/M!_]'6.OP*_NT:J,2XM/.&7UOZ>,L'$21B-3'[LU;*^-_IX:@$TRN/VFG)]98+]XOTZO;Z_3.U,YG^ M^4%6V,A(Y)OQ\\61U6O\7#PETGPO?GZ^=B*C=GXC=B(?K9[3OO+QS-V]8.[N MUHG'N.<,P2@.W8;ORNEE.G$]L#&3>K]#?#0W51'45^]F-%#5Z#8'X0^B\3 $ MOQ)7QE>4TG:N*P]B<>_%Q-Y+AM[0ULGCWX^51,;)3.=CK,+6WOY7TFDZ@N#U!F!B,;T[N5WX.-ZK[[U&)OX; MC/ 5^?^<;-/KCL7QT(_+H0Z+:^*PX"']?*&*YQ>=3Q$Z@F^3K$/3I0E+H^>>3I'B[/_^ MXE%U[O-I46^YMU]XSY50-B'Z6&N]8>N<(ZW&|-?;LB[*_ZL>LU8/A9G]AY1M8'\ZU-?8Z*MT9'^'O?P6-;=^6UPC@*FBU+1]?"F(VO>DZ+=QNTVJ:Z>9/YVC MY]4[@RD,"QYS]:\AT#U'_Z=K_YIFC*ZJQX2NN^?SY-T\1_E=L8S7@A/ME)#U MK +(=.64_7WK]'6]U:L?6W&_>C"F-HCOG.!/]PG>\]??&>XEQ34AQ>^BN D+ M^594X@V,^ !3*/H%.WZ;8E^&R*]H\]DM1_1OGQ"(I':G*<3P]<=XQZ8 M7PN9_O1\]T$G:PWCOP2_/FY#]\:=/]QPY]-%^OU$^%XO.FBFZBC>K91(?*WQ M>#T0O.TS]\Y.XW!3B+D+8R^/1@-_A=-?=Y;'UD^3K]!,MO]ZO,<6>#]L;Z^_ M$PST\K[]]Y'Q.,ID O[S,_KS> ^|=%O*MN/226[$/*|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| M*/%HG8QJ;;A4?T%5?F=S[5AD5)E!+8=0D7*DA])>+K4 U0X*% <=5_D;Q"'R M7%TL=ND)49'81DXV7I(\DE16#24!%'!@B>:-=SPLJ25$Y7MC3OH:%F)9%5]% M#S*[](*MXY#&TV[A>WU@XF0#RL6Z]N=KUBQ",M'5R-Q;%N8W"W2G4(8NJ'R6 M.K.!+/?R@%444M N60)S*<$D!9PSLVPEL1&1JB$!*ECB5!SNY=8,LQ%EE<|$M"U;GJ^UFM;G$E8SV2LKCN;G=E!$7K^.EE2P6PTK>=/F:8B1;(;N,*8'A$K+1 MCA"PEE\1RD']@_51M^UVY@L@0>]R.ES1#KWOS%I4;;X2UG8^VP/T7N;V= R& M?@^:G8?UI@6W![O!>@2F>IR,MH!"97V&629E2'G4L.X!54#V+/ -N+,8U,0' M0;L,(#3/M8M/A\76T#VS3]W+'%C0->-"!%*5$)>WM7^XM"S7:7L7P|&^[19S MWE:HRYY5I/1$XU8CR0T,V$>.P%')N\0-6[CE19-\!]I6XM%1Y^BI'Q25U1.= M!K;NWCL?VR"B67Q?)"K&:*"N6WN],MC&V.PV]4GT^5&H=RW!BQSG @1M6_I$:=A)YYDX:C,AE&B<)IV8C^GF403Z4I;&7(?M'6AHGUG;^BQ[50';S2$H!CI;&4LHR.AXGD)')ZUW'F"WVX5#VOP|=!4|:8BV M/],lBT*VOM=WIPLXRM[S=DY=<)LF"V,%;&F09MH<66;|N7'$\@93W:,5\F4: M=)>L@:SB:((QO6I!15J&%+N4B58;YNIFH_--H\WF@@(T\7QW0J,,$831[!$. MZ#ILLHY]&4.K<@.R=.CZ6(;MYKJ)95VJ)M+3P63NK$73O-BE\3+?M MA1.=5MHC5-YT!G;I0DAT(/G%VA&K<|K\P2>S!-UF1<(N3V#+H%N Z*G MMBJ,AH$:$!#!%IPB1D=ZM1>]B'= 4|2@;7>L^62_S=>7[!3/B\;CLO-YE=E M=3BG2WQEYIZ]Y(&!G25LI:6LMV/-",/LDS,_A=9;,YM#7K)62+#!TPR1X^ M\1=*5T36\0.XM07'U)S"-4=3CBR82$?,MD_=3FC&E9M&L_],<%D'J3*%=|G' M1:.KI6Z.Y#R*'],C5[83 [Z&%UN88O/SRM/+4B;:RA7;Z*S6 7MX!ODN *@8A9S(BP! 0#M#GKG CP*(Q@ ,%$=>19VD*IPQMN9+K"D4VOMI7+0N/?/2B(#E% M='S94GTO$.I,!6RZ]1"SPC80+%!:SPR[* M:2&O2[99GW:QVPT&DO#;N-MD58141\VOAZYU&>M0;]3: ME+ U '2GE8YL_>?F%8*[8]!/WW%]R/_[/U!+ 0(4 Q0 (,Z#BUFC,DP* M 0X "24 1 " 0 !A;'IM+3(P,C0Q,#,Q+GAS9%!+ M 0(4 Q0 (,Z#BUD8S/DF8PL -Y] 5 " 3 . !A M;'IM+3(P,C0Q,#,Q7V-A;"YX;6Q02P$'"% ,4 " #.@XM9NP)%X3P? !\ MW@$ %0 @ '&&0 86QZ;2TR,#(T,3 S,5]D968N>&UL4$L! M A0#% @ SH.+67M7-2"?4@ A;X$!4 (!-3D &%L M>FTM,C R-#$P,S%?;&%B+GAM;%!+ 0(4 Q0 (,Z#BUEN?D|#YSD &'. M P 5 " 0>, !A;'IM+3(P,C0Q,#,Q7W!R92YX;6Q02P$" M% ,4 " #.@XM9N.,(A#,' "A'@ "@ @ $AQ@ 97@S M,5\Q+FAT;5!+ 0(4 Q0 (,Z#BUE'G>-C'0< ,L= * M " 7S- !E>#,Q7S(N:'1M4$L! A0#% @ SH.+6;:[#$H[! @A, M H (!P=0 &5X,S)?,2YH=&U02P$"% ,4 " #.@XM9 MP?'A'=E0 0"H8@T #@ @ $DV0 <#$R-C(T-3$P<2YH=&U0 52P4& D "0 O @ *2H" end XML 61 p12624510q_htm.xml IDEA: XBRL DOCUMENT 0001677077 2024-05-01 2024-10-31 0001677077 2024-12-10 0001677077 2024-10-31 0001677077 2024-04-30 0001677077 us-gaap:SeriesAPreferredStockMember 2024-10-31 0001677077 us-gaap:SeriesAPreferredStockMember 2024-04-30 0001677077 us-gaap:SeriesBPreferredStockMember 2024-10-31 0001677077 us-gaap:SeriesBPreferredStockMember 2024-04-30 0001677077 2024-08-01 2024-10-31 0001677077 2023-08-01 2023-10-31 0001677077 2023-05-01 2023-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2024-07-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2024-07-31 0001677077 us-gaap:CommonStockMember 2024-07-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2024-07-31 0001677077 us-gaap:RetainedEarningsMember 2024-07-31 0001677077 2024-07-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2023-07-31 0001677077 us-gaap:CommonStockMember 2023-07-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-07-31 0001677077 us-gaap:RetainedEarningsMember 2023-07-31 0001677077 2023-07-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2024-04-30 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2024-04-30 0001677077 us-gaap:CommonStockMember 2024-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001677077 us-gaap:RetainedEarningsMember 2024-04-30 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2023-04-30 0001677077 us-gaap:CommonStockMember 2023-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-04-30 0001677077 us-gaap:RetainedEarningsMember 2023-04-30 0001677077 2023-04-30 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2024-08-01 2024-10-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2024-08-01 2024-10-31 0001677077 us-gaap:CommonStockMember 2024-08-01 2024-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-08-01 2024-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2024-08-01 2024-10-31 0001677077 us-gaap:RetainedEarningsMember 2024-08-01 2024-10-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2023-08-01 2023-10-31 0001677077 us-gaap:CommonStockMember 2023-08-01 2023-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-08-01 2023-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-08-01 2023-10-31 0001677077 us-gaap:RetainedEarningsMember 2023-08-01 2023-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2024-05-01 2024-10-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2024-05-01 2024-10-31 0001677077 us-gaap:CommonStockMember 2024-05-01 2024-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-05-01 2024-10-31 0001677077 us-gaap:RetainedEarningsMember 2024-05-01 2024-10-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2023-05-01 2023-10-31 0001677077 us-gaap:CommonStockMember 2023-05-01 2023-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-05-01 2023-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-05-01 2023-10-31 0001677077 us-gaap:RetainedEarningsMember 2023-05-01 2023-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2024-10-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2024-10-31 0001677077 us-gaap:CommonStockMember 2024-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2024-10-31 0001677077 us-gaap:RetainedEarningsMember 2024-10-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2023-10-31 0001677077 us-gaap:CommonStockMember 2023-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-10-31 0001677077 us-gaap:RetainedEarningsMember 2023-10-31 0001677077 2023-10-31 0001677077 us-gaap:StockOptionMember 2024-05-01 2024-10-31 0001677077 us-gaap:StockOptionMember 2023-05-01 2023-10-31 0001677077 us-gaap:RestrictedStockUnitsRSUMember 2024-05-01 2024-10-31 0001677077 us-gaap:RestrictedStockUnitsRSUMember 2023-05-01 2023-10-31 0001677077 us-gaap:WarrantMember 2024-05-01 2024-10-31 0001677077 us-gaap:WarrantMember 2023-05-01 2023-10-31 0001677077 alzm:AL001LicenseMember 2024-10-22 0001677077 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2024-06-14 0001677077 alzm:StockIncentivePlan2016Member 2016-04-30 0001677077 alzm:StockIncentivePlan2016Member 2019-02-28 2019-03-01 0001677077 srt:MaximumMember alzm:StockIncentivePlan2016Member 2016-04-29 2016-04-30 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:KeyEmployeesAndDirectorMember 2019-11-25 2019-11-26 0001677077 alzm:UnamortizedStockBasedCompensationMember 2024-10-31 0001677077 alzm:StockBasedCompensationMember 2024-05-01 2024-10-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2024-08-01 2024-10-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2023-08-01 2023-10-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2024-05-01 2024-10-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2023-05-01 2023-10-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2024-08-01 2024-10-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2023-08-01 2023-10-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2024-05-01 2024-10-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2023-05-01 2023-10-31 0001677077 alzm:Warrant2024Member 2024-05-01 2024-10-31 0001677077 alzm:Warrant2024Member 2024-10-31 0001677077 alzm:Warrant2024Member 2024-08-01 2024-08-19 0001677077 alzm:Warrant2024Member 2024-08-19 0001677077 alzm:Warrant2024Member 2024-08-01 2024-08-21 0001677077 alzm:Warrant2024Member 2024-08-21 0001677077 alzm:Warrant2024Member 2024-09-01 2024-09-11 0001677077 alzm:Warrant2024Member 2024-09-11 0001677077 srt:MinimumMember alzm:ExercisePrice1Member 2024-10-31 0001677077 srt:MaximumMember alzm:ExercisePrice1Member 2024-10-31 0001677077 alzm:ExercisePrice1Member 2024-10-31 0001677077 alzm:ExercisePrice3Member 2024-10-31 0001677077 alzm:ExercisePrice4Member 2024-10-31 0001677077 srt:MinimumMember alzm:ExercisePrice5Member 2024-10-31 0001677077 srt:MaximumMember alzm:ExercisePrice5Member 2024-10-31 0001677077 alzm:ExercisePrice5Member 2024-10-31 0001677077 alzm:AL001LicenseMember 2018-07-01 2018-07-02 0001677077 alzm:AL001LicenseMember alzm:FirstAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzm:AL001LicenseMember alzm:SecondAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzm:AL001LicenseMember alzm:ThirdAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzm:ALZN002LicenseMember 2016-04-29 2016-05-02 0001677077 alzm:ALZN002LicenseMember alzm:FirstAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzm:ALZN002LicenseMember alzm:SecondAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzm:ALZN002LicenseMember alzm:ThirdAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzm:AdditionalAL001LicenseMember 2019-11-01 2019-11-19 0001677077 alzm:AdditionalAL001LicenseMember alzm:FirstAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzm:AdditionalAL001LicenseMember alzm:SecondAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzm:AdditionalAL001LicenseMember alzm:ThirdAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2024-10-31 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2024-10-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2024-10-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2024-10-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AL001LicenseMember 2024-10-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFdaApprovalMember alzm:AL001LicenseMember 2024-10-31 0001677077 alzm:UponFdaApprovalMember alzm:AL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponINDApplicationFilingMember alzm:ALZN002LicenseMember 2024-10-31 0001677077 alzm:UponINDApplicationFilingMember alzm:ALZN002LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember alzm:ALZN002LicenseMember 2024-10-31 0001677077

alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember alzm:ALZN002LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember alzm:ALZN002LicenseMember 2024-10-31 0001677077 alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember alzm:ALZN002LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember alzm:ALZN002LicenseMember 2024-10-31 0001677077 alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember alzm:ALZN002LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFDABLAApprovalMember alzm:ALZN002LicenseMember 2024-10-31 0001677077 alzm:UponFDABLAApprovalMember alzm:ALZN002LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AdditionalAL001LicenseMember 2024-10-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AdditionalAL001LicenseMember 2024-05-01 2024-10-31 0001677077 alzm:FirstCommercialSaleMember alzm:AdditionalAL001LicenseMember 2024-10-31 0001677077 alzm:FirstCommercialSaleMember alzm:AdditionalAL001LicenseMember 2024-05-01 2024-10-31 0001677077 us-gaap:SeriesAPreferredStockMember alzm:SecuritiesPurchaseAgreementsMember 2024-05-01 2024-05-08 0001677077 us-gaap:CommonStockMember alzm:SecuritiesPurchaseAgreementsMember 2024-05-01 2024-05-10 0001677077 us-gaap:CommonStockMember alzm:SecuritiesPurchaseAgreementsMember 2024-05-10 0001677077 alzm:SecuritiesPurchaseAgreementsMember 2024-05-01 2024-05-10 0001677077 alzm:SecuritiesPurchaseAgreementsMember 2024-05-10 0001677077 us-gaap:CommonStockMember alzm:SecuritiesPurchaseAgreementsMember 2024-06-01 2024-06-25 0001677077 us-gaap:CommonStockMember alzm:SecuritiesPurchaseAgreementsMember 2024-06-25 0001677077 alzm:SeriesBConvertiblePreferredStockMember alzm:SecuritiesPurchaseAgreementsMember alzm:AultLendingMember 2024-01-01 2024-01-31 0001677077 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-01-31 0001677077 us-gaap:WarrantMember 2024-01-01 2024-01-31 0001677077 us-gaap:SeriesBPreferredStockMember 2024-01-31 0001677077 us-gaap:SeriesBPreferredStockMember 2024-03-01 2024-03-26 0001677077 us-gaap:WarrantMember 2024-03-01 2024-03-26 0001677077 us-gaap:SeriesBPreferredStockMember 2024-03-26 0001677077 us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-04-29 0001677077 us-gaap:WarrantMember 2024-04-01 2024-04-29 0001677077 us-gaap:SeriesBPreferredStockMember 2024-04-29 0001677077 2024-11-01 2024-12-10 iso4217:USD shares iso4217:USD shares pure false 2024 Q2 --04-30 0001677077 10-Q true 2024-10-31 false 001-40483 ALZAMEND NEURO, INC. DE 81-1822909 3480 Peachtree Road NE Second Floor Suite 103 Atlanta GA 30326 844 722-6303 Common Stock, $0.0001 par value per share ALZN NASDAQ Yes Yes Non-accelerated Filer true true false false 5432797 4093073 376048 673669 79194 4766742 455242 240976 176346 5007718 631588 1254750 2925059 300714 1254750 3225773 0.0001 0.0001 3000 3000 87.9867 87.9867 0 0 0.0001 0.0001 6000 6000 2100 2100 2100 2100 0.0001 0.0001 300000000 300000000 5231254 5231254 687999 687999 523 69 60162478 51426154 -56410033 -54020408 3752968 -2594185 5007718 631588 311088 1996783 517659 4362920 1046980 904939 1802814 2064732 1358068 2901722 2320473 6427652 -1358068 -2901722 -2320473 -6427652 3495 4311 15501 6147 -3495 -4311 -15501 -6147 -1361563 -2906033 -2335974 -6433799 53651 53651 -1415214 -2906033 -2389625 -6433799 -0.40 -0.40 -4.43 -4.43 -1.11 -1.11 -9.80 -9.80 3531702 3531702 656378 656378 2154761 2154761 656323 656323 188 2100 861332 86 53782414 -54994819 -1212319 755888 76 1174148 1174224 83 550 5125000 5125000 -650 3613951 361 -361 81277 81277 -1415214 -1415214 88 2100 5231254 523 60162478 -56410033 3752968 646268 65 62370775 -14883295 -47600428 -112883 615 18087 18087 83 -7002 7002 318336 318336 -2906033 -2906033 646966 65 62700196 -14876293 -50506461 -2682493 2100 687999 69 51426154 -54020408 -2594185 755888 76 1174148 1174224 83 800 7088644 7088644 -712 3787284 378 -378 311356 311356 162554 162554 -2389625 -2389625 88 2100 5231254 523 60162478 -56410033 3752968 646268 65 62001395 -14883295 -44072662 3045503 615 18087 18087 83 -7002 7002 687716 687716 -6433799 -6433799 646966 65 62700196 -14876293 -50506461 -2682493 -2389625 -6433799 25370 25370 9286 162554 687716 594475 134213 -247334 -1668953 795968 -4455843 -4811624 90000 147243 -90000 -147243 1174224 18087 7088644 8262868 18087 3717025 -4940780 376048 5140859 4093073 200079 7120133 1635489 311356   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">DESCRIPTION OF BUSINESS</td></tr></table>   Organization   Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With two current product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor.   The Company is devoting substantially all its efforts towards research and development of its two product candidates and raising capital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (“Common Stock”) and its preferred stock, par value $0.0001 per share. The Company expects to continue to incur net losses in the foreseeable future.   Reverse Stock Split   On October 27, 2023, pursuant to the authorization provided by the Company’s stockholders at a special meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of one-for-fifteen (the “First Reverse Split”). The First Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the First Reverse Split, each fifteen shares of Common Stock issued and outstanding prior to the First Reverse Split were converted into one share of Common Stock. The First Reverse Split became effective in the State of Delaware on October 31, 2023. All share amounts in these financial statements have been updated for all periods presented to reflect the First Reverse Split.   On July 10, 2024, pursuant to the authorization provided by the Company’s stockholders at its annual meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of one-for-ten (the “Second Reverse Split”). The Second Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Second Reverse Split, each ten shares of Common Stock issued and outstanding prior to the Second Reverse Split were converted into one share of Common Stock. The Second Reverse Split became effective in the State of Delaware on July 16, 2024. All share amounts in these financial statements have been updated for all periods presented to reflect the Second Reverse Split. 0.0001 0.0001 0.0001 0.0001   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">LIQUIDITY AND GOING CONCERN</td></tr></table>   The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of October 31, 2024, the Company had cash of $4.1 million, working capital of $3.5 million, an accumulated deficit of $56.4 million and stockholders’ equity of $3.8 million. For the three and six months ended October 31, 2024, the Company had net losses of $1.4 million and $2.4 million, respectively. For the six months ended October 31, 2024, cash used in operating activities was $4.5 million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.   Management believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued. These factors create substantial doubt about the Company’s ability to continue as a going concern for at least one year after the date that these condensed financial statements are issued.   The Company’s inability to continue as a going concern could have a negative impact on the Company, including its ability to obtain needed financing. The Company’s condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should it be unable to continue as a going concern.   The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. These factors create substantial doubt about our ability to continue as a going concern. However, based on the Company’s current business plan, management believes that the Company’s cash and cash equivalents at October 31, 2024, together with the anticipated receipt of funds from its “at-the-market” offering and from the sale of its Series A and Series B Convertible Preferred Stock pursuant to the securities purchase agreements related thereto, will be sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report. 4100000 3500000 56400000 3800000 1400000 2400000 4500000   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td></tr></table>   Basis of Presentation   The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2024, filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K.   Accounting Estimates   The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve

significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024 and April 30, 2024, the Company had no cash equivalents.   Fair Value of Financial Instruments   Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities.   Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.   The fair values of warrants are determined using the Black-Scholes valuation model, a "Level 3" fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants' contractual life.   Property and Equipment, Net   Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of 5 five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.   Research and Development Expenses   Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.   The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses, provided that there is no alternative future use of the rights in other research and development projects.   Stock-Based Compensation   The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company's stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.   The Company recognizes stock-based compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company's stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.   The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company's stock-based compensation could be materially different.   Warrants   The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480, Distinguishing Liabilities from Equity and FASB ASC 815, Derivatives and Hedging ("ASC 815"), depending on the specific terms of the warrant agreement.   Based on the terms of the Company's warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815.   Loss per Common Share   The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.   Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.   The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share:
<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of antidilutive securities excluded from computation of earnings per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">116,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">121,054</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">873,450</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">67,665</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">990,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td

style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">188,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in">(1)</td><td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify">The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14.</td></tr></table>   Recent Accounting Standards   From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption.   Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its condensed financial statements. Basis of Presentation   The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2024, filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K.   Accounting Estimates   The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024 and April 30, 2024, the Company had no cash equivalents.   0 0 Fair Value of Financial Instruments   Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities.   Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.   The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.   Property and Equipment, Net   Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of 5 five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.   P5Y Research and Development Expenses   Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.   The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses, provided that there is no alternative future use of the rights in other research and development projects.   Stock-Based Compensation   The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.   The Company recognizes stock-based compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.   The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.   Warrants   The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480, Distinguishing Liabilities from Equity and FASB ASC 815, Derivatives and Hedging (“ASC 815”), depending on the specific terms of the warrant agreement.   Based on the terms of the Company’s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815.   Loss per Common Share   The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.   Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.   The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share: <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of antidilutive securities excluded from computation of earnings per share</td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align:

bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">116,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">121,054</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">873,450</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">67,665</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">990,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">188,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in">(1)</td><td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify">The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14.</td></tr></table>   <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of antidilutive securities excluded from computation of earnings per share </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">116,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">121,054</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">873,450</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">67,665</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">990,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">188,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in">(1)</td><td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify">The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14.</td></tr></table> 116999 121054 84 250 873450 67665 990533 188969 <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLkkA8l7RYBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Recent Accounting Standards</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's financial position or results of operations upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its condensed financial statements.</p> <p id="xdx_800_eus-gaap--OtherCurrentAssetsTextBlock_z2EtFPlEccxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">4.</td><td>PREPAID EXPENSES AND OTHER CURRENT ASSETS</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other current assets were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zp6360GtyP1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241031_zrBnMf9ZLoHl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20240430_zfxVdxEKjD01" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--PrepaidClinicalTrialExpenses_iI_pp0p0_maPEAOAzUiy_zu4y3rJcxvI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">490,911</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzUiy_zruKMZL2rvCj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--

OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzUiy_zGjojI8b7Tn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,426</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">18,671</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzUiy_z82835lwKRN2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">673,669</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">79,194</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   On October 22, 2024, the Company entered into a Study Start-up Agreement with Massachusetts General Hospital (“Mass General Agreement”) in preparation for five clinical research trials for its AL001 product candidate. The Mass General Agreement required a prepayment of $514,000. Prepaid clinical trial expenses at October 31, 2024 represented the unamortized portion of clinical trial expense and will be amortized as used.   On June 14, 2024, the Company purchased directors’ and officers’ insurance for 12 months in the amount of $227,000. Prepaid insurance at October 31, 2024 represented the unamortized portion of directors’ and officers’ insurance.</p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zp6360GtyP1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241031_zrBnMf9ZLoHl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20240430_zfxVdxEKjD01" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--PrepaidClinicalTrialExpenses_iI_pp0p0_maPEAOAzUiy_zu4y3rJcxvI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">490,911</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzUiy_zruKMZL2rvCj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzUiy_zGjojI8b7Tn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,426</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">18,671</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzUiy_z82835lwKRN2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">673,669</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">79,194</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 490911 163332 60523 19426 18671 673669 79194 514000 227000 <p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zJ3OqgLXNDZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">5.</td><td style="text-align: justify">STOCK-BASED COMPENSATION</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><i>2016 Stock Incentive Plan</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of 83,333 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On March 1, 2019, the Company’s stockholders approved an additional 50,000 shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><i>2021 Stock Incentive Plan</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, the Company’s board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Subject to the 2021 Plan.</i> The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 66,667 shares, which number will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2021 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Restricted Stock.</i> In May 2021, the Company issued restricted stock awards pursuant to the 2021 Plan to one employee. The restricted stock award vests over 48 months. The award requires continued service to the Company during the vesting period. The vesting provisions of individual awards may vary as approved by the Board. Compensation expense for restricted stock is generally recorded based on its market value on the date of grant and recognized ratably over the associated service and performance period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Options.</i> All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life calculated using the simplified method. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock option activity for the six months ended October 31, 2024 is presented below: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVctCE3A4dBc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of share-based payment arrangement, option, activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares
 Available <br/> for Grant</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of
 Shares</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Remaining
 Contractual
 Life (years)</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic
 Value</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at April 30, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20240501__20241031_zZ4U65rAVeEf" style="width: 9%; text-align: right" title="Shares available for grant begining (in shares)">62,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240501__20241031_zIqJcQ3h1435" style="width: 9%; text-align: right" title="Number of shares begining (in shares)">98,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240501__20241031_zxhtTdR9bZZg"

style="width: 9%; text-align: right" title="Weighted average exercise price begining (in dollars per share)">178.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20241031_z00GzKlfDCz style="width: 9%; text-align: right" title="Weighted average remaining contractual life begining (years)">5.22</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240501__20241031_zshmCgIsHPWj" style="width: 9%; text-align: right" title="Aggregate intrinsic value begining">70,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--SharesAvailableForGrantOptionsGranted_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharesAvailableForGrantOptionsExercised_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharesAvailableForGrantOptionsExpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Options expired">3,333</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240501__20241031_z9XsCgWFMKIa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options expired">(3,333)</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Options expired">150.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at October 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20240501__20241031_zN1Txv3U3hPd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant end (in shares)">65,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240501__20241031_zxf8EEBPqtt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares end (in shares)">94,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240501__20241031_z119PtSMDeBf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price end (in dollars per share)">179.11</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240501__20241031_z9iracl22JH4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life end (years)">4.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240501__20241031_zN4BreSfmOO7" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value end">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at October 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest at end">88,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options vested and expected to vest at end">179.39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c2024050 style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options vested and expected to vest at end">4.65</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options vested and expected to vest at end">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at October 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable at end">87,043</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options exercisable at end">178.87</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zNNf3Nqwstk style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options exercisable at end">4.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options exercisable at end">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options.   Restricted stock unit activity for the six months ended October 31, 2024 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zSiEgKzV0rhd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of nonvested restricted stock units activity</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Weighted Average Grant Date Fair Value </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">Unvested at April 30, 2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240501__20241031_znAntT7Wjie1" style="width: 15%; text-align: right" title="Unvested shares, Beginning balance">167</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240501__20241 style="width: 15%; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Beginning balance">375.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240501__202 style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested</td><td style="text-align: left"> </td>

<td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Vested">83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240501__202 style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Vested">375.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested shares, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240501__202410 style="padding-bottom: 1pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Cancelled">- </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Unvested at October 31, 2024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240501__20241031_zw3UdzQE05Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested shares, Ending balance">84</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240501__20241 style="padding-bottom: 2.5pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Ending balance">375.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Performance Contingent Stock Options Granted to Employee   On November 26, 2019, the Board granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pdd" title="Options granted">28,333 performance and market contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $225.00 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company's initial public offering ("IPO") for its common stock, or (ii) stepped target prices for a change in control transaction. The target prices ranged from $1,500 per share to $6,000 per share. <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember" title="Terms of award">In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%.   On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $1,500 per share to $3,000 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of October 31, 2024, management believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards.   On November 29, 2022, the Compensation Committee of the Board granted 13,333 performance-based stock option to the Chief Executive Officer at an exercise price of $175.50 per share, of which 50% vest upon the completion and announcement of topline data from the Company's Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company's Phase II clinical trial of ALZN002 within four years from the grant date. During the three months ended July 31, 2023, management believed that it was probable that the performance condition of the completion and announcement of topline data from the Company's Phase II clinical trial of AL001 would be achieved and had recognized the related stock-based compensation. As of October 31, 2024, management believed that the achievement of the second performance condition was not probable and, as a result, no compensation cost has been recognized related to Phase I/IIA of ALZN002.   Performance Contingent Stock Options Granted to TAMM Net   On March 23, 2021, the Company issued performance-based stock options to certain team members at TAMM Net, Inc. ("TAMM Net") to purchase an aggregate of 3,000 shares of Common Stock at a per share exercise price of $225.00 per share, of which 50% would vest upon the completion of Phase I of AL001 by March 31, 2022, and the remaining 50% would vest upon completion of Phase I/IIA of ALZN002 by December 31, 2022.   On January 19, 2023, the Board modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. The modified performance criteria was not met on or before March 31, 2024 and, as a result, the remaining unvested stock options were cancelled and no compensation cost has been recognized for these awards related to ALZN002.   Performance Contingent Stock Options Granted to Consultants   On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of 1,334 shares of Common Stock with an exercise price of $363.00 per share, of which 333 vest upon completion of each of the Phase II clinical trials of AL001 for a BD indication, AL001 for a PTSD indication, AL001 for an MDD indication and ALZN002 for an Alzheimer's indication.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, the Board modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate and the indication listed below, and (b) obtained a "Study May Proceed" letter from the U.S. Food and Drug Administration ("FDA") for the additional Investigational New Drug ("IND") on/or before December 31, 2023, as follows: (i) AL001 – BD; (ii) AL001- MDD; (iii) AL001 – PTSD; and (iv) ALZN002 – Alzheimer's.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended April 30, 2024, the Company filed INDs for BD, MDD and PTSD and received a "Study May Proceed" letter for BD in October 2023, MDD in November 2023 and PTSD in December 2023. As a result, 75% of the performance grant vested and the Company recognized stock-based compensation related to the vesting. As of October 31, 2024, management believed that the achievement of the remaining requisite performance condition was not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002 – Alzheimer's.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><i>Stock-Based Compensation Expense</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company's results of operations included expenses relating to stock-based compensation for three and six months ended October 31, 2024 and 2023, were comprised as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zt1KAqdUZDv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of stock-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended October 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"> Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">142,603</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">81,277</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">175,733</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">162,554</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0"

style="border-bottom: Black 1pt solid; text-align: right" title="Total">545,113</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">81,277</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">175,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">162,554</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">687,716</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   As of October 31, 2024, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $284,000. The weighted-average period over which such stock-based compensation expense will be recognized was approximately 0.9 years.</p> 83333 50000 P10Y <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVctCE3A4dBc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of share-based payment arrangement, option, activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares
 Available <br/> for Grant</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of
 Shares</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Remaining
 Contractual
 Life (years)</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic
 Value</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at April 30, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20240501__20241031_zZ4U65rAVeEf" style="width: 9%; text-align: right" title="Shares available for grant begining (in shares)">62,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240501__20241031_zIqJcQ3hI435" style="width: 9%; text-align: right" title="Number of shares begining (in shares)">98,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240501__20241031_zxhtTdR9bZZg" style="width: 9%; text-align: right" title="Weighted average exercise price begining (in dollars per share)">178.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20241031_z00GzKlfDCz style="width: 9%; text-align: right" title="Weighted average remaining contractual life begining (years)">5.22</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240501__20241031_zshmCgIsHPWj" style="width: 9%; text-align: right" title="Aggregate intrinsic value begining">70,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--SharesAvailableForGrantOptionsGranted_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharesAvailableForGrantOptionsExercised_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharesAvailableForGrantOptionsExpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Options expired">3,333</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240501__20241031_z9XsCqWFMKIa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options expired">(3,333</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Options expired">150.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at October 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20240501__20241031_zN1Txv3U3hPd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant end (in shares)">65,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240501__20241031_zxf8EEBPqtt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares end (in shares)">94,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240501__20241031_z119PtSMDeBf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price end (in dollars per share)">179.11</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240501__20241031_z9iracI22JH4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life end (years)">4.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240501__20241031_zN4BreSfmOO7" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value end">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at October 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest at end">88,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options vested and expected to vest at end">179.39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c2024050 style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options vested and expected to vest at end">4.65</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td

id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options vested and expected to vest at end">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at October 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable at end">87,043</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options exercisable at end">178.87</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zNNf3NqwstKe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options exercisable at end">4.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options exercisable at end">15,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 62000 98000 178.12 P5Y2M19D 70500 3333 3333 150.00 65333 94667 179.11 P4Y10M24D 15100 88001 179.39 P4Y7M24D 15100 87043 178.87 P4Y7M17D 15100 <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zSiEgKzV0rhd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of nonvested restricted stock units activity</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Weighted Average Grant Date Fair Value </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">Unvested at April 30, 2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240501__20241031_znAntT7Wjie1" style="width: 15%; text-align: right" title="Unvested shares, Beginning balance">167</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240501__20241 style="width: 15%; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Beginning balance">375.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240501__202 style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Vested">83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240501__202 style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Vested">375.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested shares, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240501__2024103 style="padding-bottom: 1pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Unvested at October 31, 2024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240501__20241031_zw3UdzQE05Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested shares, Ending balance">84</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240501__20241 style="padding-bottom: 2.5pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Ending balance">375.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 167 375.00 83 375.00 84 375.00 28333 In the event any of the stock price milestones are not achieved within three years <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zt1KAqdUZDv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of stock-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended October 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"> Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total">142,603</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">81,277</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">175,733</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">162,554</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">545,113</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">81,277</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">175,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">162,554</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">687,716</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 142603 81277 175733 162554 545113 81277 175733 162554 687716 284000 P0Y10M24D   <table cellpadding="0"

cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"> </td><td style="width: 0.25in">6.</td><td style="text-align: justify">WARRANTS</td></tr></table>   During the three months ended October 31, 2024, the Company issued warrants to purchase an aggregate of 440,000 shares of common stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)">12.50 per share.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 36pt"></td><td style="width: 22.45pt">(i)</td><td style="text-align: justify">On August 19, 2024, the Company issued a warrant to purchase 160,000 shares of Common Stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)">12.50 in connection with the sale of convertible preferred stock to Orchid Finance, LLC (“Orchid”) for $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zN6ksDfygfu5" title="Value of common stock sold">2,000,000. Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $571,000.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 36pt"></td><td style="width: 22.5pt">(ii)</td><td style="text-align: justify">On August 21, 2024, the Company issued a warrant to purchase 200,000 shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)">12.50 in connection with the sale of convertible preferred stock to Orchid for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zRzvjrNAi55d" title="Value of common stock sold">2,500,000. Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $486,000.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 36pt"></td><td style="width: 22.5pt">(iii)</td><td style="text-align: justify">On September 11, 2024, the Company issued a warrant to purchase 80,000 shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)">12.50 in connection with the sale of convertible preferred stock to Orchid for $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zTmwf9omOlG" title="Value of common stock sold">1,000,000. Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $69,000.</td></tr></table>   Warrant activity for the six months ended October 31, 2024 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantActivityTableTextBlock_zWMLNR3BTmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of warrant activity</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Number Outstanding </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Weighted Average Exercise Price </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Outstanding at April 30, 2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240501__20241031_zF0F44KaE1GI" style="width: 15%; text-align: right" title="Class of warrant or right, outstanding, beginning">240,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240501__20241031_zZ8SJdEkcPK1" style="width: 15%; text-align: center" title="Weighted average exercise price, beginning">$67.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20240501__20241031_pdd" style="text-align: right" title="Class of warrant or right, outstanding, granted">640,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98A_ecustom--WeightedAverageExercisesPriceGranted_c20240501__20241031_pdd" style="text-align: center" title="Weighted average exercise price, granted">$12.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Cancelled/Expired</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingCancelledexpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of warrant or right, outstanding, cancelled/expired">(6,999</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td id="xdx_98E_ecustom--WeightedAverageExercisePriceCancelledexpired_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: center" title="Weighted average exercise price, cancelled/expired">$320.28</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Outstanding at October 31, 2024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240501__20241031_z2Cy4zu45xT" style="border-bottom: Black 2.5pt double; text-align: right" title="Class of warrant or right, outstanding, ending">873,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240501__20241031_zdJEUTA9lwr7" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average exercise price, ending">$24.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The following table summarizes information about Common Stock warrants outstanding and exercisable at October 31, 2024: <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z6sfzHeW9Gh8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap">Schedule of common stock warrants outstanding</td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td

style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: center">$12.00-$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)">12.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Class of Warrant or Right, Outstanding">850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">4.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">12.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number of warrant exercisable">850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">12.38</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$450.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Class of Warrant or Right, Outstanding">23,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">450.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number of warrant exercisable">23,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">450.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: center">$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Exercse price (in dollars per share)">937.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of Warrant or Right, Outstanding">408</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_z8IiHBUXHcZd" title="Weighted average remaining contractual life (years)">1.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">937.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrant exercisable">408</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">937.50</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: center">$12.00 - $937.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">873,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4.7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">24.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrant exercisable">873,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">24.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 440000 12.50 160000 12.50 2000000 571000 200000 12.50 2500000 486000 80000 12.50 1000000 69000 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantActivityTableTextBlock_zWMLNR3BTmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of warrant activity</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Number Outstanding </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Weighted Average Exercise Price </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Outstanding at April 30, 2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240501__20241031_zF0F44KaE1Gl" style="width: 15%; text-align: right" title="Class of warrant or right, outstanding, beginning">240,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240501__20241031_zZ8SJdEkcPK1" style="width: 15%; text-align: center" title="Weighted average exercise price, beginning">$67.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20240501__20241031_pdd" style="text-align: right" title="Class of warrant or right, outstanding, granted">640,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98A_ecustom--WeightedAverageExercisesPriceGranted_c20240501__20241031_pdd" style="text-align: center" title="Weighted average exercise price, granted">$12.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Cancelled/Expired</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingCancelledexpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of warrant or right, outstanding, cancelled/expired">(6,999)</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td id="xdx_98E_ecustom--WeightedAverageExercisePriceCancelledexpired_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: center" title="Weighted average exercise price,

cancelled/expired">$320.28</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Outstanding at October 31, 2024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240501__20241031_z2Cy4zu45xT" style="border-bottom: Black 2.5pt double; text-align: right" title="Class of warrant or right, outstanding, ending">873,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240501__20241031_zdJEUTA9lwr7" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average exercise price, ending">$24.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 240449 67.45 640000 12.50 -6999 320.28 873450 24.35 <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z6sfzHeW9Gh8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap">Schedule of common stock warrants outstanding</td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: center">$12.00-$12.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Class of Warrant or Right, Outstanding">850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">4.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">12.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number of warrant exercisable">850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">12.38</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Exercse price (in dollars per share)">450.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Class of Warrant or Right, Outstanding">23,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">450.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number of warrant exercisable">23,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">450.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: center">$937.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of Warrant or Right, Outstanding">408</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">937.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrant exercisable">408</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">937.50</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: center">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)">12.00 - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)">937.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--

ClassOfWarrantOrRightOutstanding_iI_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zIQihYGkCStb" title="Class of Warrant or Right, Outstanding">873,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zT1TcctG5qy9" title="Weighted average remaining contractual life (years)">4.7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">24.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrant exercisable">873,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">24.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 12.00 12.50 850000 P4Y8M12D 12.38 850000 12.38 450.00 23042 P1Y9M18D 450.00 23042 450.00 937.50 408 P1Y7M6D 937.50 408 937.50 12.00 937.50 873450 P4Y8M12D 24.35 873450 24.35   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">7.</td><td style="text-align: justify">COMMITMENTS AND CONTINGENCIES</td></tr></table>   Contractual Obligations   On July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of South Florida (the "AL001 Licenses"), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the field of Alzheimer's, under United States Patent Nos. (i) 9,840,521, entitled "Organic Anion Lithium Ionic Cocrystal Compounds and Compositions", filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled "Lithium Co-Crystals for Treatment of Neuropsychiatric Disorders", filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021, the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments to the AL001 Licenses (collectively, the "AL001 License Agreements"). The Third Amendments to the AL001 Licenses modified the timing of the payments of the license fees.   The AL001 License Agreements require that the Company pay combined royalty payments of <span id="xdx_906_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pdd" title="Percentage of royalty payments on net sales of product">4.5% on net sales of products developed from the licensed technology for AL001. The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 14,853 shares of Common Stock. Minimum royalties for AL001 License Agreements are $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties">40,000 on the first anniversary of the first commercial sale, $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties">80,000 on the second anniversary of the first commercial sale and $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties">100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements.   On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the "ALZN002 License"), pursuant to which the Licensor granted the Company a royalty-bearing exclusive worldwide license limited to the field of Alzheimer's Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled "Amyloid Beta Peptides and Methods of Use," filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31, 2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, the Company entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, the Company entered into the Seventh Amendment to the ALZN002 License (collectively, the "ALZN002 License Agreement"). The Seventh Amendment to the ALZN002 License modified the timing of the payments of the license fees.   The ALZN002 License Agreement requires the Company to pay royalty payments of <span id="xdx_90C_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pdd" title="Percentage of royalty payments on net sales of product">4% on net sales of products developed from the licensed technology for ALZN002. The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 24,012 shares of Common Stock. Minimum royalties for ALZN002 are $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties">20,000 on the first anniversary of the first commercial sale, $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties">40,000 on the second anniversary of the first commercial sale and $<span id="xdx_900_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties">50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement.   On November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the "November AL001 License"), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimer's and (ii) psychiatric diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17, 2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the "November AL001 License Agreements"). The Second Amendments to the November AL001 License modified the timing of the payments for the license fees.   The November AL001 License Agreements require the Company to pay royalty payments of 3% on net sales of products developed from the licensed technology for AL001 in those fields. The Company paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which the Company's obligations to pay royalties expire under the applicable license agreement. Under the various license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while the Licensor remains the owner of any equity securities of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally, the Company is required to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Original AL001 Licenses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p> <table cellpadding="0" cellspacing="0" id="xdx_89E_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zCMacsEn2O14" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: top; background-color: White"> <td> </td> <td>Schedule of contractual obligation, fiscal year maturity</td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap">Payment</td> <td style="padding-bottom: 1pt; white-space: nowrap; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap">Due Date</td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap">Event</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment">50,000</td> <td style="width: 1%; text-align: center">[*]</td> <td style="width: 49%">Completed September 2019</td> <td style="width: 1%"> </td> <td style="width: 38%">Pre-IND meeting</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_98A_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">65,000</td> <td style="text-align: center">[*]</td> <td><span id="xdx_908_eus-gaap--

OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg____zShljCml5rJ5" title="Due date">Completed June 2021</td> <td> </td> <td>IND application filing</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_987_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">190,000</td> <td style="text-align: center">[*]</td> <td>Completed December 2021</td> <td> </td> <td>Upon first dosing of patient in a clinical trial</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">500,000</td> <td style="text-align: center">[*]</td> <td>Completed March 2022</td> <td> </td> <td>Upon completion of first clinical trial</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">1,250,000</td> <td style="text-align: center"> </td> <td>March 2025</td> <td> </td> <td>Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">10,000,000</td> <td style="text-align: center"> </td> <td>8 years from the effective date of the agreement</td> <td> </td> <td>Upon FDA new drug application approval</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F08_zkszjVw2weqb" style="width: 9pt"></td><td id="xdx_F11_zh3FeDOQSOg5">Milestone met and payment made</td></tr></table>   ALZN002 License: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="width: 16%; text-align: right" title="Payment">50,000</td> <td style="white-space: nowrap; width: 1%; text-align: center"> *</td> <td style="width: 82%">Completed January 2022</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">50,000</td> <td style="white-space: nowrap"> </td> <td>Upon first dosing of patient in first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_989_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">500,000</td> <td style="white-space: nowrap"> </td> <td>Upon completion of first Phase IIB clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_980_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">1,000,000</td> <td style="white-space: nowrap"> </td> <td>Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">10,000,000</td> <td style="white-space: nowrap"> </td> <td>Upon first commercial sale</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F04_zqRn9VuSZ6id" style="width: 9pt">*</td><td id="xdx_F15_zVcMtheF8a39">Milestone met and payment made</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional AL001 Licenses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Event</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td id="xdx_986_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment">2,000,000</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 49%"><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">March 2026</td> <td style="width: 1%"> </td> <td style="width: 38%"> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_98D_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="text-align: right" title="Payment">16,000,000</td> <td style="white-space: nowrap"> </td> <td>August 1, 2029</td> <td> </td> <td> First commercial sale</td></tr> </table> 0.045 The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 14,853 shares of Common Stock. Minimum royalties for AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. 200000 40000 80000 100000 0.04 The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 24,012 shares of Common Stock. Minimum royalties for ALZN002 are $20,000 on the first anniversary of the first commercial sale, $40,000 on the second anniversary of the first commercial sale and $50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. 200000 20000 40000 50000 0.03 20000 40000 80000 100000 <table cellpadding="0" cellspacing="0" id="xdx_89E_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zCMacsEn2O14" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: top; background-color: White"> <td> </td> <td>Schedule of contractual obligation, fiscal year maturity</td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap">Payment</td> <td style="padding-bottom: 1pt; white-space: nowrap; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap">Due Date</td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap">Event</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment">50,000</td> <td style="width: 1%; text-align: center">[*]</td> <td style="width: 49%">Completed September 2019</td> <td style="width: 1%"> </td> <td style="width: 38%">Pre-IND meeting</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_98A_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">65,000</td> <td style="text-align: center">[*]</td> <td>Completed June 2021</td> <td> </td> <td>IND application filing</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_987_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">190,000</td> <td style="text-align: center">[*]</td> <td>Completed December 2021</td> <td> </td> <td>Upon first dosing of patient in a clinical trial</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">500,000</td> <td style="text-align: center">[*]</td> <td>Completed March 2022</td> <td> </td> <td>Upon completion of first clinical trial</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)">*

<td>$</td> <td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">1,250,000</td> <td style="text-align: center"> </td> <td>March 2025</td> <td> </td> <td>Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment">10,000,000</td> <td style="text-align: center"> </td> <td>8 years from the effective date of the agreement</td> <td> </td> <td>Upon FDA new drug application approval</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F08_zkszjVw2weqb" style="width: 9pt">*</td><td id="xdx_F11_zh3FeDOQSOg5">Milestone met and payment made</td></tr></table>   ALZN002 License: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="width: 16%; text-align: right" title="Payment">50,000</td> <td style="white-space: nowrap; width: 1%; text-align: center">*</td> <td style="width: 82%">Completed January 2022</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">50,000</td> <td style="white-space: nowrap"> </td> <td>Upon first dosing of patient in first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_989_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">500,000</td> <td style="white-space: nowrap"> </td> <td>Upon completion of first Phase IIB clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_980_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">1,000,000</td> <td style="white-space: nowrap"> </td> <td>Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment">10,000,000</td> <td style="white-space: nowrap"> </td> <td>Upon first commercial sale</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F04_zqRn9VuSZ6id" style="width: 9pt">*</td><td id="xdx_F15_zVcMtheF8a39">Milestone met and payment made</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional AL001 Licenses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Event</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td id="xdx_986_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment">2,000,000</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 49%"><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">March 2026</td> <td style="width: 1%"> </td> <td style="width: 38%"> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td id="xdx_98D_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="text-align: right" title="Payment">16,000,000</td> <td style="white-space: nowrap"> </td> <td><span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">August 1, 2029</td> <td> </td> <td> First commercial sale</td></tr> </table> 50000 Completed September 2019 65000 Completed June 2021 190000 Completed December 2021 500000 Completed March 2022 1250000 March 2025 10000000 8 years from the effective date of the agreement 50000 Completed January 2022 50000 Upon first dosing of patient in first Phase I clinical trial 500000 Upon completion of first Phase IIB clinical trial 1000000 Upon first patient treated in a Phase III clinical trial 10000000 Upon first commercial sale 2000000 March 2026 16000000 August 1, 2029   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">8.</td><td style="text-align: justify">EQUITY TRANSACTIONS</td></tr></table>   The Company is authorized to issue 10,000,000 shares of Preferred Stock, $0.0001 par value. The Board has designated 3,000 shares as Series A Convertible Preferred Stock and 6,000 shares as Series B Convertible Preferred Stock. The rights, preferences, privileges and restrictions on the remaining authorized 9,991,000 shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.   Series A Convertible Preferred Stock   On May 8, 2024, the Company and Orchid entered into a securities purchase agreement (the “Orchid SPA”) for the purchase of up to <span id="xdx_904_ecustom--NumberOfSharesPurchase_c20240501__20240508__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase">2,500 shares of Series A Convertible Preferred Stock and warrants to purchase shares up to 2,000,000 shares of Common Stock in several tranche closings.   On May 10, 2024, the Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_90B_ecustom--NumberOfSharesPurchase_c20240501__20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase">80,000 shares of Common Stock with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Exercise price">12.50, for a total purchase price of $<span id="xdx_90B_ecustom--SharesPurchasePrice_pn3n3_dm_c20240501__20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zgzGrOum0xV2" title="Shares purchase price">1.0 million. The purchase price was paid by the surrender and cancellation of a term note issued by the Company to Orchid of $311,356, consisting of $310,000 of principal and $1,356 of accrued and unpaid interest, $100,000 discount and net cash of $588,644.   On June 25, 2024, the Company sold 150 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_903_ecustom--NumberOfSharesPurchase_c20240601__20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase">120,000 shares of Common Stock with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Exercise price">12.50, for a total purchase price of $<span id="xdx_907_ecustom--SharesPurchasePrice_pn3n3_dm_c20240601__20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zIKQwZpJ5xqa" title="Shares purchase price">1.5 million. The purchase price was paid in cash.   On August 19, 2024, the Company sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase 160,000 shares of Common Stock with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240819__us-gaap--StatementEquityComponentsAxis__custom--

Warrant2024Member_zafbXf1dFdg7" title="Exercise price">12.50 to Orchid, for a total purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zoVbk177Zodd" title="Value of common stock sold">2.0 million. The purchase price was paid in cash.   On August 21, 2024, the Company sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase 200,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zToR3gYZfe7i" title="Value of common stock sold">2.5 million less $100,000 discount. The purchase price was paid in cash.   On September 11, 2024, the Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of Common Stock with an exercise price of $12.50 to Orchid, for a total purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zLHblYMy2TM6" title="Value of common stock sold">1.0 million. The purchase price was paid in cash.   The Series A Convertible Preferred Stock has a stated value of $1,000 per share and holders of the Series A Convertible Preferred Stock are entitled to cumulative cash dividends at an annual rate of 15%, or $1,500.00 per share (“Dividend Amount”), based on the stated value per share. Notwithstanding the foregoing, for as long as any share(s) of Series A Preferred Stock shall remain outstanding, the Dividend Amount shall be paid either in shares of Series A Preferred Stock or cash, at Orchid’s discretion, in each case equal to the Dividend Amount. Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock cased on the conversion price (“Series A Conversion Price”), which is defined as (a) the state value of the Series A Preferred Stock being converted pus all accrued but unpaid dividends, divided by (b) the greater of (i) $2.50 per share (“Floor Price”), and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of the Common Stock during the three trading days immediately prior to the date of the conversion. The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, but not below the Floor Price. The Floor Price shall, however, be adjusted for stock splits, stock dividends, combinations or similar transactions. The holders of the Series A Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series A Convertible Preferred Stock is entitled to cast, shall not be lower than $5.63 (the “Voting Floor Price”), which represents the closing sale price of the Common Stock on the trading day immediately prior to the execution date of the Orchid SPA. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event, the holders of Series A Convertible Preferred Stock receive a liquidation preference ahead of holders of Common Stock.   Series B Convertible Preferred Stock   On January 31, 2024, the Company and Ault Lending, LLC (“Ault Lending”) entered into a securities purchase agreement (the “AL SPA”) for the purchase of up to 6,000 shares of Series B Convertible Preferred Stock and warrants to purchase shares up to <span id="xdx_902_ecustom--NumberOfSharesPurchase_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zhDraN3PYyU" title="Number of shares purchase">600,000 shares of the Company’s Common Stock. The AL SPA provides that Ault Lending may purchase up to $6 million of Series B Convertible Preferred Stock in one or more closings. <span id="xdx_902_eus-gaap--TerminationLoansDescription_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember" title="Termination loans description">Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the “Termination Date”). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination Date.   On January 31, 2024, the Company sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Number of common stock sold">1,220 shares of Series B Convertible Preferred Stock and warrants to purchase 122,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $1.22 million. The purchase price was paid by the cancellation of $<span id="xdx_906_ecustom--CancellationsOfCashAdvances_pn3n3_dm_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmnxxTkCvA54" title="Cancellations of cash advances">1.15 million of cash advances made by Ault Lending to the Company between November 9, 2023 and January 31, 2024 and a subscription receivable of $<span id="xdx_902_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_pp0p0_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9mj0Kr0NPki" title="Subscription receivable">70,000.   On March 26, 2024, the Company sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Number of common stock sold">780 shares of Series B Convertible Preferred Stock and warrants to purchase 78,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $780,000.   On April 29, 2024, the Company sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240401__20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfveuRCKRuw6" title="Number of common stock sold">100 shares of Series B Convertible Preferred Stock and warrants to purchase 10,000 shares of Common Stock with an exercise price of $12.00, for a total purchase price of $100,000.   The Series B Convertible Preferred Stock has a stated value of $1,000 per share (“Stated Value”) and does not accrue dividends. Each share of Series B Convertible Preferred Stock is convertible into a number of shares of Common Stock determined by dividing the Stated Value by $10.00 (the “Conversion Price”). The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series B Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Company Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to cast, shall not be lower than $8.73 (the “Voting Floor Price”), which represents the closing sale price of the Common Stock on the trading day immediately prior to the Execution Date. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series B Convertible Preferred Stock receive a liquidation preference ahead of holders of Common Stock.   The warrants have an exercise price of $12.00 (the “Exercise Price”) and become exercisable on the first business day after the six-month anniversary of issuance (the “Initial Exercise Date”) and have a five-year term, expiring on the fifth anniversary of the Initial Exercise Date. The Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.   Common Stock   At-the-Market Offering   On October 3, 2024, the Company entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the “ATM Offering”), as sales agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the ATM Offering. On October 3, 2024, the Company filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately $6.5 million in shares of Common Stock in the ATM Offering.   The offer and sale of the shares will be made pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023.   During the six months ended October 31, 2024, the Company sold an aggregate of 755,888 shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $1.2 million.   Orchid SPA   During the three months ended October 31, 2024, Orchid converted 649.5363 shares of Series A Convertible Preferred Stock into 3,613,951 shares of Common Stock. During the six months ended October 31, 2024, Orchid converted 712.0133 shares of Series A Convertible Preferred Stock into <span

id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20240501__20241031_pdd" title="Number of shares issued">3,787,284 shares of Common Stock. 10000000 0.0001 3000 6000 9991000 2500 80000 12.50 1000000.0 311356 310000 1356 100000 588644 120000 12.50 1500000 160000 12.50 2000000.0 200000 12.50 2500000 80000 12.50 1000000.0 600000 Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the "Termination Date"). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination Date. 1220 122000 12.00 1220000 1150000 70000 780 78000 12.00 780000 100 10000 12.00 100000 755888 1200000 649.5363 3613951 712.0133 3787284   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">9.</td><td style="text-align: justify">RELATED PARTY TRANSACTIONS</td></tr> </table>   In connection with the Orchid SPA, the Company agreed to pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. During the three and six months ended October 31, 2024, origination fees due to Ault Lending were $275,000 and $400,000, respectively. 275000 400000   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">10.</td><td style="text-align: justify">SUBSEQUENT EVENTS</td></tr></table>   From November 1, 2024 to December 10, 2024, the Company sold an aggregate of 201,543 shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $280,000.   Management has evaluated events through the date the financial statement were available to be issued and determined that there have been no other events that occurred that would require adjustment to our disclosures in the condensed financial statements. 201543 280000 false false false false The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB ASC 260-10-45-14. Milestone met and payment made Milestone met and payment made '

"